WO2012012478A1 - Aldosterone synthase inhibitors - Google Patents

Aldosterone synthase inhibitors Download PDF

Info

Publication number
WO2012012478A1
WO2012012478A1 PCT/US2011/044598 US2011044598W WO2012012478A1 WO 2012012478 A1 WO2012012478 A1 WO 2012012478A1 US 2011044598 W US2011044598 W US 2011044598W WO 2012012478 A1 WO2012012478 A1 WO 2012012478A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
optionally substituted
cyclopropyl
group
benzimidazole
Prior art date
Application number
PCT/US2011/044598
Other languages
French (fr)
Inventor
Scott B. Hoyt
Min K. Park
Clare London
Yusheng Xiong
D. Jonathan Bennett
Jaiqiang Cai
Paul Ratcliffe
Andrew Cooke
Emma Carswell
John Maclean
Rohit Saxena
Bheemashankar A. Kulkarni
Archana Gupta
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Priority to US13/811,059 priority Critical patent/US9382226B2/en
Priority to EP11810314.2A priority patent/EP2595482A4/en
Publication of WO2012012478A1 publication Critical patent/WO2012012478A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention involves compounds of structural Formula (I) and the pharmaceutically acceptable salts thereof. The compounds of the invention are effective at selectively inhibiting CYP11B2, and are therefore useful for the treatment or prophylaxis of disorders that are associated with elevated aldosterone levels, including, but not limited to, hypertension and heart failure.

Description

ALDOSTERONE SYNTHASE INHIBITIORS
RELATED APPLICATIONS
This application claims benefit of provisional application USSN 61/366,231, filed July 21 , 2010, and provisional application USSN 61/473,417, filed April 8, 2010, both herein incorporated by reference.
BACKGROUND OF THE INVENTION
Aldosterone is a steroid hormone secreted in the adrenal cortex. In primary cells of the distal tubules and collecting ducts of the kidney, aldosterone binding to the mineralocorticoid receptor (MR) results in the retention of sodium and water and excretion of potassium, which in turn leads to increased blood pressure. Aldosterone also causes inflammation that leads to fibrosis and remodeling in the heart, vasculature and kidney. This inflammation may proceed by MR-dependent as well as MR-independent mechanisms (Gilbert, K. C. et al., Curr. Opin.
Endocrinol. Diabetes Obes., vol. 17, 2010, pp. 199 - 204).
Mineralocorticoid receptor antagonists (MRAs) such as spironolactone and eplerenone have been used previously to block the effects of aldosterone binding to MR. When given in addition to standard therapies such as angiotensin-converting enzyme (ACE) inhibitors and loop diuretics, the nonselective MRA spironolactone and the selective MRA eplerenone significantly reduced morbidity and mortality in patients with heart failure or myocardial infarction (Pitt, B. et al., New Engl. J. Med., vol. 341, 1999, pp. 709 - 717; Pitt, B. et al., New Engl. J. Med., vol. 348, 2003, pp. 1382 - 1390). However, the nonselective MRA spironolactone can also bind to and act at other steroid receptors, and as a consequence its use is associated with sexual side effects such as gynecomastia, dysmenorrhoea and impotence (Pitt, B. et al., New Engl. J. Med., vol. 341, 1999, pp. 709 - 717; MacFadyen, R. J. et al., Cardiovasc. Res., vol. 35, 1997, pp 30 - 34;
Soberman, J. E. et al., Curr. Hypertens. Rep., vol. 2, 2000, pp 451 - 456). Additionally, both spironolactone and eplerenone are known to cause elevated plasma postassium levels
(hyperkalemia) and elevated aldosterone levels.
An alternative method of blocking the effects of aldosterone is to inhibit its biosynthesis. CYP11B2 (aldosterone synthase) is a mitochondrial cytochrome P450 enzyme that catalyzes the final oxidative steps in the conversion of 11 -deoxycorticosterone, a steroidal precursor, to aldosterone (Kawamoto, T. et al., Proc. Natl. Acad. Sci. USA, vol. 89, 1992, pp. 1458 - 1462). Compounds that inhibit CYP1 1B2 should thus inhibit the formation of aldosterone. Such compounds, particularly those of nonsteroidal structure, should provide the beneficial effects of MRAs, without the adverse effects derived from steroid receptor binding or MR-independent inflammatory pathways.
CYPl 1B1 (steroid- 1 1 β -hydroxylase) is a related enzyme that catalyzes the formation of glucocorticoids such as Cortisol, an important regulator of glucose metabolism. Because human CYPl 1B2 and CYPl 1B1 are greater than 93% homologous, it is possible for nonselective compounds to inhibit both enzymes (Kawamoto, T. et al, Proc. Natl. Acad. Sci. USA, vol. 89, 1992, pp 1458 - 1462; Taymans, S. E. et al., J. Clin. Endocrinol. Metab., vol. 83, 1998, pp 1033 - 1036). It would be preferable, however, for therapeutic agents to selectively inhibit CYPl 1B2 and the formation of aldosterone with diminished inhibition of, or affect on, CYPl 1B1 and the production of Cortisol. The compounds of the invention provide an alternative to previous treatments for elevated aldosterone levels and selectively inhibit CYPl 1B2 as compared to CYP11B1.
SUMMARY OF THE INVENTION
In it many embodiments, the present invention provides for a novel class of
benziniidazole analogues, which are inhibitors of CYPl 1B2, or metabolites, stereoisomers, salts, solvates or polymorphs thereof, processes of preparing such compounds, pharmaceutical compositions comprising one or more such compounds, processes of preparing pharmaceutical compositions comprising one or more such compounds and methods of treatment, prevention, inhibition or amelioration of one or more disease states associated with inhibiting CYPl 1B2 by administering an effective amount at least one of the inventive benziniidazole analogues to a patient in need thereof.
In one aspect, the present application discloses a compound or a pharmaceutically acceptable salt, metabolite, solvate, prodrug or polymorph of said compound, said compound having the general structure shown in Formula I
Figure imgf000004_0001
I harmaceutically acceptable salt thereof
wherein: Het is a heteroaromatic
Figure imgf000005_0001
Rla? Rib and RIC are independently:
H; halogen; -C ; -N02; -OR5; -NR8R9; -N(R13)C(O)Ri0; -N(RI3)SO2-Ri0; -C(0)R10 ; - C(0)N(R6)(R7), -C(0) R10 ; -S02N(R6)(R7) or -S(O)m-RJ0; alkyl optionally substituted one or more times by halogen, -CN, -OR5, -N(R13)C(0)R10 or -C(0)N(R6)(R7);
cycloalkyl optionally substituted one or more times by halogen, alkyl, or haloalkyl; aryl optionally substituted one or more times by halogen, -OR5, alkyl, or haloalkyl or
heteroaryl optionally substituted one or more times by halogen, -OR5, alkyl or haloalkyl;
R2 is:
-OR5, alkyl; alkyl-Rll; cycloalkyl optionally substituted one or more times by alkyl and halogen; and -C1-C2 alkyl-cycloalkyl wherein the cycloalkyl group is optionally substituted one or more times by alkyl and halogen;
R3 is:
H; halogen; -CN; -N02; -OR5a; -NR8R9; -N(R°)C(0)R10; C(0)R10 -C(0)N(R6)(R7), - C(0)OR10 or -S(0)m-R10; alkyl optionally substituted one or more times by halogen or - OR5a ; cycloalkyl optionally substituted one or more times by halogen, -OR5a, alkyl, or haloalkyl; aryl optionally substituted one or more times by halogen, -ORSa, alkyl, or haloalkyl or heteroaryl optionally substituted one or more times by halogen, -OR5a, alkyl or haloalkyl;
R is:
H; halogen; -CN; -N02; -OR b; -NR8R9; -N(R13)C(0)R10; -C(0)R10 -C(0)N(R6)(R7), - C(0)OR10 or -S(0)m-R10; alkyl optionally substituted one or more times by halogen or - OR5b ; cycloalkyl optionally substituted one or more times by halogen, -OR5b, alkyl, or haloalkyl; aryl optionally substituted one or more times by halogen, -OR5b, alkyl, or haloalkyl or heteroaryl optionally substituted one or more times by halogen, -OR5b, alkyl or haloalkyl; or R3 and R4 are joined together to form a 5-7 membered carbocyclic or heterocyclic ring that is fused to the pyridyl ring to which R.3 and R4 are attached, wherein the ring formed by R3 and R4 is optionally substituted with 1 to 3 of R 12;
R5, R5a a d R5b are each independently H; alkyl optionally substituted with halogen; or
aralkyl wherein the aryl ring is optionally substituted one or more times by halogen, -
OR5c, alkyl or haloalkyl;
R5c is H or alkyl optionally substituted with halogen;
6 and R? are each independently:
H, alkyl optionally substituted with halogen; cyclo alkyl optionally substituted with alkyl or halogen; aryl optionally substituted one or more times by halogen, -OR5, alkyl, or haloalkyl or heteroaryl optionally substituted one or more times by halogen, -OR5, alkyl or haloalkyl;
or R6 and R? join together with the nitrogen to which they are attached to form a 3-7
membered saturated heterocyclic ring;
R8 and R9 are each independently:
H; alkyl; or aralkyl wherein the aryl ring is optionally substituted one or more times by halogen, -OR5, alkyl or haloalkyl;
RlO is independently H; alkyl optionally substituted one or more times with halogen; cycloalkyl optionally substituted one or more times by halogen, alkyl or haloalkyl; or aryl wherein the aryl ring is optionally substituted one or more times by halogen, -OR5, alkyl or haloalkyl
Rll is haloalkyl or -OR5 ;
l2 1S independently halogen or alkyl optionally substituted one or more time by halogen; Rl3 is H or alkyl; and
m is 0, 1 or 2.
The compounds of the invention are effective at selectively inhibiting CYP11B2, and are therefore useful for the treatment or prophylaxis of disorders that are associated with elevated aldosterone levels, including, but not limited to, hypertension and heart failure. Therefore, an object of the invention is to provide methods of treatment comprising administering a therapeutically or prophylactically effective amount of a compound of Formula I to a patient in need of treatment for elevated aldosterone levels. A further object is to provide the use of compounds of Formula I in combination with other therapeutically effective agents, including one or more additional drugs useful for the treatment of hypertension, heart failure or other medical conditions found in such patients. The invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which comprise compounds of Formula I. Moreover, the compounds of this invention may be used to validate in vitro assays, such as, for example the V79 Human CYPl 1B2 and V79 Human CYPl IBl assays discussed later in the application. These and other objects will be evident from the description contained herein.
DETAILED DESCRIPTION OF THE INVENTION
In an embodiment, the present invention provides compounds represented by structural
Formula I or pharmaceutically acceptable salt thereof, wherein the various moieties are as described as above.
Another embodiment of the present invention is compounds or their pharmaceutically acceptable salts of Formula I represented by structural Formula la
Figure imgf000007_0001
la
or a pharmaceutically acceptable salt thereof wherein:
Rla, Rib and Rlc are independently selected from the group consisting of:
-H, -F, -CI, -Br, -CN, -OR5, -S02NR6R ,
-C1-C6 alkyl optionally substituted with 1 to 3 of ~-F,
-C3-C7 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of-CH3 or -F;
R2 is selected from the group consisting of:
(a) -C1-C5 alkyl-Rl 1, (b) --C1-C4 alkyl; (c) cyclopropyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of-CH3 or -F or (d) - Ci- C2 alkyl-cyclopropyl wherein cyclopropyl is optionally substituted with 1 or 2
substituents independently selected from the group consisting of -CH3 or -F; R3 is selected from the group consisting of:
-H, -F, -CI, -Br, -CN, -OR5a, -Ci ¼ perfluoroalkyl,
-Cj -Cg alkyl optionally substituted with 1 to 3 of -F and optionally substituted with - OH, or
-C3-C7 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of ~~CH3 or -F;
R4 is selected from the group consisting of:
(a) -H, -F, -CI, -Br5 -CN, -OR5b, -NR8R9, -CC^R1^ or -CORlO,
(b) -Ci-Cg perfluoroalkyl,
(c) ~C] -C7 alkyl optionally substituted with 1 to 6 of -F and optionally substituted with 1 or 2 substituents independently selected from the group consisting of (i) -OR5b or (ii) aryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of-F, -CI and -Ci -C3 alkyl optionally substituted with 1 to 3 of -F,
(d) -C3-C7 cycloalkyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of -Ci -Cg alkyl, -CF3 or -F,
(e) aryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of -F, -CI and -C1-C3 alkyl optionally substituted with 1 to 3 of-F or
(f) heteroaryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of -F, -CI and -C1 -C3 alkyl optionally substituted with 1 to 3 of -F; or R3 and R4 are joined together to form a 5-7 membered carbocyclic or heterocyclic ring that is fused to the pyridyl ring to which R3 and R4 are attached, wherein the ring formed by R3 and R4 is optionally substituted with 1 to 3 of Rl 2;
R5, R5a and R5b are each independently selected from the group consisting of-H or -Ci-Cg alkyl optionally substituted with 1 to 3 of -F;
R6 and R? are each independently selected from the group consisting of
(a) -Ci-C<5 alkyl optionally substituted with 1 to 3 of-F, (b) -C3-C7 cycloalkyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of -CH3 and -F, (c) aryl or (d) heteroaryl,
or R6 and R7 join together with the nitrogen to which they are attached to form a 3-7
membered saturated heterocyclic ring; IIS and R9 are each independently selected from the group consisting of
-H, or -Ci-Cg alkyl, or -CH2-phenyl wherein phenyl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of-F, -CI or -CF3;
RlOis selected from the group consisting of
-Cl-Cg alkyl optionally substituted with 1 to 3 of-F,
-C3-C7 cycloalkyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of -CH3 and -F; or
-phenyl which is optionally substituted with 1 to 3 substituents independently selected from the group consisting of -F, -CI or -CF3
Rll is selected from the group consisting of -CH2F, -CHF2 or -CF3;
Rl2 is independently selected at each occurrence from the group consisting of-F, -CI or
-C1-C3 alkyl optionally substituted with 1 to 3 of -F.
Another embodiment of the present invention is compounds or their pharmaceutically acceptable salts of Formula I represented by structural Formula lb
Figure imgf000009_0001
lb
or a pharmaceutically acceptable salt thereof wherein
Ria, Rib and Rlc are independently selected from the group consisting of:
-H, -F, -CI, -Br, -CN, -OR5, -S02NR6R7 -C(0)OR10
-Ci-Cg alkyl optionally substituted with 1 to 3 of -F, or
-C3-C7 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of-CH3 and -F;
R2 is selected from the group consisting of:
(a) -C1-C5 alkyl-Rl !, (b) -C1-C4 alkyl; (c) cyclopropyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of -CH3 or -F or (d) - Cl- C2 alkyl-cyclopropyl wherein cyclopropyl is optionally substituted with 1 or 2 substituents independently selected from the group consisting of -CH3 or ~~F; R3 is selected from the group consisting of:
-H, -F, -CI, -Br, -CN, -OR5a -C1-C6 perfluoroalkyl,
-Cj-C6 alkyl optionally substituted with 1 to 3 of-F and optionally substituted with - OH, or
-C3-C7 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of-CH3 or -F;
R4 is selected from the group consisting of:
(a) -H, -F, -CI, -Br, -CN, -OR5b -NR8R9 -CO2 10 or -CORlO,
(b) -C1-C6 perfluoroalkyl,
(c) -C 1 -C7 alkyl optionally substituted with 1 to 6 of -F and optionally substituted with 1 or 2 substituents independently selected from the group consisting of (i) -OR5b or (ii) aryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of-F, -CI or -C1-C3 alkyl optionally substituted with 1 to 3 of-F,
(d) -C3-C7 cycloalkyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of -Ci -ϋ alkyl, -CF3 or -F,
(e) aryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of-F, -CI or -C1-C3 alkyl optionally substituted with 1 to 3 of-F and
(f) heteroaryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of -F} -CI or -C] -C3alkyl optionally substituted with 1 to 3 of -F; or R3 and R4 are joined together to form a 5-7 membered carbocyclic or heterocyclic ring that is fused to the pyridyl ring to which and R4 are attached, wherein the ring formed by R and R4 is optionally substituted with 1 to 3 of Rl 2;
R5, RSa and R5b are each independently selected from the group consisting of ~H or -Ci-Cg alkyl optionally substituted with 1 to 3 of-F;
R6 and R? are each independently selected from the group consisting of
(a) -Cj-C^ alkyl optionally substituted with 1 to 3 of -F, (b) -C3-C7 cycloalkyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of -CH3 or -F, (c) aryl or (d) heteroaryl,
or R6 and R? join together with the nitrogen to which they are attached to form a 3-7
membered saturated heterocyclic ring; R8 and R9 are each independently selected from the group consisting of
-H, -Cl-Cg alkyl or -CH2-phenyl wherein phenyl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of-F, ~C1 or -CF3;
Rl is selected from the group consisting of
-Cl-Cg alkyl optionally substituted with 1 to 3 of ~F,
-C3-C7 cycloalkyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of -CH3 or -F; or
- phenyl which is optionally substituted with 1 to 3 substituents independently selected from the group consisting of-F, -CI or -CF3;
Rll is selected from the group consisting of -CH2F, -CHF2 or -CF3;
Rl2 is independently selected at each occurrence from the group consisting of -F, -CI or
-Ci-C3alkyl optionally substituted with 1 to 3 of-F.
Another embodiment of this invention is compounds of Formula I, la or lb wherein R3 is selected from the group consisting of:
-H. -F, -CI, -Br, -CN, -OR.5a -C 1 -C6 perfluoroalkyl, -C 1 -Ce alkyl optionally substituted with 1 to 3 of -Fs or
-C3-C7 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of-CH3 or -F.
Another embodiment of this invention is compound of any of the embodiments above wherein at least one Rla , Rlb or Rlc is selected from the group consisting of -H, -F, -CI, -Br, - N02, -CN, Ci-C6 alkyl (e.g., methyl, ethyl, isopropyl), Ci-C6 alkyl substituted with -OH, halogen, or N(R13)C(0)-Ci-C6 alkyl, -OC]-C6 alkyl (e.g., methoxy, ethoxy, isopropyloxy),- N(Ri3)C(0)-CrC6 alkyl, -C(0)N(H)C C6 alkyl, -NH2, -NH(d-C6 alkyl), -N(CrC6 alkyl)( Cr C6 alkyl), -C(0)OH, -C(0)0-Ci-C6alkyl, -S-Ci-C« alkyl, -S(0)-C C6 alkyl, -S(0)2-C1-C6 alkyl, - N(R13)S(0)2-C1-C6 alkyl, or optionally Ci-C6 alkyl substituted heteroaryl, wherein the heteroaryl is an isooxazolyl, pyrazolyl, oxazolyl, imidazolyl or pyridyl ring.
Another embodiment of this invention are compounds of any of the embodiments above wherein R2 is -OH, C Ce alkyl (e.g., methyl, ethyl, isopropyl), Ci-C6 alkyl substituted with -OH or halogen, -O-Q-Ce alkyl (e.g., methoxy, ethoxy, isopropyloxy), cyclopropyl optionally substituted by halogen, -OH or -O-Cy-C alkyl or -OCH2-phenyl, wherein the phenyl ring is optionally substituted by halogen, -OH or -0-Ci-C6 alkyl. Another embodiment of this invention are compounds of any of the embodiments above where R3 and R4 are independently H, halogen -CN, -Ci-Cg alkyl substituted optionally substituted with -OH, -0-Ci-C6 alkyl, or halogen, -O-Ci-Ce alkyl (e.g., methoxy, ethoxy, isopropyloxy), - C(0)Ci-C6aJkyl, -C(0)OH, -C(0)0-d-C6 alkyl, -S-CrC6 alkyl, -S(0)-d-C6 alkyl, -S(0)2-Ci-C6 alkyl, -NH2? -NH(CrC6 alkyl), -N(Ci-C6 alkyl)( C C6 alkyl), optionally halo substituted phenyl, or optionally Ci-C6 alkyl substituted heteroaryl, wherein the heteroaryl is an isooxazolyl, pyrazolyl, oxazolyl, imidazolyl or pyridyl ring or
R3 and R4 together w
Figure imgf000012_0001
Another embodiment of this invention is compounds of Formula la or lb having structural
Formula II or the pharmaceutically acceptable salts thereof wherein Rlc is -H, R2 is cyclopropyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of -CH3 or -F, and the variables Rla, ib, 3 and R are as defined in Formula la or lb: wherein cyclopropyl is optionally substituted as described above in Formula la or lb.
Figure imgf000012_0002
Another embodiment of this invention is compounds or pharmaceutically acceptable salts thereof of any of the embodiments identified above wherein (a) 3 is -H and R4 is selected from the group consisting of -H, -F, -CI, -Br, -CN or -C1-C7 alkyl optionally substituted with 1 to 6 of -F, particularly wherein one or two terminal carbons is -CF3, and optionally substituted with 1 or 2 of -OR^b; or (b) R3 and R4 are joined together to form a 5-7 member carbocyclic or heterocyclic ring that is fused to the pyridyl ring to which R3 and 4 are attached wherein the ring formed by R3 and R4 is optionally substituted with 1 to 3 of Rl 2. Another aspect of this embodiment is compounds where R12 is alkyl or halogen. Alternatively, another embodiment of this invention is compounds of pharmaceutically acceptable salts thereof of any of the embodiments identified wherein
Figure imgf000013_0001
wherein R5b is -H or -C1 -C3 alkyl optionally substituted with 1 to 3 of -F, and R4a and R4b are each independently selected from the group consisting of (a) -C1-C3 alkyl or (b) -C1 -C3 alkyl substituted with 1 to 3 of -F, preferably wherein the terminal carbon is -CF3.
A further embodiment of this invention is compounds of Formula la or lb or the pharmaceutically acceptable salts thereof wherein:
Rla, Rib and Rlc are each independently selected from -H, -F, -CF3 or -OCH3; and/or
R2 is selected from (a) -C] ~C3alkyl, (b) -Ci -C2alkyl-Rl 1, (c) ~(CH2)(i-2)-cyclopropyl wherein cyclopropyl is optionally substituted with -CH3 or -F, or (d) cyclopropyl optionally substituted with -CH3 or -F; and/or
R3 is -H or is joined together with R4 to form a 5-7 mernbered carbocyclic or heterocyclic ring that is fused to the pyridyl ring to which R and R4 are attached selected from the group consisting of
Figure imgf000013_0002
R4 when not oined with R3, is selected from -H, -F, -CN, -OCH3, -COCH3, -COOCH3, -CF3,
Figure imgf000013_0003
wherein 5b is -H or -CH3 , and R4 and R4b a e each independently selected from the group consisting of -CFI3 and -CF3 ; and/or
5 and R5a are each independently selected from the group consisting of -H, -CH3 and -CF3,
A further embodiment of this invention is compounds of Formula la or lb described above or their pharmaceutically acceptable salts wherein R6 and R are each -C 1 -C3 alkyl optionally substituted with 1 to 3 of -F. A further embodiment of this embodiment of the inventions are compounds or their pharmaceutically acceptable salts wherein R6 and R7 are each ~Ci-C3alkyl optionally substituted with 1 to 3 of-F; and/or US and R.9 are each independently selected from the group consisting of -H„ or -C1-C3 alkyl.
In another embodiment are compounds of Formula la or lb or the pharmaceutically acceptable salts thereof wherein R3 is -H and R.4 is selected from -H, -C(OH)(CH3)2 or - C(OCH3)(CH3)2-
As used herein except if noted otherwise, "alkyl" is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. Commonly used abbreviations for alkyl groups are used throughout the specification. For example the term "Ci _6 alkyl" (or "Ci-C6 alkyl"), means linear or branched chain alkyl groups, including ail isomers, having the specified number of carbon atoms and includes all of the hexyl and pentyl isomers as well as n~, iso-, sec- and fef -butyl (butyl, s-butyl, i-butyl, t-butyl; Bu = butyl), n- and /-propyl (Pr - propyl), ethyl (Et) and methyl (Me).
"Halo" refers to fluorine, chlorine, bromine or iodine radicals. Preferred are fluoro, chloro or bromo, and more preferred are fluoro and chloro.
"Halogen" means fluorine, chlorine, bromine, or iodine.
"Haloalkyl" means a halo-alkyl- group in which the alkyl group is as previously described. The bond to the parent moiety is through the alkyl. Non-limiting examples of suitable haloalkyl groups include fluoromethyl, difluoromethyl, -CH2CF3, -CH2CHF2 - CH2CH2F, or an alkyl group with one or more terminal carbons tri-substituted with a halogen (e.g., -F) such as, for example -C 1 -C3alkyI-CF3 , -CH(CH3)(CF3), -CH(CF3)2 and the like.
"Cycloalkyl" is a cyclized alkyl ring having the indicated number of carbon atoms.
Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyciohexyl and cycloheptyl. The cycloalkyl ring may be substituted on any available carbon which results in the creation of a stable structure, including the ring carbon which serves as the point of attachment to the rest of the molecule.
"Aryl" unless otherwise indicated, means mono- and bicyclic aromatic rings containing 6- 12 carbon atoms. Examples of aryl include phenyl, naphthyl, indenyl and the like. "Aryl" also includes monocyclic rings fused to an aryl group. Examples include tetrahydronaphthyl, indanyl and the like. Phenyl is preferred in all embodiments of this invention..
"Heteroaryl" unless otherwise indicated, means a mono- or bicyclic aromatic ring or ring system containing at least one heteroatom selected from O, S and N, with each heteroaryl containing 5 to 10 atoms. Examples include pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyi, oxadiazolyl, thiadiazolyl, thiazoiyi, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl, and the like, Heteroaryl also includes a 5-6 membered heteroaryl ring fused to a non-aromatic or partially or fully aromatic ring which optionally contains one or more heteroatoms. Heteroaryl also includes such groups in charged form, e.g., pyridinium, and heteroaryls substituted with oxo (=0).
"Aralkyl" means an aryl-alkyl- group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non-limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.
R6 and R7 can be joined together with the nitrogen to which they are attached to form a
3-7 membered saturated heterocyclic ring, wherein the ring is composed of carbon atoms and at least one N atom and optionally one or two additional heteroatoms selected from N, S and 0. Examples include but are not limited to aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, azepanyl, 1 ,4-diazepanyl, 1,4-oxazepanyl, and 1,4-thiazepanyl.
When R3 and R4 are joined together to form a 5-7 membered carbocyclic ring that is fused to the pyridyl ring to which R3 and R4 are attached, "carbocyclic" means a
cycloalkyl, aryl or partially unsaturated ring composed of 5-7 carbon atoms wherein two of the carbons are shared between the fused rings. When R3 and 4 are joined together to form a 5-7 membered heterocyclic ring fused to the pyridyl ring to which R3 and R4 are attached,
"heterocyclic" means fully saturated, partially unsaturated or aryl ring composed of carbon atoms and one, two or three heteroatoms selected from N, S and O, wherein two carbons are shared between the fused rings. Examples of such fused ring systems wherein R3 and R4 together represent a 6-membered carbocyclic ring and a 6 membered heterocyclic ring, respectively, include but are not limited to:
Figure imgf000015_0001
When a moiety can be optionally substituted, it means that each carbon and heteroatom (when present) available for substitution in the given moiety may be independently unsubstituted or substituted with the specified number of substituents that are the same or different at each occurrence and which result in the creation of a stable structure as is understood to be reasonable by one skilled in the art, unless specified otherwise.
In some instances the number of substituents which may be optionally present on a moiety is specified, for example but not limited to, 1 to 3 of -F (fluoro). For example, an alkyl group that can be optionally substituted with 1 to 3 of -F includes, but is not limited to, -CH3, -
CH2F, -CHF2> -CF3, -CH2CH3, -CH2-CH2F -CH2-CHF2, -CHF-CH2F, -CH2CF3, -CHF- CHF2, -(CH2)2CH3, -CH(CF3)-CH3, -(CH2)3-CF35 -(CH2)2CH(CF3)CH3, and -(CH2)5~CF3, as appropriate for the defined number of carbon atoms for the given alkyl group. An alkyl group with one or more terminal carbons tri-substituted with -F is preferred, e.g., -Ci-C3alkyl-CF3, -CH(CH3)(CF3), -CH(CF3)2 and the like; -CF3 is most preferred. "Perfluoroalkyl" means an alkyl group wherein all hydrogens are replaced with fluoro.
Halo, halide or halogen refers to -F (fluoro), -CI (chloro), -Br (bromo) and -I (iodo). Unless expressly depicted or described otherwise, variables depicted in a structural formula with a "floating" bond, such as each of substituents x a, Rib, and R c in structural Formula I, are permitted on any available carbon atom in the ring to which each is attached.
The present invention encompasses all stereoisomeric forms of the compounds of Formula la. Centers of asymmetry that are present in the compounds of Formula I can all independently of one another have (R) configuration or (S) configuration. When bonds to the chiral carbon are depicted as straight lines in the structural Formulas of the invention, it is understood that both the (R) and (S) configurations of the chiral carbon, and hence both enantiomers and mixtures thereof, are embraced within the Formula. Similarly, when a compound name is recited without a chiral designation for a chiral carbon, it is understood that both the (R) and (S) configurations of the chiral carbon, and hence individual enantiomers and mixtures thereof, are embraced by the name. The production of specific stereoisomers or mixtures thereof may be identified in the Examples where such stereoisomers or mixtures were obtained, but this in no way limits the inclusion of all stereoisomers and mixtures thereof from being within the scope of this invention.
The invention includes all possible enantiomers and diastereomers and mixtures of two or more stereoisomers, for example mixtures of enantiomers and/or diastereomers, in all ratios. Thus, enantiomers are a subject of the invention in enantiomerically pure form, both as levorotatory and as dextrorotatory antipodes, in the form of racemates and in the form of mixtures of the two enantiomers in all ratios. In the case of a cis/trans isomerism the invention includes both the cis form and the trans form as well as mixtures of these forms in all ratios. The preparation of individual stereoisomers can be carried out, if desired, by separation of a mixture by customary methods, for example by chromatography or crystallization, by the use of stereochemically uniform starting materials for the synthesis or by stereoselective synthesis. Optionally a derivatization can be carried out before a separation of stereoisomers. The separation of a mixture of stereoisomers can be carried out at an intermediate step during the synthesis of a compound of Formula I or it can be done on a final racemic product. Absolute stereochemistry may be determined by X-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing a stereogenic center of known configuration. Where compounds of this invention are capable of tautomerization, all individual tautomers as well as mixtures thereof are included in the scope of this invention. The present invention includes all such isomers, as well as salts, solvates (including hydrates) and solvated salts of such isomers including racemates, enantiomers, diastereomers and tautomers and mixtures thereof.
Reference to the compounds of this invention as those of a specific formula or embodiment, e.g., Formula I, or any other generic structural formula, embodiment or specific compound described or claimed herein, is intended to encompass the specific compound or compounds falling within the scope of the formula or embodiment, including salts thereof, particularly pharmaceutically acceptable salts, solvates of such compounds and solvated salt forms thereof, where such forms are possible unless specified otherwise.
In the compounds of Formula I, the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of Formula I. For example, different isotopic forms of hydrogen (H) include protium (*H) and deuterium (¾). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. Isotopically-enriched compounds within Formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates. When the compounds of Formula I contain one or more acidic or basic groups the invention also includes the corresponding physiologically or toxicologically acceptable salts, in particular the pharmaceutically utilizable salts. Thus, the compounds of Formula I which contain acidic groups can be used according to the invention, for example, as alkali metal salts, alkaline earth metal salts or as ammonium salts. Examples of such salts include but are not limited to sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids.
Compounds of Formula I which contain one or more basic groups, i.e. groups which can be protonated, can be used according to the invention in the form of their acid addition salts with inorganic or organic acids as, for example but not limited to, salts with hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, benzenesulfonic acid,
methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, trifluoroacetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, etc. If the compounds of Formula la simultaneously contain acidic and basic groups in the molecule the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions). Salts can be obtained from the compounds of Formula I by customary methods which are known to the person skilled in the art, for example by combination with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange from other salts. The present invention also includes all salts of the compounds of Formula I which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of physiologically (i.e., pharmaceutically) acceptable salts.
Furthermore, compounds of the present invention may exist in amorphous form and/or one or more crystalline forms, and as such all amorphous and crystalline forms and mixtures thereof of the compounds of Formula I are intended to be included within the scope of the present invention, in addition, some of the compounds of the instant invention may form solvates with water (i.e., a hydrate) or common organic solvents. Such solvates and hydrates, particularly the pharmaceutically acceptable solvates and hydrates, of the instant compounds are likewise encompassed within the scope of this invention, along with un-solvated and anhydrous forms. Any pharmaceutically acceptable pro-drug modification of a compound of this invention which results in conversion in vivo to a compound within the scope of this invention is also within the scope of this invention. For example, esters can optionally be made by esterification of an available carboxylic acid group or by formation of an ester on an available hydroxy group in a compound. Similarly, labile amides can be made. Pharmaceutically acceptable esters or amides of the compounds of this invention may be prepared to act as pro-drugs which can be hydrolyzed back to an acid (or -COO- depending on the pH of the fluid or tissue where conversion takes place) or hydroxy form particularly in vivo and as such are encompassed within the scope of this invention. Examples of pharmaceutically acceptable pro-drug modifications include, but are not limited to, -Ci_6alkyl esters and -Ci-6alkyl substituted with phenyl esters.
Accordingly, the compounds within the generic structural formulas, embodiments and specific compounds described and claimed herein encompass salts, isomers, tautomers, physical forms (e.g., amorphous and crystalline forms) and soivated forms thereof and any combination of these forms, as well as pro-drug forms thereof, unless specified otherwise.
Compounds of the present invention are effective at inhibiting the synthesis of aldosterone by inhibiting CYPl 1B2 (aldosterone synthase), and they are therefore useful agents for the therapy and prophylaxis of disorders that are associated with elevated aldosterone levels. Accordingly, an object of the instant invention is to provide a method for inhibiting aldosterone synthase, and more particularly selectively inhibiting CYP11B2, in a patient in need thereof, comprising administering a compound of Formula I to the patient in an amount effective to inhibit aldosterone synthesis, or more particularly to selectively inhibit CYPl 1B2, in the patient. A selective inhibitor of CYPl 1B2 is intended to mean a compound that preferentially inhibits CYP11B2 as compared to CYP11B1. The inhibition of CYP11B2, as well inhibition of CYPl 1B1, by the compounds of Formula I can be examined, for example, in the inhibition assays described below.
In general, compounds that have activity as aldosterone synthase inhibitors can be identified as those compounds which have an IC50 of less than or equal to about 10 μΜ;
preferably less than or equal to about 250 nM; and most preferably less than or equal to about 100 nM, in the V79-Human-CYP11B2 Assay described below. In general, aldosterone synthase inhibitors that are selective for inhibition of CYPl 1B2 as compared to CYPl 1B1 are those that show at least 3-fold greater inhibition for CYPl 1B2 compared to CYPl 1B1 ; preferably at least 20-fold inhibition for CY l 1B2 compared to CYPl 1B1; and more preferably at least 100-fold greater inhibition for CYP11B2 compared to CYPl 1B1, in the V79-Human-CYP11B2 Assay as compared to the V79-Human-CYP11B1 Assay.
Due to their ability to inhibit aldosterone synthase, the compounds of the present invention are useful to treat and/or reduce the risk for hypertension, heart failure such as congestive heart failure, diastolic dysfunction, left ventricular diastolic dysfunction, diastolic heart failure, systolic dysfunction, hypokalemia, renal failure, in particular chronic renal failure, restenosis, metabolic syndrome, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collagen, fibrosis and remodeling following hypertension and endothelial dysfunction, cardiovascular diseases such as atherosclerosis, renal dysfunction, liver diseases, vascular diseases, cerebrovascular diseases, retinopathy, neuropathy, insulinopathy, endothelial dysfunction, ischemia, myocardial and vascular fibrosis, myocardial necrotic lesions, vascular damage, myocardial infarction, left ventricular hypertrophy, cardiac lesions, vascular wall hypertrophy, endothelial thickening, and fibrinoid necrosis of coronary arteries.
The dosage amount of the compound to be administered depends on the individual case and is, as is customary, to be adapted to the individual circumstances to achieve an optimum effect. Thus, it depends on the nature and the severity of the disorder to be treated, and also on the sex, age, weight and individual responsiveness of the human or animal to be treated, on the efficacy and duration of action of the compounds used, on whether the therapy is acute or chronic or prophylactic, or on whether other active compounds are administered in addition to compounds of Formula la. A consideration of these factors is well within the purview of the ordinarily skilled clinician for the purpose of determining the therapeutically effective or prophylacticaliy effective dosage amount needed to prevent, counter, or arrest the progress of the condition. It is expected that the compound will be administered chronically on a daily basis for a length of time appropriate to treat or prevent the medical condition relevant to the patient, including a course of therapy lasting days, months, years or the life of the patient.
In general, a daily dose of approximately 0.001 to 30 nig/kg, preferably 0.001 to 20 mg/kg, in particular 0.01 to 10 mg kg (in each case mg per kg of bodyweight) is appropriate for administration to an adult weighing approximately 75 kg in order to obtain the desired results. The daily dose is preferably administered in a single dose or, in particular when larger amounts are administered, can be divided into several, for example two, three or four individual doses, and may be, for example but not limited to, 0.1 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.25 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 40 mg, 50 mg, 75 mg, 100 mg, etc., on a daily basis. In some cases, depending on the individual response, it may be necessary to deviate upwards or downwards from the given daily dose.
The term "patient" includes animals, preferably mammals and especially humans, who use the instant active agents for the prevention or treatment of a medical condition.
Administering of the drug to the patient includes both self-administration and administration to the patient by another person. The patient may be in need of treatment for an existing disease or medical condition, or may desire prophylactic treatment to prevent or reduce the risk of said disease or medical condition.
The term therapeutically effective amount is intended to mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, a system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician. A prophylactically effective amount is intended to mean that amount of a
pharmaceutical drug that will prevent or reduce the risk of occurrence of the biological or medical event that is sought to be prevented in a tissue, a system, animal or human by a researcher, veterinarian, medical doctor or other clinician. It is understood that a specific daily dosage amount can simultaneously be both a therapeutically effective amount, e.g., for treatment of hypertension, and a prophylactically effective amount, e.g., for prevention of myocardial infarction.
In the methods of treatment of this invention, the compound may be administered via any suitable route of administration such as, for example, orally, parenterally, or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. Oral formulations are preferred, particularly solid oral dosage units such as pills, tablets or capsules.
Accordingly, this invention also provides pharmaceutical compositions comprised of a compound of Formula I and a pharmaceutically acceptable carrier. For oral use, the
pharmaceutical compositions of this invention containing the active ingredient may be in forms such as pills, tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients, which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, mannitol, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid;
binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. Pharmaceutical compositions may also contain other customary additives, for example, wetting agents, stabilizers, emulsifiers, dispersants, preservatives, sweeteners, colorants, flavorings, aromatizers, thickeners, diluents, buffer substances, solvents, solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants.
Oral immediate-release and time-controlled release dosage forms may be employed, as well as enterically coated oral dosage forms. Tablets may be uncoated or they may be coated by known techniques for aesthetic purposes, to mask taste or for other reasons. Coatings can also be used to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water or miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid. Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose.
The instant invention also encompasses a process for preparing a pharmaceutical composition comprising combining a compound of Formula I with a pharmaceutically acceptable carrier. Also encompassed is the pharmaceutical composition which is made by combining a compound of Formula I with a pharmaceutically acceptable carrier. The carrier is comprised of one or more pharmaceutically acceptable excipients. Furthermore, a therapeutically effective amount of a compound of this invention can be used for the preparation of a medicament useful for inhibiting aldosterone synthase, inhibiting CYP11B2, for normalizing a disturbed aldosterone balance, or for treating or preventing any of the medical conditions described herein, in dosage amounts described herein.
The amount of active compound of Formula I and its pharmaceutically acceptable salts in the pharmaceutical composition may be, for example but not limited to, from 0.1 to 200 mg, preferably from 0,1 to 50 mg, per dose on a free acid/free base weight basis, but depending on the type of the pharmaceutical composition and potency of the active ingredient it could also be lower or higher. Pharmaceutical compositions usually comprise 0.5 to 90 percent by weight of the active compound on a free acid/free base weight basis.
Since the compounds of Formula I inhibit aldosterone synthase, apart from use as pharmaceutically active compounds in human medicine and veterinary medicine, they can also be employed as a scientific tool or as aid for biochemical investigations in which such an effect on aldosterone synthase and aldosterone levels is intended, and also for diagnostic purposes, for example in the in vitro diagnosis of cell samples or tissue samples. The compounds of Formula la can also be employed as intermediates for the preparation of other pharmaceutically active compounds.
One or more additional pharmacologically active agents may be administered in combination with a compound of Formula I. An additional active agent (or agents) is intended to mean a pharmaceutically active agent (or agents) different from the compound of Formula la. Generally, any suitable additional active agent or agents, including but not limited to antihypertensive agents, anti-atherosclerotic agents such as a lipid modifying compound, antidiabetic agents and/or anti-obesity agents may be used in any combination with the compound of Formula I in a single dosage formulation (a fixed dose drug combination), or may be
administered to the patient in one or more separate dosage formulations which allows for concurrent or sequential administration of the active agents (co-administration of the separate active agents). Examples of additional active agents which may be employed include but are not limited to angiotensin converting enzyme (ACE) inhibitors (e.g, alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moexepril, moveltipril, perindopril, quinapril, ramipril, spirapril, temocapril, or trandolapril); dual inhibitors of angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) such as omapatrilat, sampatrilat and fasidotril; angiotensin II receptor antagonists (e.g., , candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan) neutral endopeptidase inhibitors (e.g., thiorphan and phosphoramidon), aldosterone antagonists, renin inhibitors (e.g. urea derivatives of di- and tri-peptides (See U.S. Pat. No. 5,116,835), amino acids and derivatives (U.S. Patents 5,095,119 and 5,104,869), amino acid chains linked by non-peptidic bonds (U.S. Patent
5,114,937), di- and tri-peptide derivatives (U.S. Patent 5,106,835), peptidyl amino diols (U.S. Patents 5,063,208 and 4,845,079) and peptidyl beta-aminoacyl aminodiol carbamates (U.S.
Patent 5,089,471); also, a variety of other peptide analogs as disclosed in the following U.S. Patents 5,071,837; 5,064,965; 5,063,207; 5,036,054; 5,036,053; 5,034,512 and 4,894,437, and small molecule renin inhibitors (including diol sulfonamides and sulfrayls (U.S. Patent
5,098,924), N-morpholino derivatives (U.S. Patent 5,055,466), N-heterocyclic alcohols (U.S. Patent 4,885,292) and pyrolimidazolones (U.S. Patent 5,075,451); also, pepstatin derivatives (U.S. Patent 4,980,283) and fluoro- and chloro-derivatives of statone-containing peptides (U.S. Patent 5,066,643), enalkrein, RO 42-5892, A 65317, CP 80794, ES 1005, ES 8891, SQ 34017, aliskiren (2(S),4(S),5 (S),7(S)-N-(2-carbamoyl-2-methylpropyl)-5 -amino-4-hydroxy-2,7- diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)-phenyl]-octanamid hemifumarate) SPP600, SPP630 and SPP635), endothelin receptor antagonists, vasodilators, calcium channel blockers (e.g., amlodipine, bepridil, diltiazem, felodipine, gallopamil, nicardipine, nifedipine, niludipine, nimodipine, nisoldipine veraparmil), potassium channel activators (e.g., nicorandil, pinacidil, cromakalim, minoxidil, aprilkalim, loprazolam), diuretics (e.g., hydrochlorothiazide) including loop diuretics such as ethacrynic acid, furosemide, bumetanide and torsemide, sympatholitics, beta-adrenergic blocking drugs (e.g., acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, metoprolol, metoprolol tartate, nadolol, propranolol, sotalol, timolol); alpha adrenergic blocking drugs (e.g., doxazocin, prazocin or alpha methyldopa) central alpha adrenergic agonists, peripheral vasodilators (e.g. hydralazine), lipid lowering agents (e.g., simvastatin, lovastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin, ezetimibe); niacin in immediate-release or controlled release forms, and particularly in niacin in combination with a DP antagonist such as laropiprant (TREDAPTIVE®) and/or with an HMG-Co A reductase inhibitor; niacin receptor agonists such as acipimox and acifran, as well as niacin receptor partial agonists; or with other drugs beneficial for the prevention or the treatment of the above-mentioned diseases including nitroprasside and diazoxide.
Additional active agents may be administered in combination with a compound of this invention include metabolic altering agents such as (1) insulin sensitizing agents, for example (i) PPARy agonists, such as the glitazones (e.g. pioglitazone, rosiglitazone, netoglitazone, rivoglitazone, and balaglitazone) and other PPAR ligands, including (a) PPARa/γ dual agonists, such as muraglitazar, aleglitazar, sodelglitazar, and naveglitazar, (b) PPARa agonists, such as fenofibric acid derivatives (gemfibrozil, clofibrate, ciprofibrate, fenofibrate and bezafibrate), (ii) biguanides, such as metformin and its pharmaceutically acceptable salts, in particular, metformin hydrochloride; (2) insulin or insulin analogs, such as insulin lispro, insulin detemir, insulin
glargine, insulin glulisine, and inhalable formulations of each thereof; (3) sulfonylurea and non- sulfonylurea insulin secretagogues, such as tolbutamide, glyburide, glipizide, glimepiride,
mitiglinide, and meglitinides, such as nateglinide and repaglinide; and (4) incretin mimetics, such as GLP-1, GLP-1 analogs, derivatives, and mimetics, and GLP-1 receptor agonists such as
exenatide, liraglutide and taspoglutide.
Dipeptidyl peptidase-IV (DPP-4) inhibitors can be used in combination with compounds of this invention including, but not limited to, sitagliptin (disclosed in US Patent No. 6,699,871), vildagliptin, saxagliptin, alogliptin, denagliptin, carmegliptin, dutogliptin, melogliptin, and linagliptin. Antiobesity compounds can be combined with compounds of this invention, for example, topiramate, zonisamide, naltrexone, phentermine, bupropion, fenfluramine, dexfenfluramine, sibutramine; lipase inhibitors, such as orlistat and cetilistat; neuropeptide Y] or Y5 antagonists such as MK-0557; and CBl receptor inverse agonists and antagonists such as rimonabant and taranabant. Any active agent used in combination with a compound of this invention may be in a pharmaceutically acceptable salt form thereof.
The compounds of the present invention can be prepared according to the procedures of the following Schemes using appropriate materials and are further exemplified by the specific
Examples which follow. Moreover, by utilizing the procedures described herein, one of ordinary skill in the art can readily prepare additional compounds of the present invention claimed herein.
Throughout the synthetic schemes, abbreviations are used with the following meanings unless otherwise indicated: Ac = acetate; aq, aq. = aqueous; Ar = aryl; BOC, Boc - 1- butyloxycarbonyl; Bn = benzyl; BSA = bovine serum albumin; Bu = butyl, t-Bu = fert-butyl;
BuLi, ft-BuLi = fi-butyllithium; CBZ, Cbz = Benzyloxycarbonyl; cone, cone. = concentrated; cPr = cyclopropyl; DAST = (diethylamino)sulfur trifluoride; dba = dibenzylideneacetone; DCM = dichloromethane; DIAD = diisopropylazodicarboxylate; DIBAL, DIBAL-H =
diisobutylaluminum hydride; DIEA = diisopropylethylamine; DMAC, DMA =
dimethylacetamide; DME = 1,2-dimethoxyethane; DMEM - Dulbecco's modified eagle
medium; DMAP = 4-dimethylaminopyridine; DMF = N,N-dimethylformamide; DMSO =
dimethylsulfoxide; eq. = equivalent(s); EDC = N-[3-(dimethylamino)propyl]-N- ethylcarbodiimide; EDTA = ethylenediaminetetraacetic acid;ESI = electrospray ionization; Et = ethyl; EtOAc = ethyl acetate; EtOH = ethanol; FBS = Fetal Bovine Serum; h, hr = hour; HATU = N- t(dimethylamino)- 1 H- 1 ,2,3-triazolo[4,5 -b]pyridin- 1 -ylmethylene] -N-methylmethanaminium hexafluorophosphate N-oxide; HOAc = acetic acid; HOAt = 3H-[l,2,3]-triazolo[4,5-b]pyridin-3- ol; HOBt = lH-benzotriazol-l-ol; HPLC = High pressure liquid chromatography; HTRF = homogenous time resolved fluorescence; IP A, i-PrOH = isopropanol; iPr = isopropyl; LAH = Lithium aluminum hydride; LCMS - liquid chromatography - mass spectroscopy; LHMDS = lithium bis(trimethylsilyl)amide; Me - methyl; MeOH = methanol; min, min. = minute; μΨ - microwave; NMP - N-methylpyrrolidinone; N R = nuclear magnetic resonance; OMs, mesyl = methanesulfonyl; Oxone, OXONE = potassium peroxymonosulfate; PBS - phosphate buffered saline;Pd2dba3 = tra(dibenzylidineacetone)dipalladium; Pd/C = palladium on activated carbon; Ph = phenyl; Pr = propyl; Py - pyridyl; RT, rt = room temperature; sat. = saturated; TBAF = tetrabutylammonium fluoride; TBAI = tetrabutylammonium iodide; TFA - trifiuoroacetic acid; THF = tetrahydrofuran; TLC = thin layer chromatography; prep TLC = preparative thin layer chromatography; Tosyl = toluenesulfonyl; triflate, OTf = trifluoromethanesulfonate; triflic = trifluoromethanesulfonic; Xantphos = 4,5-bis(diphenylphosphino)-9,9-dimethyIxanthene.
Pyridine aldehydes may be obtained commercially, are known in the literature, and may be prepared by a variety of methods by those skilled in the art. One such method, shown in Scheme 1, involves reaction of ketone 1 with a Grignard reagent in a solvent such as
tetrahydrofuran at low temperature to give alcohol 2. Heating of 2 in the presence of a catalyst such as Pd(OAc)2, a ligand such as Xantphos, carbon monoxide, and a base such as triethylamine in a solvent such as methanol may then provide pyridine ester 3. Exposure of ester 3 to a reducing agent such as diisobutylaluminum hydride in a mixed solvent system such as toluene and dichloromethane at low temperature affords pyridine aldehyde 4.
Scheme 1
Figure imgf000026_0001
Where RY = CF3, such pyridine aldehydes may be prepared by a variety of methods by those skilled in the art. One such method, outlined in Scheme 2, involves treatment of ketone 5 with (trifiuoromethyl)trimethylsilane and tetrabutylammonium fluoride in a solvent such as tetrahydrofuran at room temperature to provide alcohol 6. Alcohol 6 may then be converted to aldehyde 8 by the same method described in Scheme 1 for the conversion of alcohol 2 to aldehyde 4.
Scheme 2
Figure imgf000027_0001
Heteroaryl aldehydes such as napthyridine aldehydes may be prepared by a variety of methods by those skilled in the art. One method for napthyridine synthesis is shown in Scheme 3, and involves ozonolysis of known napthyridine 9 {Chem. Pharm. Bull. 1986, 34, 2018 - 2023) in a mixed solvent system such as dichloromethane and methanol to provide napthyridine aldehyde 10.
Scheme 3
Figure imgf000027_0002
Pyridine carboxylic acids may be obtained commercially, are known in the literature, and may be prepared by a variety of methods by those skilled in the art. One such method, outlined in Scheme 4, involves treatment of known ester 11 {Montash. Chem. 1995, 126, 805 - 809) with a base such as aqueous sodium hydroxide in a solvent such as methanol at room temperature to provide carboxylic acid 12.
Scheme 4
Figure imgf000027_0003
11 12
2-Heteroaryl benzimidazoles may be prepared by a variety of methods by those skilled in the art. One such method, shown in Scheme 5, involves heating of fluoronitrobenzene 13 in the presence of an amine, a base such as K2CO3., and an additive such as KF to afford nitroaniline 14. Exposure of 14 to a catalyst such as Pd/C under an atmosphere of hydrogen in a solvent such as methanol effects reduction to give diamine 15. Diamine 15 may then be condensed with a heteroaryl aldehyde 16 in the presence of OXONE® in a mixed solvent system such as DMF and ¾0 at room temperature to yield 2-heteroaryl benzimidazole 17. Alternatively, diamine 15 may be condensed with 16 in the presence of Na2S205 in a solvent such as DMF at elevated temperature to provide 17. The heteroaryl aldehydes 16 employed in these reactions may be obtained commercially, or may synthesized according to procedures outlined in Schemes 1 - 3
Scheme 5
Figure imgf000028_0001
An alternative method for the synthesis of 2-heteroaryl benzimidazoles is outlined in Scheme 6. In this approach, diamine 15 may be coupled to a heteroaryl carboxylic acid 18 using standard methods for amide bond formation. For example, 15 and 18 may be coupled in the presence of N- [3 - (dimethylamino)propyl] -N-ethylcarbodiimide (EDC), 1 H-benzotriazoI - 1 -ol (HOBt), and a base such as diisopropylethylamine in a solvent such as dichloromethane at room temperature to afford amide 19. Alternatively, 15 and 18 may be coupled in the presence of N- [(dimethylamino)-lH-l,253-triazolo[4,5-b]pyridin-l-yImethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU), 3H-[l,2,3]-triazolo[4,5-b]pyridin-3-ol (HOAt), and a base such as diisopropylethylamine in a solvent such as dichloromethane to provide amide 19. Amide 19 may then be cyclized to benzimidazole 17 by heating in the presence of an acid such as acetic acid. Scheme 6
Figure imgf000029_0001
HATU, HOAt, DIEA
Figure imgf000029_0002
17
Once synthesized, 2-heteroaryl benzimidazoles may undergo a variety of further modifications. As shown in Scheme 7, fluorobenzimidazoles such as 20 may be heated in the presence of a metal alkoxide in a solvent such as DMSO to afford alkoxy benzimidazoles such as 21.
Scheme 7
Figure imgf000029_0003
20 21
2-Heteroaryl benzimidazoles such as 22 may also undergo modifications such as those outlined in Scheme 8. Treatment of 22 with a base such as sodium hydride and an alkyl iodide R5-I in a solvent such as tetrahydrofuran may provide alkylated product 23.
Scheme 8
Figure imgf000029_0004
In yet another route, compounds of general Formula la can be synthesized according to Scheme 9. Bisani ne 15 was treated with carbonyldiimidazole to give benzimidazolone 24 which was then converted to 2-bromobenzimidazole 25 by heating with oxyphosphorus bromide. A Suzuki coupling between 25 and boronic ester 26 gives desired compound 17. Scheme 9
Figure imgf000030_0001
The desired boronic ester 26 can be synthesized according to Scheme 10. Lithiation of 3- bromo-5-fluoropyridine with LDA followed by methylation gives intermediate 28 which was then converted to corresponding boronic ester 26 by a standard palladium chemistry.
Figure imgf000030_0002
As will be known to those skilled in the art, in all schemes, the products of Formula la and all synthetic intermediates may be purified from unwanted side products, reagents and solvents by recrystallization, trituration, preparative thin layer chromatography, flash
chromatography on silica gel as described by W. C. Still et al, J. Org. Chem. 1978, 43, 2923, or reverse-phase HPLC. Compounds purified by HPLC may be isolated as the corresponding salt.
Additionally, in some instances the final compounds of Formula la and synthetic intermediates may be comprised of a mixture of cis and trans isomers, enantiomers or diastereomers. As will be known to those skilled in the art, such cis and trans isomers, enantiomers and diastereomers may be separated by various methods including crystallization, chromatography using a homochiral stationary phase and, in the case of cis/trans isomers and diastereomers, normal-phase and reverse-phase chromatography.
Chemical reactions were monitored by LCMS, and the purity and identity of the reaction products were assayed by LCMS (electrospray ionization) and NMR. LCMS spectra were recorded on an Agilent 1100 series instrument equipped with an Xterra MS CI 8 column (3.5 μΜ, 3.0 x 50 mm i.d.) and UV detector. iH NMR spectra were recorded on a Varian 500 MHz spectrometer, and are internally referenced to residual protio solvent signals. Data for iH NMR are reported with chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br s = broad singlet, br m = broad multiplet), coupling constant (Hz), and integration. Unless otherwise noted, all LCMS ions listed are [M + H]. All temperatures are degrees Celsius unless otherwise noted.
Intermediates and final compounds having a chiral carbon can be prepared as racemates, or chiral intermediates can be resolved and the enantiomers used separately to synthesize enantiomeric downstream intermediates and final products. In the instances where chiral compounds were separated by chiral HPLC purification, the term "enantiomer A" refers to the first eluting enantiomer and the term "enantiomer B" refers to the second eluting enantiomer under the specified conditions. As a result, the chemical nomenclature may indicate that an S and/or an R enantiomer was obtained, but the absolute stereochemistry of the separate enantiomers A and/or B was not determined.
Preparative HPLC was performed using a SunFire Prep CI 8 OBD column (5 μΜ, 19 x 100 mm i.d.) on Gilson instruments equipped with UV detectors.
Flash chromatography on silica gel was performed using pre-packed silica gel columns on Biotage Horizon or Biotage SP-1 instruments equipped with UV detectors.
The following examples are provided so that the invention might be more fully understood. They should not be construed as forming the only genus that is considered as the invention nor limiting the invention in any way.
Example 1
Figure imgf000031_0001
2,4-Difluoronitrobenzene (1.00 g, 6.29 mmol), potassium fluoride (0.365 g, 6.29 mmol), potassium carbonate (0.869 g, 6.29 mmol), and 40% methylamine in water (0.58 mL, 7.5 mmol) were added to a vial and heated in a microwave at 90 °C for 10 min. The reaction was then diluted with dichloromethane, washed with water and brine, dried over magnesium sulfate, and concentrated to provide the title compound: 1H NMR (500 MHz, CDC13) δ 8.22 (dd> J= 9.4, 6.1 Hz, 1 H)s 8.16 (br s, 1 H), 6.48 (dd, J= 11.5, 2.6 Hz, 1 H), 6.40 - 6.36 (m, 1 H), 3.01 (d, J= 5.0 Hz, 3 H).
Figure imgf000032_0001
To the title compound from Example 1 Step A (0.267 g, 1.57 mmol) were added palladium on carbon (0.027 g) and methanol (7.85 mL). The resulting mixture was stirred under an atmosphere of hydrgoen at room temperature overnight. The mixture was then filtered through CELITE® using dichloromethane, and the filtrate was concentrated. Purification by flash chromatography (50% ethyl acetate in hexanes, then 100% ethyl acetate) provided the title compound: 1H NMR (500 MHz, CDC13) δ 6.61 (dd, J = 8.2, 5.6 Hz, 1 H), 6.36 - 6.30 (m, 2 H), 3.22 (br s, 3 H), 2.84 (s, 3 H).
Step C. 6-Fluo -2-f 5-methoxypyridin-3-yI)- 1 -methyl- lH-benzimidazole
Figure imgf000032_0002
To a solution of 5-methoxypyridine-3-carbaldehyde (0.052 g, 0.378 mmol) in DMF (1.89 mL) were added the title compound from Example 1 Step B (0.053 g, 0.38 mmol) and Na2S205 (0.288 g. 1.51 mmol). The resulting mixture was stirred at 120 °C overnight, then cooled to room temperature and diluted with water and ethyl acetate. The organic layer was separated, washed with water and brine, dried over magnesium sulfate, filtered, and concentrated.
Purification by flash chromatography on silica gel (50% ethyl acetate in hexanes, then 100% ethyl acetate) provided the title compound: LCMS m/z 258.17 [M + H]+; !H NMR (500 MHz, CDC13) δ 8.56 (d, J= 1.6 Hz, 1 H), 8.46 (d, J= 2.9 Hz, 1 H), 7.66 (dd, J - 8.6, 4.8 Hz, 1 H), 7.65 (t, J = 2.1, 2.1 Hz, 1H), 7.12 - 7.06 (m, 2 H), 3.95 (s, 3 H), 3.88 (s, 3 H). The compounds in Table 1 were all prepared using chemistry described in Example 1.
Table 1
Figure imgf000033_0003
Example 5
Figure imgf000033_0001
6-Methoxy-2-f 5-methoxypyridm-3-yl)- 1 -methyl- 1 H-benzimidazole
To a solution of the title compound from Example 1 Step C (0.010 g, 0.038 mmol) in dimethylsulfoxide (0.2 mL) was added a solution of sodium methoxide in methanol (25 wt %, 0.018 mL' 0.078 mmol). The reaction was heated at 165 °C for 1 hour, then cooled to room temperature and purified by flash chromatography (50% ethyl acetate in hexanes, then 100% ethyl acetate) to provide the title compound: LCMS m/z 270.25 [M + Η]+; Ή NMR (500 MHz, CDC13) δ 8.55 (d, - 1.5 Hz, 1 H), 8.43.(d, J= 2.7 Hz, 1 H), 7.72 (d5 J= 8.8 Hz, 1 H), 7.66 (dd, J = 2.5, 1.8 Hz, 1 H), 6.98 (dd, J= 8.8, 2.3 Hz, 1 H), 6.86 (d, J= 2.3 Hz, 1 H), 3.95 (s, 3 H), 3.92 (s, 3 H), 3.88 (s, 3 H).
Examples 6 and 7: racemate and enantiomers
Figure imgf000033_0002
Step A. 2-( 5-Bromopyridin-3-yl)- 1,1,1 -trifluoropropan-2-ol
Figure imgf000034_0001
To a solution of 3-acetyl-5-bromopyridine (0.20 g, 1.0 mmol) in tetrahydrofuran (3.3 mL) were added a solution of trimethyl(trifluoromethyl)silane in tetrahydrofuran (0.5 M, 4.0 mL, 2.0 mmol) and a solution of tetrabutylammonium fluoride in tetrahydrofuran (1.0 M, 0.1 mL, 0.1 mmol). The resulting reaction mixture was stirred at room temperature for 1 h, then diluted with water and dichioromethane. The organic layer was separated, dried over magnesium sulfate, filtered and concentrated. Purification by flash chromatography on silica gel (0 to 6%
dichioromethane in acetone) provided the title compound: LCMS m/z 271.75 [M + H]+; 1H NMR (500 MHz, CDC13) δ 8.71 (s, 1 H), 8.68 (s, 1 H), 8.1 l(s, 1 H), 3.12 (br s, 1 H), 1.82 (s, 3
H).
Step B. Methyl - Ll,l-trifluoro-2-hvdroxypropan-2-yl)pyridine-3-carboxylate
Figure imgf000034_0002
A mixture of the title compound from Step A (0.170 g, 0.628 mmol), Pd(OAc)2 (2.8 mg, 0.01 mmol), Xantphos (0.015 g, 0.025 mmol), methanol (0.254 mL, 6.28 mmol), and triethylamine (8.96 mL, 1.25 mmol) was stirred under an atmosphere of carbon monoxide at 70 °C overnight. The reaction mixture was cooled to room temperature, diluted with ethyl acetate, filtered through Celite using ethyl acetate and concentrated under reduced pressure. Purification by column chromatography on silica gel (30% ethyl acetate in hexanes) provided the title compound: LCMS m/z 250.02 [M + H]+ ; 1H NMR (500 MHz, CDC13) 6 9.22 (s, 1 H), 9.00 (s, 1 H), 8.52 (s, 1 H), 3.98 (s, 3 H), 2.94 (br s, 1 H), 1.86 (s, 3 H).
Step C. 5 -(1,1,1 -Trifluoro-2-hydroxypropan-2-yl pyridine-3-carbaldehyde
Figure imgf000034_0003
To a cooled (-78 °C) solution of the title compound from Step B (0.14 g, 0.56 mmol) in toluene (3.23 mL) and dichioromethane (3.23 mL) was added a solution of di-isobutyl aluminum hydride in toluene (1.0 M, 1.29 mL, 1.29 mmol). After 10 min, the reaction was quenched with water (1 mL), allowed to warm to room temperature, and dried over magnesium sulfate.
Concentration of the filtrate under reduced pressure provided the title compound: !H NMR (500 MHz, CDCI3) 5 10.16 (s, 1 H), 9.08 (s, 1 H), 9.07 (s, 1 H), 8.41 (s, 1 H), 3.30 (br s, 1 H), 1.88 (s, 3 H).
Step D. N-cvclopropyl- -fluoro-2-nitroaniline
Figure imgf000035_0001
2,4-Difluoronitrobenzene (1.00 g, 6.29 mmol), potassium fluoride (0.365 g, 6,29 mmol), potassium carbonate (0.869 g, 6.29 mmol), and cyclopropylamine (0.52 mL, 7.54 mmol) were added to a vial and heated in a microwave at 90 °C for 10 min. The reaction was then diluted with dichloromethane, washed with water and brine, dried over magnesium sulfate, and concentrated to provide the title compound; LCMS m/z 196.95 [M + H]+; ]H NMR (500 MHz, CDCI3) 5 8.20 (dd, J= 9.5, 6.0 Hz, 2 H), 6,95 (dd, J= 11.4, 2.6 Hz, 1 H), 6.43 - 6.39 (m, 1 H), 2.58 - 2.53 (m, 1 H), 0.96 - 0.92 (m, 2 H), 0.69 - 0.66 (m, 2 H).
Step E. N2~cvclopropyl-4-fluorobenzene- 2-diamine
Figure imgf000035_0002
To the title compound from Step D (1.23 g, 6.27 mmol) were added 10% palladium on carbon (0.123 g, 1.16 mmol) and methanol (31.3 mL). The resulting mixture was stirred under an atmosphere of hydrogen at room temperature overnight. The reaction mixture was then filtered through CELITE® using dichloromethane and concentrated under reduced pressure. Purification by flash chromatography on silica gel (0 to 30% ethyl acetate in hexanes) provided the title compound: Ή NMR (500 MHz, CDC13) δ 6.76 (dd, J = 10.9, 2.8 Hz, 1 H), 6.60 (dd, J= 8.4, 5.6 Hz, 1 H), 6.34 (ddd, J= 11.2, 8.4, 2.8 Hz, 1 H), 4.17 (br s, 1 H), 3.01 (br s, 2 H), 2.42 - 2.38 (m, 1 H), 0.77 ~~ 0.72 (m, 2 H), 0.54 - 0.51 (m, 2 H).
Step F. 2- [5-( 1 -cyclopropyl-6-fluoro- 1 H-benzimidazol-2-vDpyridin-3-yl1 -1,1.1 -trifluoropropan- 2-ol
Figure imgf000035_0003
To a solution of the title compound from Step E (0.058 g, 0.35 mmol) in DMF (1.68 mL) and water (0.06 mL) were added the title compound from Step C (0.076 g, 0.35 mmol) and OXONE® (0.139 g, 0.226 mmol). The resulting mixture was stirred at room temperature for lhour, then diluted with ethyl acetate and water. Solid potassium carbonate was added until the aqueous layer was basic (pH ~ 9). Ethyl acetate was then added, and the organic layer was separated, washed with water and brine, dried over magnesium sulfate, filtered, and concentrated. Purification by flash column chromatography on silica gel (10% acetone in dichloromethane, then 30% acetone in dichloromethane) provided the title compound as a racemic mixture. That racemic mixture was then separated into two enantiomers by HPLC (ChiraiCel AS column, 25% MeOH (0.2% DEA)/C02, 70 mL/min, 100 bar, 35 °C). Data for Example 6 (Enantiomer A):
LCMS mJz 365.99 [M + H]+; 1H NMR (500 MHz, CDC13) δ 9.14 (s, 1 H), 8.85 (s, 1 H), 8.59 (s, 1 H), 7.76 (dd, J= 8.8, 4.8 Hz, 1 H), 7.30 (dd, J= 8.5, 2.1 Hz, 1 H), 7.11 - 7.07 (m, 1 H), 4.85 (br s, 1 H), 3.55 - 3.53 (m, 1 H), 1.79 (s, 3 H), 1.22 - 1.12 ( m, 2 H), 0.80 - 0.72 (m, 2 H). Data for Example 7 (Enantiomer B): LCMS m/z 365.97 [M + H]+; Ή NMR (500 MHz, CDC13) δ 9.16 (s, 1 H), 8.88 (s, 1 H), 8.57 (s, 1 H), 7.76 (dd, J- 8.8, 4.8 Hz, 1 H), 7.30 (dd, J- 8.5, 2.0 Hz, 1 H), 7.10 -7.05 (m, 1 H), 3.91 (br s, 1 H), 3.56 - 3.55 (m, 1 H), 1.84 (s, 3 H), 1.18 - 1.15 ( m, 2 H), 0.80 - 0.71 (m, 2 H).
Example 8
Figure imgf000036_0001
Step A. L6-naphthyridine-8-carbaldehvde
Figure imgf000036_0002
A solution of ethyl (2Z)-3-(l,6-naphthyridin~8-yl)prop-2-enoate (30 g) in
dichloromethane (500 mL) and methanol (125 mL) was cooled to -78 °C and reacted with ozone until the color of the reaction mixture became light blue (-3 h). The reaction was purged with nitrogen to remove the residual ozone. Methyl sulfide (60 mL) was then added, and the reaction was allowed to warm to room temperature and then concentrated. The resulting residue was dissolved in dichloromethane (300 mL), washed with water (100 mL) and saturated aqueous sodium bicarbonate (100 mL) and dried over sodium sulfate. The solvent was removed and product was slurried in heptane/ethyl acetate mixture (5:1). The solid was then filtered and dried under reduced pressure to provide the title compound: LCMS m/z 158.97 [M + H]+; 5H NMR (500 MHz, CDC13) δ 11.39 (s, 1 B), 9.09 (s, 1 H), 9.13 (ra, 1 H), 9.07 (s, 1 H), 8.43 (d, J = 8.3 Hz, 1 H), 7.78 (dd, J= 8.7, 4.8 Hzs 1 H), 7.63 (dd, J- 8.2, 4.2 Hz, 1 H), 7.34 (dd, J= 8.7, 2.2 Hz, 1 H), 7.07 (m, 1 H), 3.55 - 3.53 (m, 1 H), 0.62 - 0.61 (m, 4 H).
Figure imgf000037_0001
To a solution of N2-cyclopropyl-4~fluorobenzene-l,2-diamine (0.080 g, 0.48 mmol) in DMF (1.17 mL) and water (0.04 mL) were added the title compound from Example 8 Step A (0.084 g5 0.53 mmol) and OXONE® (0.192 g, 0.313 mmol). The resulting mixture was stirred at room temperature for 1 hour, then diluted with ethyl acetate and water. Solid potassium carbonate was added until the aqueous layer was basic (pH ~ 9). Ethyl acetate was added, and the organic layer was separated, washed with water and brine, dried over magnesium sulfate, filtered and concentrated. Purification by flash chromatography on silica gel (50% ethyl acetate in hexanes, then 100 % ethyl acetate) provided the title compound: LCMS m/z 304.99 [M + H]+; 1H NMR (500 MHz, CDC13) δ 9.09 (s, 1 H), 9.13 (m, 1 H), 9.07 (s, 1 H), 8.43 (d, J= 8.3 Hz, 1 H), 7.78 (dd, J= 8.7, 4.8 Hz, 1 H), 7.63 (dd, J= 8.2, 4.2 Hz, 1 H), 7.34 (dd, J= 8.7, 2.2 Hz, 1 H), 7.07 (m, 1 H), 3.55 - 3.53 (m, 1 H), 0.62 - 0.61 (m, 4 H).
The compounds in Table 2 were all prepared using the synthetic procedures described in Examples 6 - 8.
Table 2
Figure imgf000037_0002
Figure imgf000038_0001
benzimidazole
Figure imgf000039_0001
Figure imgf000040_0001
Example 37
Figure imgf000040_0002
To a cooled (-78 °C ) solution of 3-acetyl-5-bromo pyridine (1.98 g, 9.90 mmol) in tetrahydrofuran (33 mL) was added dropwise a solution of methyl magnesium bromide in diethyl ether (3.0 M, 6.60 mL, 19.8 mmol). The reaction was warmed to room temperature, and the resulting mixture was stirred at room temperature overnight. The reaction was then quenched with saturated aqueous ammonium chloride solution and extracted with diethyl ether. The organic extracts were combined, washed with brine, dried over magnesium sulfate, filtered and concentrated. Purification by flash chromatography on silica gel (0 - 60% ethyl acetate in hexanes) provided the title compound: LCMS m/z 217.83 [M + Hf; Ή NMR (500 MHz, CDC13) δ 8.61 (s, 1 H), 8.53 (s, 1 H), 8.01 (d, J= 1.9 Hz, 1 H), 2.38 (br s, 1 H), 1.61 (6 H).
Step B. Methyl 5-(2-hydroxypropan-2-yl)pyridine-3-carboxylate
Figure imgf000041_0001
A mixture of the title compound from Step A (1.99 g, 9.21 mmol), palladium acetate (0.041 g, 0.041 mmol), Xantphos (0.213 g, 0.368 mmol), methanol (3.73 mL, 92.1 mmol), and triethylamine (18.33 mL, 132.0 mmol) was stirred under an atmosphere of carbon monoxide at 70 °C overnight. The reaction was then cooled to room temperature, diluted with ethyl acetate, filtered through CELITE® and concentrated under reduced pressure. Purification by flash chromatography on silica gel (30% ethyl acetate in hexanes) provided the title compound: LCMS m/z 195.99 [M + H ; 1H NMR (500 MHz, CDC13) δ 9.09 (d, J= 1.8 Hz, 1 H), 8.92 (d, J= 2.2 Hz, 1 1-I), 8.41 (t, J= 2.0 Hz, 1 H), 3.96 (s, 3 H), 2.27 (br s, 1 H), 1.64 (s, 6 H).
Figure imgf000041_0002
To a cooled (-78 °C) solution of the title compound from Step B (0.50 g, 2.6 mmol) in toluene (15 mL) and dichloromethane (15 mL) was added a solution of diisobutyl aluminum hydride in toluene (1.0 M, 6.0 mL, 6.0 mmol). After 10 mm, the reaction was quenched with water (5 mL), allowed to warm to room temperature and dried with magnesium sulfate.
Concentration of the filtrate under reduced pressure provided the title compound: ]H NMR (500
MHz, CDCI3) δ 10.10 (s, 1 H), 8.99 (d, J= 2.3 Hz, 1 H), 8.93 (s, 1 H), 8.30 (s, 1 H), 2.22 (br s, 1 H), 1.67 (s, 6 H).
Figure imgf000041_0003
To a solution of N -cyclopropyl-4-fluorobenzene-l,2-diamine (0.479 g, 2.88 mmol) in DMF (6.97 mL) and water (0.23 mL) were added the title compound from Step C (0.302 g, 1.83 mmol) and OXONE® (0.729 g, 1.19 mmol). The resulting mixture was stirred at room temperature for 1 hour, then diluted with ethyl acetate and water. Solid potassium carbonate was added until the aqueous layer was basic (pH ~ 9). Ethyl acetate was added, and the organic layer was separated, washed with water and brine, dried over magnesium sulfate, filtered and concentrated. Purification by flash chromatography on silica gel (100% ethyl acetate) provided a product that was further purified by reverse phase HPLC (CI 8 OBD column, 20 to 90% acetonitrile/water, both 0.1% v/v trifluoroacetitic acid). Fractions containing the desired product were combined, washed sequentially with aqueous 1 N sodium hydroxide solution and brine, dried over magnesium sulfate, filtered and concentrated to provide the title compound: LCMS m/z 312.01 [M + H]+; 1H NMR (500 MHz, CDC13) δ 9.09 (d, J= 1.7 Hz, 1 H), 9.85 (d, J= 1. Hz, 1 H), 8.40 (s, 1 H), 7.73 (dd, J= 8.8, .8 Hz, 1 H), 7.29 (dd, J= 8.7, 2.2 Hz, 1 H), 7.08 - 7.04 (m, 1 H), 3.57 - 3.55 (m, 1 H), 2.21 (br s, 1 H), 1.69 (s, 6 H), 1.20 - 1.16 ( m, 2 H), 0.79 0.75 (m, 2 H).
Example 38
Figure imgf000042_0001
Step A. N-cvclopropyl- -difluoro-2-mtroaniline
Figure imgf000042_0002
2,4,5-Trifluoronitrobenzene (2.00 g, 11.3 mmol), potassium fluoride (0.656 g, 11.3 mmol), potassium carbonate (1.561 g, 11.29 mmol), and cyclopropylamine (0.93 ml, 13.55 mmol) were added to a vial and heated in a microwave at 90 °C for 10 min. The reaction was then diluted with dichloromethane, washed with water and brine, dried over magnesium sulfate, and concentrated under reduced pressure. Purification by flash chromatography on silica gel (0 -
15% ethyl acetate in hexanes) provided the title compound: Ή NMR (500 MHz, CDC13) δ 8.04 (dd, J- 10.4, 8.5 Hz, 1 H), 7.09 (dd, J- 12.6, 7.0 Hz, 1 H), 2.55 - 2.54 (m, 1 H), 0.97 - 0.93 (m, 2 H), 0.69 - 0.66 (m, 2 H). Step B. N-cvclopropyl-4 -difluorobenzene-1.2-diamine
Figure imgf000043_0001
To the title compound from Step A (1.22 g, 5.69 mmol) were added 10% palladium on carbon (0.122 g, 1.15 mmol) and methanol (28.5 mL). The resulting mixture was stirred under an atmosphere of hydrogen at room temperature overnight. The mixture was then filtered through CELITE® using dichloromethane, and the filtrate was concentrated. Purification by flash chromatography on silica gel (0 - 30% ethyl acetate in hexanes) provided the title compound: Ή NMR (500 MHz, CDC13) δ 6.83 (dd, J= 12.4, 7.9 Hz, 1 H), 6.51 (dd, J= 11.3, 7.8 Hz, 1 H), 3.82 (br s, 1 H), 3.15 (br s, 2 H), 2.40 ~ 2.37 (m, 1 H), 0.77 - 0.73 (m, 2 H), 0.52 - 0.50 ( m, 2 H).
Figure imgf000043_0002
To a solution of methyl 5-(2-hydroxypropan-2-yl)pyridine-3-carboxylate (0.179 g, 0.915 mmol) in methanol (4.57 mL) was added 1 N aqueous sodium hydroxide solution (2.74 mL, 2.74 mmol). The reaction was stirred at room temperature for 30 min and then concentrated under reduced pressure. The resulting residue was acidified via the addition of 1 N aqueous hydrogen chloride solution until the pH was ~2. Ethyl acetate was then added, and and the extracted organics were dried over magnesium sulfate, filtered and concentrated to provide the title compound: LCMS m/z 182.01 [M + H]+; 1H NMR (500 MHz, CD3OD) δ 8.91 (s, 1 H), 8.79 (d, J- 1.8 Hz, 1 H), 8.43 (d, J= 1.9 Hz, 1 H), 1.51 (s, 6 H).
Step D. N-[2-(cyclopropylamino -4,5-difluorophenyl]-5-(2-hydroxypropan-2-yl)pyridine-3- carboxamide
Figure imgf000043_0003
To a solution of the title compound from Step B (0.074 g, 0.40 mmol) in dichloromethane (2.1 mL) were added the title compound from Step C.(0.080 g, 0.44 mmol), HATU (0.168 g, 0.442 mmol), HO At (0.060 g, 0.44 mmol) and diisopropylethylamine (0.285 mL, 1.61 mmol). The reaction was stirred at room temperature for 1 hour, then diluted with dichloromethane, washed sequentially with water and brine, dried over magnesium sulfate, filtered and
concentrated under reduced pressure. Purification by flash chromatography on silica gel (50 - 100% ethyl acetate in hexanes) provided the title compound: LCMS m/z 330.04 [M + H]+; JH NMR (500 MHz, CDC13) δ 8.96 (s, 1 H), 8.90 (d, J- 7.2 Hz, 1 H), 8.35 (s, 1 H), 7.66 (br s, 1 H), 7.31 (d, J= 10.7 Hz, 1 H), 7.04 - 7.00 (m, 1 H), 4.31 (br s, 1 H), 2.80 (br s, 1 H), 2.44 (t, J= 6.1, 3.1 Hz, 1 H), 1.66 (s, 6 H), 0.78 - 0.77 (m, 2 H), 0.53 - 0.51 (m, 2 H).
Figure imgf000044_0001
A solution of the title compound from Step D (0.070 g, 0.20 mmol) in acetic acid (1.0 mL) was heated at 100 °C for 1 hour, and then cooled to room temperature. The resulting mixture was concentrated under reduced pressure, diluted with ethyl acetate, washed sequentially with aqueous 1 N sodium hydroxide solution and brine, dried over magnesium sulfate, filtered and concentrated. Purification by flash chromatography on silica gel (50 - 80% ethyl acetated in hexanes) provided the title compound: LCMS m/z 330.04 [M + H]+; 1H NMR (500MHz, CDC13) δ 9.09 (s, 1 H), 8.87 (s, 1 H), 8.44 (d, J = 1.8 Hz, 1 H), 7.58 (dd, J= 10.3, 7.3 Hz, 1 H), 7.40 (dd, J= 9.7, 7.0 Hz, 1 H), 3.59 - 3.58 (m, 1 H), 2.89 (br s, 1 H), 1.69 (s, 6 H), 1.22 - 1.19 ( m, 2 H), 0.79 - 0.78 (m, 2 H).
Example 39
1 -cyclopropyl-5 ,6-difluoro-2-[5 -(2-methoxypropan-2-yl)pyridin-3 -yl] - 1 H-benzimidazole
Figure imgf000044_0002
To a cooled (0 °C ) solution of 2-[5-(l-Cyclopropyl~5,6-difluoro-lH-benzimidazoi-2- yl)pyridin-3-yl]propan-2-ol (from Example 38 Step E) (0.086 g, 0.26 mmol) in tetrahydrofuran (1.3 mL) was added sodium hydride (60% dispersion in mineral oil, 0.026 g, 0.65 mmol). After 1 hour, iodomethane (0.024 mL, 0.389 mmol) was added. The reaction was then warmed to room temperature and stirred overnight. The reaction mixture was diluted with ethyl acetate, washed with water and brine, dried over magnesium sulfate, filtered and concentrated.
Purification by flash chromatography on silica gel (30 - 60% ethyl acetate in hexanes) provided the title compound: LCMS m/z 344.03 [M + H]+; 1H NMR (500 MHz, CDC13) δ 9.09 (d, J= 1.9
H, 1 H), 8.79 (d, J = 2.0 Hz, 1 H), 8.29 (t, J- 2.0, 2.0 Hz, 1 H), 7.58 (dd, J = 10.3, 7.3 Hz, 1 H), 7.40 (dd, J = 9.7, 7.1 Hz, 1 H), 3.59 - 3.57 (m, 1 H), 3.16 (s, 3 H), 1.63 (s, 3 H), 1.60 (s, 3 H),
I .20 - 1.17 (m, 2 H)5 0.79 ~ 0.76 (m, 2 H). Example 40
Figure imgf000045_0001
Step A. 5-acetylpyridine-3-carboxylic acid
Figure imgf000045_0002
To a solution of methyl 5-acetylpyridine-3-carboxylate (0.15 g, 0.84 mmol) in methanol (2.10 mL) was added aqueous IN sodium hydroxide solution (2.51 mL, 2.51 mmol). The resulting mixture was stirred at room temperature for 1 hour, then concentrated under reduced pressure to give a residue that was acidified with aqueous 1 N hydrogen chloride solution and extracted with ethyl acetate. The organic extracts were combined, dried over magnesium sulfate, filtered and concentrated to provide the title compound: 1H NMR (500 MHz, CDC13) δ 9.43 (d, J = 1.4 Hz, 1 H), 9.36 (s, 1 H), 8.84 (s, 1 H), 2.70 (s, 3 H).
Step B. 5-acetyl-N-|'2-(cvclopropylamino -4-fluorophenvllpyridine-3-carboxamide
Figure imgf000045_0003
To a solution of N2-cyclopropyl-4-fluorobenzene-l,2-diamine (0.082 g, 0.495 mmol) in dichloromethane were added the title compound from Step A (0.090 g, 0.545 mmol), HATU (0.207 g, 0.545 mmol), HOAt (0.074 g, 0.545 mmol), and diisopropylethylamine (0.35 mL, 1.98 mmol). The reaction was stirred at room temperature for 1 hour, then diluted with dichloromethane, washed with water and brine, dried over magnesium sulfate, filtered and concentrated. Purification by flash chromatography on silica gel (30 - 60% ethyl acetate in hexanes) provided the title compound: LCMS mlz 314.14 [M + H]+; 1H NMR (500 MHz, CDC13) δ 9.33 (s, 1 H), 9.29 (s, 1 H), 8.72 (s, 1 H), 8.02 (br s, 1 H), 7.19 - 7.16 (m, 1 H), 6.91 (d, J= 10.5 Hz, 1 H), 6.50 - 6.47 (m, 1 H), 4.64 (br s, 1 H), 2.69 (s, 3 H), 2.45 - 2.44 (m, 1 H), 0.78 - 0.77 (m, 2 H), 0.52 - 0.51 (m, 2 H).
Step C. 1 - [ 5 -( 1 -cycloprop -6-fluoro- 1 H-benzimidazol-2 -yl)pyridin-3 -yl] ethanone
Figure imgf000046_0001
A solution of the title compound from Step B (0.10 g, 0.32 mmol) in acetic acid (1.60 mL) was heated at 100 °C for 1 hour, then cooled to room temperature and concentrated under reduced pressure. The resulting residue was diluted with ethyl acetate, washed sequentially with aqueous 1 N sodium hydroxide solution and brine, dried over magnesium sulfate, filtered and concentrated. Purification by flash chromatography on silica gel (50 - 80% ethyl acetate in hexanes) provided the title compound: LCMS m/z 296.07 [M + Hf; lH NMR (500 MHz, CDC13) δ 9.41 (d, J= 1.9 Hz, 1 H), 9.26 (d, J= 1.9 Hz, 1 H), 8.22 (m, 1 H), 7.75 (dd, J= 8.8, 4.8 Hz, 1 H), 7.32 (dd, J= 8.6, 2.3 Hz, 1 H), 7.10 - 7.06 (m, 1 H), 3.65 - 3.61 (m, 1 H), 2.73 (s, 3 H), 1.26 - 1.20 (m, 2 H), 0.81 - 0.77 (m, 2 H).
Example 41
Figure imgf000046_0002
Step A. N-[2-(cvclopropylamino)-4-fluorophenyl]-5-fluoropyridine-3-carboxamide
Figure imgf000046_0003
2
To a solution of the title compound from N -cyclopropyl-4-fluorobenzene-l,2-diamine (0.065 g, 0.39 mmol) in dichloromethane (1.96 mL) were added 5-fluoropyridine-3-carboxylic acid (0.061 g, 0.43 mmol), EDC (0.082 g, 0.43 mmol) , HOBt (0.066 g, 0.43 mmol), and diisopropylethylamine (0.280 mL, 1.56 mmol). The reaction was stirred at room temperature overnight, then diluted with dichloromethane, washed sequentially with water and brine, dried over magnesium sulfate, filtered and concentrated. Purification by flash chromatography on silica gel (30 - 50% ethyl acetate in hexanes) provided the title compound: LCMS m/z 290.14 [M + H]+; 1H NMR (500 MHz, CDC13) δ 8.90 (s, 1 H), 8.66 (d, J= 2.0 Hz, 1 H), 7.97 (d, J- 8.3 Hz, 1 H), 7,48 (br s, 1 H), 7.19 (m, 1 H), 6.92 (d, J= 10.9 Hz, 1 H), 6.52 - 6.49 (m, 1 H), 4.50 ( br s, 1 H), 2.47 - 2.44 (m, 1 H), 0.81 ~~ 0.77 (m, 2 H), 0.54 - 0.51 (m, 2 H).
Step B. 1 -cyclopropyl~6-fluoro-2-( 5-fluoropyridin-3 -ylV 1 H-benzimidazole
Figure imgf000047_0001
A solution of the title compound from Step A (0.038 g, 0.131 mmol) in acetic acid (0.66 mL) was heated at 100 °C for 1 hour, then cooled to room temperature and concentrated under reduced pressure. The resulting residue was diluted with ethyl acetate, washed sequentially with aqueous 1 N sodium hydroxide solution and brine, dried over magnesium sulfate, filtered and concentrated. Purification by flash chromatography (30 - 50% ethyl acetate in hexanes) provided the title compound: LCMS m/z 272.16 [M + H]+; 1H NMR (500 MHz, CDC13) δ 9.06 (s, 1 H), 8.60 (d, J- 2.7 Hz, 1 H), 8.03 (m, 1 H), 7.73 (dd, J= 8.8, 4.8 Hz, 1 H)> 7.30 (dd, J= 8.6, 2.4 Hz, 1 H), 7.10 - 7.06 (m, 1 H), 3.59 - 3.55 (m, 1 H), 1.25 - 1.22 (m, 2 H), 0.83 - 0.80 (m, 2 H).
The compounds in Table 3 were prepared using the synthetic procedures described in Examples 37 - 41.
Table 3
Figure imgf000047_0002
Figure imgf000048_0001
The compounds in Table 4 were all prepared using chemistry described in Example 1. Table 4
Figure imgf000049_0001
Example 63
Step A. l-cvclopro
Figure imgf000050_0001
Carbonyldiimidazole (4.3g) was added to the solution of Nl-cyclopropyl-4,5- difluorobenzene- 1 ,2-diamine (3.2g) in THF (30ml). The mixture was stirred at rt for 20 hours, then diluted with ethyl acetate (200ml) and washed with hydrochloric acid (1M, 200ml). Organic layer dried over sodium sulphate, solvent removed to give expected product as a black solid (2.5g). 'H NMR (CD3OD)6: 7.20 (dd, 1H), 6.95 (dd, 1H), 2.86 (m, 1H), 1.11 (m, 2H), 0.94 (m, 2H).
Step B. 2-Bromo-l-cyclopropyl-5.6-difluorophenyl-lH-benzimidazole
Figure imgf000050_0002
To a stirring solution of l-cyclopropyl-5J6-difluoro-lH-benzo[d]imidazol-2(3H)-one (2.5 g) in Toluene (150 ml) was added phosphoryl tribromide (13.64 g). Reaction mixture was stirred under nitrogen at reflux overnight. Reaction cooled, diluted with DCM (150ml) and slowly added to stirring 40°C water. Mixture stirred for 30min, sodium carbonate added until pH 10. Mixture poured into separating funnel, organic layer washed with water, dried over sodium sulphate and solvent removed under reduced pressure to afford 800mg expected product. !H NMR (CDC13)5: 7.45 (dd, 1H), 7.30 (dd, 1H), 3.20 (m, 1H), 1.30 (m, 2H), 1.20 (in, 2H).
Step C. 3-bromo-5-fluoro-4-meth lpyridine
Figure imgf000050_0003
Diisopropylamine (136 mmol, 19.11 ml, 13.80 g) and THF (120 ml) were combined in a 3-necked flask under nitrogen and cooled to -78 °C. N-butyllithium (2.5M in hexane) (125 mmol, 50.0 ml) was added dropwise and the mixture stirred at -78 °C for 30 minutes. A solution of 3-bromo-5-fluoropyridine (1 4 mmol, 20 g) in THF (40 ml) was added dropwise and stirring continued at -78 °C for a further 30 minutes. lodomethane (136 mmol, 8.49 ml, 19.36 g) was added and the reaction mixture allowed to warm slowly to room temperature and stirred for 18 hours. The reaction was diluted with 1 : 1 saturated sodium bicarbonate solution / water (200ml) and extracted with EtOAc (600ml). Organics were washed with saturated sodium chloride solution (100ml) and dried over sodium sulphate. Solvent was evaporated under reduced pressure to afford crude product as a brown oil. Purification by silica chromatography eluting with 0% to 15% EtOAc / heptane afforded product 3~bromo-5-fluoro-4-methylpyridine (54.1 % yield) as a clear oil. EH NMR (CDC13)6: 8.49 (s, 1H), 8.31 (s, 1H), 2.37 (s, 3H).
Step D 3-fluoro-4-methyl-5-f4 A5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl) yridme
Figure imgf000051_0001
3-bromo-5-fluoro-4-methylpyridine (9.25 mmol, 2.93 g) bis(pinacolato)diboron (11.10 mmol, 2.82 g) l, -bis(diphenylphosphino)ferrocenedichloropalladium(II) (0.463 mmol, 0.335 g) and potassium acetate (18.50 mmol, 1.816 g) were combined in dioxane (37.0 mL) and heated to 80 °C for 24 hours, under nitrogen. The reaction was allowed to cool to room temperature, EtOAc (400ml) added and the mixture filtered through CELITE® and washed with 1 :1 saturated sodium bicarbonate solution / water (2 x 200ml) and brine (100ml). Organics were dried over sodium sulphate and solvent evaporated under reduced pressure to yield crude product as a brown oil. Purification by silica chromatography eluting with 25 to 50% EtOAc / heptane afforded 3-fluoro-4-methyl-5-(4J4,5,5-tetramethyl-l!3,2-dioxaborolan-2-yl)pyridine. 1H NMR (CDC13)5: 8.68 (s, IH), 8.39 (s, 1H), 2.48 (s, 3H), 1.38 (s, 12H).
Step E. l-cvclopropyl-5,6-difluoro-2-(5-fluoro-4-methylpyridin-3-yl)-lH-benzimidazole
Figure imgf000051_0002
2-bromo-l-cyclopropyl-5,6-difluoro-lH-benzo[d] imidazole (0.549 mmol, 150mg) 5- fluoro-4-methylpyridin-3-ylboronic acid (0.824 mmol, 128 mg) palladium(II)acetate (0.027 mmol, 6.17 mg) 2-dicyclohexylphosphino-2\6>-dimethoxybiphenyl (0.055 mmol, 22.55 mg) and potassium phosphate, tribasic (1.099 mmol, 233 mg) were combined in a microwave vial and dioxane (1962 μΐ,) and water (785 μί) added. The vial was flushed with nitrogen and heated in a microwave to 180 °C for 1 hour. The reaction mixture was diluted with EtOAc (20ml) filtered through celite and washed with saturated sodium bicarbonate solution (20ml). Organics were dried over sodium sulphate and solvent evaporated under reduced pressure to afford crude product as a brown oil. Purification by preparative HPLC (basic phase) and evaporation of solvent in a genevac afforded product l-cyclopropyl-5,6-difluoro-2-(5-fluoro-4-methylpyridin-3- yl)-lH-benzimidazole as a white solid. LCMS m/z 304 [ + H ; 1H NMR (CDC13)5: 8.53 (s, 1H), 8.52 (s, 1H), 7.58 (t, 1H), 7.41 (t, IB), 3.35 (m, 1H), 2.35 (s, 3H), 1.01 (m, 2H), 0.67 (m, 2H).
The compounds in Table 5 were all prepared using chemistry described in Example 63.
Table S
Figure imgf000052_0001
Figure imgf000053_0001
F benzimidazole
Figure imgf000053_0002
l-cvciQpropyl-2-(pyridin-3-yl)-lH-benzofd]imidazole-6-carbonitri e
Figure imgf000053_0003
Step A. 3- cvclopropyIamino)-4-nitrobenzonitrile:
To a stirred solution of 3-fluoro-4-nitrobenzonitrile (2.0 g, 0.012 mol) in DCM (20 ml), was added 2CO3 (3.3 g, 0.024 mol) and cyclopropyl amine (6.7 ml, 0.096 mol) and the resulting solution was continued to stir at room temperature for 3 h. The reaction was diluted with cold water and extracted with dichloromethane (3 x 100 ml). The combined organic layers were washed with brine, dried over Na2SC>4 and concentrated under vacuum to afford the title compound 3-(cyclopropylamino)-4-nitrobenzonitrile as a yellow solid. 1H NMR (400 MHz, CDCI3), δ: 8.24-8.22 (d, J- 8.8 Hz, 1H), 8.07 (bs, 1H), 7.64 (s, IH), 6.94-6.92 (d, J= 8.8 Hz, IH), 2.59-2.58 (m, IH), 1.25-0.97 (m, 2H), 0.71-0.58 (m, 2H). MS (M+l): 204.
Step B, 4-amino-3-(cyclopropylamino benzonitrile:
To a stirred solution of 3-(cyclopropylamino)-4-nitrobenzonitrile ( 2.0 g, 0.009mol) in EtOH (20 ml) was hydrogenated using Pd/C for 2h at room temperature. The reaction was filtered through CELITE® and the filter bed was thoroughly washed with EtOH. The resulting solution was concentrated to provide 4-amino-3-(cyclopropylamino) benzonitrile as a brownish solid. 1H NMR (400 MHz, DMSO-<¼), δ: 6.92 (bs, IH), 6.88-6.86 (d, J= 8 Hz, 1 H), 6.55-6.53 (d, J =8.4 Hz, IH), 5.50 (bs, IH), 5.44 (s, 2H), 2.36-2.34 (m, IH), 0.76-0.71 (m, 2H), 0.39-0.34 (m, 2H). MS (M+l): 174.
Step C. l-cyclopropyl-2-(pyridin-3-yl -lH-benzo[d]imidazole-6-carbonitrile Γ75):
To a solution of 4-amino-3-(cyclopropylamino) benzonitrile, (0.2 g, 0.0011 mol) and icotinaldehyde (0.14 g, 0.0012 mol) in DMF (5 ml) and H20 (2 ml) was added OXONE® monopersulphate (0.84 g, 0.0013 mol). Reaction mass was stirred at room temperature for 3h. The reaction mixture was basified with 10% K2C03 solution to pH~8-10 and extracted with EtOAc (3 x 20 ml). The combined organic layers were washed with brine, dried over Na2S04 and concentrated under vacuum to afford the crude compound, which was purified by column chromatography to obtain title compound l-cyclopropyl-2-(pyridine-3-yl)-lH- benzo[d]imidazole-6-carbonitrile. 1H NMR (400 MHz, DMSO-c¾), δ: 9.21 (s, IH), 8.77-8.76 ( d, J- 4.4 Hz, IH), 8.45-8.43 (d, J-8 Hz, IH), 8.25 ( s, IH), 7.89-7.87 (d, J- 8Hz, IH), 7.68— 7.61 (m, 2H), 3.91-3.87 ( m, IH), 1.17-1.12 (m , 2H), 0.71-0.70 (m, 2H). MS (M+l): 261.12; purity 97.77%.
The compounds in Table 6 were prepared following the synthetic procedure as described in Example 75.
Table 6
Figure imgf000054_0001
l-cyclopropyl-2-(5-fluoropyridm- 279.08
77 3 -yl)- 1 H-benzimidazole-6- carbonitrile
2-(3-chloropyridin-4-yl)-l- 295.07
78 cyclopropyl- 1 H-benzimidazoIe-6- carbonitrile
2-(3-fluoropyridin-4-yl)-l - 279.08
79 cyclopropyl- 1 H-benzimidazole-6-
A F carbonitrile
80 1 -cyclopropyl-2-(pyridin-4-yl)-l H- 261.11 benzimi dazole-6-carbonitri) e
81 1 -methyl-2-(pyridin-3-yl)- 1 H- 235.06 benzimidazole-6-carbonitrile
8.2 2-(isoqumolm-4-yl)- 1 -methyl- 1 - benzimidazole-6-carbonitrile 285.07
2-(5-methoxypyridin-3-yl)-l -
83 methyl- 1 H-benzimidazo3e-6- 265.07
' o— carbo itrile
84 2-(5 -cyanopyridin-3-yl)- 1 -methyl- 260.06
I CN 1 H-benzimidazole-6-carbonitrile
85 2-(5-fluoropyridin-3 -yl)- 1 -methyl-
\ F 1 H-benzimidazole-6-carbonitriIe 253.04
86 2-(5-bromopyridin-3-yl)- 1 -methyl-
^ Br lH-benzimidazole-6-carbonitrile 312.97
Figure imgf000056_0001
benzimidazole-6-carbonitrile 2-(5-bromopyridin-3-yl)-l -
97 cyciopropyl - 1 H-benzimidazole-6- 341.0 carbonitrile
2-(4-ethyl-5-fluoropyr idin- 3 -yl)- 1 -
98 methyl- 1 H-benzimidazole-6- 281.1
\ F carbonitrile
99 1 -met3iyl-2-(pyridin-3-yl)- 1 H- 235.25 benzimidazole-6-carbonitrile
2- [5 -fluoro-4-(hydroxymethyl)
100 pyridin-3-yl]- 1 -methyl- 1H- 283.1
OH benzimidazole~6-carbonitrile
101 5-bromo-2-(5-fluoropyridin-3~yl)- 1 -methyl- 1 H-benzirnidazole 308.02
102 4-(5-bromo- 1 -methyl- 1 H- benzimidazol-2-yl)isoquinoline
338.07
103 5-bromo- 1 -methyl-2-(pyridin-3-
! yl)- 1 H-benzimidazole 290.03
104 5 -bromo-2-(5 -methoxypyridin-3 >
yl)- 1 -methyl- 1 H-benzimidazole 318.2
4-(5 -bromo- 1 -methyl- 1 H-
105
1 V benzimidazol-2-yl)- 8 - 356.04 fluoroisoquinoline
106 5-bromo- 1 -methyl~2-(pyridin-4- 287.96 yl)- 1 H-benzimidazole
Figure imgf000058_0001
benzimidazole
Figure imgf000059_0001
Figure imgf000060_0001
benzimidazole
Figure imgf000061_0001
carbonitrile
Figure imgf000062_0001
carbonitrile
Figure imgf000063_0001
Figure imgf000064_0001
6-bromo- 1 -cyclopropyl-2-(5-
175 methoxypyridin-3 -yl)- 1 H- 344.03 benzimidazole
6-bromo-l-cyclopropyl-2~[5-
176 (trifluoromethyl)pyridin~3 -yl] - 1 H- 383.18
> F F benzimidazole
6-bromo-2- (5-bromopyridin-3 -yl)- 395.08 1 -cyclopropyl- 1 H-benzimidazole
178 6-bromo- 1 -cyclopropyl-2-(pyridin- 315.18
4-yl)- 1 H-benzimidazole
366.1
179 6-bromo- 1 -cyclopropyl-2-(pyridin- 4-yl)~ 1 H-benzimidazole (M+2)
6-bromo- 1 -cyclopropyl-2-(4- 330.4
180 methylpyridin-3 -yl)- 1 H- (M+2) benzimidazole
181 6~bromo- 1 -cyclopropyl-2-(pyridin-
1 3 -yl)- 1 H-benzimidazole 287.98
308.12
182 5s6-dichloro-2-(5-methoxypyridin- 3-yl)- 1 -methyl- 1 H-benzimidazole
296.97
183 5f6-dichloro-2-(5-fluoropyridin-3- yl)- 1 -methyl- 1 H-benzimidazole
\
5,6-dichloro-2-(5-methoxy-4- 322.01
184 methylpyridin-3 -yl)- 1 -methyl- 1 H- benzimidazole
185 5,6-dichloro-l-methyl-2-(pyridin- 279.14
1 4-yl)- 1 H-benzimidazole
Figure imgf000066_0001
benzimidazol-5 -amine
Figure imgf000067_0001
CT OH acid
Figure imgf000068_0001
carbonitrile
Figure imgf000069_0001
benzimidazole 1 -cyclopropyl-2-(4-ethyI-5- fluoropyridm-3-y 1)- 5 , 6-difluoro- 318.2
A < F 1 H-benzimidazole
1 -cyclopropyl-2-[5-(3,5- difluorophenyl)pyridin-3-yl]-5,6- 384.1 difluoro- 1 H-benzimidazole
[3 -(5 ,6-difluoro- 1 -methyl- 1 H- benzimidazol-2-yl)-5- 294.1
OH fluoropyridin-4-yl] methanol
274.12
6-chloro-2-(5-methoxypyridin-3 -
I OMe yl)- 1 -methyl- 1 H-benzimidazole
244.01
6-chloro- 1 -methyl-2-(pyridin-3 -yl)- 1 H-benzimidazole
262.05
6-chloro-2-(5-fluoropyridin-3-yl)-
1 p 1 -methyl- 1 H-benzimidazole
6-chloro~2~(5-methoxy-4- 288.08 methylpyridin-3 -yl)- 1 -methyl- 1 H-
Figure imgf000070_0001
benzimidazole
5-(6-chloro- 1 -methyl- 1 H- 269.03 benzimidazol-2-yl)pyridine-3 - CN carbonitrile
6-chloro-2-(5-fluoro-4- 276.1 methylpyridin-3-yl)- 1 -methyl- 1H- benzimidazole
323.98
2-(5 -bromopyridin- 3 -yl)~6-chloro~
^ Br 1 -methyl- 1 H-benzimidazole
6-chloro-2-[5-(3,5- 339.12 dimethylisoxazol-4-yl)pyridin-3 -
0' yl] - 1 -methyl- 1 H-benzimidazole
Figure imgf000071_0001
5-(6-chloro- 1 -cyclopropyl- 1H- 295.01
252 benzimidazol-2-yi)pyridine-3 - ON carbonitrile
6-chloro- 1 -cyclopropyl-2-(5- 314.1
253 methoxy-4-met ylpyridin-3-yl)- 1 H-benzimidazole
6-chloro- 1 -cyclopropyl-2-(4-ethyl-
254 5-fluoropyridin-3-yl)- 1 H- 316.1 benzimidazole
255 4-(6-chloro-l -cyclopropyl- 1H- 320.1
h i) benzimidazol-2-yl)isoquinolme
295.93
256 4-(5,7-difluoro-l~methyl-lH- benzimidazol-2-yl)isoq noline
246.02
257 4-(5s7-difluoro- 1 -methyl- 1H-
T * benzimidazol-2-yl)isoquinoline
264.06
258 5 , 7-difluoro-2-(5 -fluoropyridin-3 - yl)- 1 -methyl- 1 H-benzimidazole
2-(5-bromopyridin-3 -yl)- 5 ,7- 325.96
259 difluoro- 1 -methyl- 1 H-
J ^ Br benzimidazole
276.13
260 5 , 7-difluoro-2-(5-methoxypyridin- 3-yl)- 1 -methyl- 1 H-benzimidazole
5 -(5 ,7-difluoro- 1 -methyl- 1 H- 271.06
261
I benzimidazol-2-yl)pyridine~3- ^ CN carbonitrile
5,7-difluoro-l-methyl-2-(5- 260.08
262 me thyipyridin-3 -yl)- 1 H- benzimidazole
Figure imgf000073_0001
Figure imgf000074_0001
F b> benzimidazole
Figure imgf000075_0001
1 -methyl- 1 H-benzimidazole
Figure imgf000076_0001
Figure imgf000077_0001
F benzimidazole 2-(5-fluoropyridin~3-yl)- 1 -methyl-
316 lH-benzimidazole-5-carboxylic 272.25
acid
1 -cyclopropyl-2-[5-(3,5-
317 dimethylisoxazol-4-yl)pyndin-3- 367.37
N'' yl] - 5 , 6-difluoro~ 1 H-benzimidazole
2-[5-(3,5-dimethylisoxazoi-4-
318 yl)pyridin-3-yl] - 1 -methyl- 1 H- 330.36
N benzimidazole-6-carbonitrile
319 1 -methy l-2-(p ridin-4-yl)- 1 H- 235.26
benzimidazole-6-carbonitriIe
320 2-(3-chloropyridin-4-yI)- 1 -methyl- 269.71
V CI 1 H-benzimidazole-6-carbonitrile
EXAMPLE 321
Figure imgf000078_0001
l-CvclQproDyl- -flif- yrazol-3-yl)-2- 5- trifluorom thγl)pyrid■n-3- ] lif-beBzimida2ole
Br
Figure imgf000078_0002
F Cyclopropylamine. DIPEA, DMF Raney Ni, H2
Figure imgf000078_0003
Step A. (5-bromo-2-nitro-phenyl)-cyclopropylamine:
To solution of 4-bromo-2-fluoronitrobenzene (2.0 g, 0.0091 mol) in DMF (10 ml) was added carefully DIPEA (3.25 ml, 0.0182 mol) and cyclopropylamine (0.7 ml, 0.0091 mol) and the resulting solution was stirred at room temperature for 14h. The reaction was quenched with ice-water and extracted with diethyl ether (3 x 100 ml). The combined organic layers were washed with brine dried over Na2S04 and concentrated under vacuum to afford the title compound (5-bromo-2-nitro-phenyl)-cyclopropylamine as a yellow solid. 0¾ΒΓΝ202; 1H NMR (400 MHz, DMSO-<¾), δ: 8.08 (brs, 1H), 8.02 - 7.99 (d, J= 8.8 Hz, 1H), 7.47 (s, 1H), 7.26 (s, 1H), 6.82 - 6.79 (dd, J- 8.8 Hz, 1.6 Hz, 1H), 2.58 - 2.54 (m, 1H), 0.97 - 0.88 (m, 2H), 0.69 - 0.65 (m, 2H). MS (M+l): 258.
Step B. 4-bromo-N-cyclopropyl-benzene-l,2-diamine:
A stirred solution of (5-bromo-2-nitro-phenyl)-cyclopropylamine (1.0 g, 0.0038 mol) in MeOH (20 ml) was hydrogenated using Raney-Ni for 12 h at room temperature. The reaction mixture was filtered through CELITE® and the filter bed was thoroughly washed with methanol. The resulting solution was concentrated to provide 4-Bromo-N-cyclopropyl-benzene~l,2-diamine as a black sticky solid. C9Hi 1BrN2; Crude Ή NMR (400 MHz, DMSO-<¾), δ: 6.80 (d, J - 2.0 Hz, 1H), 6.67 - 6.65 (d, J- 6.8 Hz, 1H), 6.55 - 6.62 (m, 1H), 5.28 (brs, 1H), 4.73 (brs, 1H), 2.40 - 2.30 (m, 1H), 0.73 - 0.69 (m, 2H), 0.40 - 0.39 (m, 2H). MS (M+l): 228.
Step C. 6-bromo-l-cvclopropyl-2-(5-trifluoromethyl-pyridin-3-yl)-lH-benzoimidazole:
To a solution of 4-bromo-N-cyclopropyl-benzene-l,2-diamine (0.5 g, 0.0022 mol) and 5- trifluoromethyl-pyridine-3-carbaldehyde (0.38 g, 0.0022 mol) in DMF (5 ml) and water (2 ml) was added OXONE® monopersulphate (1.62 g, 0.00264 mol). Reaction mixture was stirred at room temperature for 3 h. The reaction mixture was diluted with 10% K2C03 solution to pH~8- 10 and extracted with EtOAc (3 x 20 ml). The combined organic layers were washed with brine dried over Na2S04 and concentrated under vacuum to afford the crude compound which was purified by column chromatography to obtain title compound 6-bromo-l-cyclopropyl-2-(5- trifluoromethyl-pyridin-3-yl)-lH-benzoimidazole.
Step P. 1 -cyclopropyl-6-ί 1 H-pyrazol-3 -yP-2- [5 -(trifluoromethyl pyr idin-3 -yl] - 1 H- benzimidazole (321V
To a solution of 6-bromo-l-cyclopropyl-2-(5-trifluoromethyl-pyridin-3-yl)-lH- benzoimidazole (0.15 g, 0.00026 mol) in ethanol toluene water (6 ml 3 ml 1.5 ml respectively) mixture in a sealed tube was added 3-(4,4,5,5-tetramethyl-[l53,2]dioxaborolan-2-yl)-lH-pyrazole (0.1 g, 0.00052 mol) and Na2C03 (0.082 g5 0.000785 mol) and argon was purged for 15 min. Then Pd (PPh3)4 (0.015 g, 0.000013 mol) was added and heated at 80°C for 5 h. The solvent was evaporated and the resulting residue was added water. The aqueous layer was extracted with ethyl acetate (3 x 20 ml). The combined organic layers were washed with brine dried over Na2S04 and concentrated under vacuum to afford the crude compound which was purified by column chromatography to obtain title compound l-cyclopropyl-6-(lH-pyrazo]-3-yl)-2-[5- (trifluoromethyl)pyridin-3-yl]-lH-benzimidazole (321) as an off white solid. SH NMR (400 MHz, DMSO-4f), δ: 12.85 (s, IH), 9.49 (s, IH ), 9.12 (s, IB), 8.75 (s, IH), 8.09 (s} 1H)5 7.79 - 7.67 (m, 3H), 7.54 - 7.52 (m, IH), 6.79 (s, IH), 3.96 (bs, IH), 1.15 (d, J- 5.6 Hz, 2H), 0.73 (bs 2H). MS (M+1): 370.6, Purity 99.94%.
The compounds in Table 7 were prepare following the synthetic procedure as described Example 321
Table 7
Figure imgf000081_0001
methyl- 1 H-benzimidazo le
Figure imgf000082_0001
Figure imgf000082_0002
6-Chloro- -fluoro-l-methyl-2 4-(trifluorom
Figure imgf000082_0003
Figure imgf000082_0004
Step A. 5-chloro~4-fluoro~N-methyl-2-nitroaniIme:
To a solution of 4-chloro 2,5-difluoro nitrobenzene (2.0 g, 0.010 mol) in DMF (15 ml) was added DIPEA (4.5 ml, 0.026 mol) followed by MeN¾ (5 ml, 0.010 mol, 2M in THF) and the resulting solution was stirred at room temperature for 12h. The reaction was quenched with ¾0 and extracted with EtOAc (3 x 30 ml). The combined organic layers were washed with brine dried over Na2S04 and concentrated under vacuum to get crude product which was purified column chromatography to get the title compound 5-chloro-4-fluoro-N-methyl-2-nitroaniline as a yellow solid, 1H NMR (400 MHz, DMSO-<¾), δ: 8.20 (s, 1H), 8.09 d, J= 10 Hz, 1H), 7.22-7.20 (d, J = 6.4 Hz, 1H), 2.95 (s, 3H). MS (M+1): 205.12
Step B. 5-chloro-4-fluoro-Nl-methylbenzene-l 2-diamine:
A stirred solution of 5-chloro-4-fluoro-N-methyl-2-nitroaniline (8; 1.5 g, 0.0078 mol) in
MeOH (20 ml) was hydrogenated using Raney Ni for 6h at room temperature. The reaction was filtered through CELITE® and the filter bed was thoroughly washed with MeOH. The resulting solution was concentrated to provide 5-chloro-4-fluoro-Nl-methylbenzene-l 2-diamine as a brownish solid. 1H NMR (400 MHz, DMSO-<s¾), δ: 6.49-6.47 (d, J- 11.6 Hz, 1H), 6.30-6.28 (d, J= 7.6 Hz, 1H) 4.96 (bs, 2H), 4.74 (bs, 1H), 2.67 (s5 3H). MS (M+l): 175.1.
Step C N-(4-chloro-5-fluoro-2-f methyl amino)phenyl)-4-(tri-fluoromethyl nicotinamide:
To the solution of compound 5-chloro-4-fluoro-Nl-methylbenzene-l 2-diamine (0.3 g, 0.00172 mol) and 4-trifluoromethylnicotinic acid (0.36 g, 0.00189 mol) in DMF (5 ml) was added EDC-HCl (0.27 g, 0.00206 mol) followed by HOBt (0.39 g, 0.00206 mol) and Et3N (0.047 g, 0.00344 mol). Reaction mixture was heated at 80 °C for 12h. Reaction mass was quenched with ice water and layers were separated. The aqueous layer was extracted with EtOAc (3 10 ml). The combined organic extracts were washed with sat NaHC03 solution and brine dried over Na2S04 and concentrated to get crude product which was purified by column chromatography to provide N-(4-chloro-5-fiuoro-2-(methyl amino)phenyI)-4-(tri-fluoromethyl)mcotinamide as a brown colored solid. 1H NMR (400 MHz, DMSO-<¾), δ: 10.08 (s, 1H), 9.20 (s, 1H), 8.99-8.98 (d, J= 4.8 Hz, 1H), 8.75-8.74 (d, J= 4.8 Hz, 1H), 7.91-7.89 (d, J= 5.2 Hz, 1H), 7.39-7.37 (d, J= 10.4 Hz, 1H), 6.72-6.71 (d, J= 72 Hz, 1H), 5.36 ( bs, 1H), 2.74-2.73 (d, J= 4.0 Hz, 3H). MS (M+l): 348.12.
Step D. 6-chloro- -fluoro- 1 -methyl-2- [4-(trifluoromemyl)pyridm-3 - yl] - 1 H-benzimidazole
(335):
To the solution of compound N-(4-chloro-5-fluoro-2-(methylamino) phenyl)-4-(tri- fluoromethyl) nicotinamide (0.1 g, 0.0028 mol) in DMA (5 ml) was added DBU (0.05 g, 0.0037 mol). Reaction mixture was heated at 140 °C for 24h. Reaction mass was quenched with ice water and layers were separated. The aqueous layer was extracted with EtOAc (3 10 ml). The combined organic extracts were washed with brine dried over Na2S04 and concentrated to get crude product which was purified by column chromatography to provide 6-chloro- 5 -fluoro- 1- methyl-2-[4-(trifluoromethyl)pyridin-3-yl]-lH-benzimidazole 335; as a white colored solid. Ή NM (400 MHz, DMSO-t¾), δ: 9.11-9.09 (d, J - 5.2 Hz, 1H), 9.03 (s, 1H), 8.07-8.04 (m, 2H), 7.82-7.79 (d, J= 10 Hz, 1H), 3.65 (s, 3H). MS (M+l): 330.12, Purity 99.52%.
The compounds in Table 8 were prepared following the synthetic procedure as described in Example 335.
Table 8
Figure imgf000084_0002
EXAMPLE 342 and 343
Figure imgf000084_0001
l-Methoxy-S-diiethylsalfii YD^-fpYridiB^-yD-l i -benzimidazQle and l-Methoxy-5-(methylsulfonylV2-(pyridiii-3-Yl>-lff-benzimidazole
Figure imgf000085_0001
Step A. 5-Crnethyl-thio -2-nitro-N-('pyTidin-3-ylmethvI)anilme
To a stirred solution of 2,4-difluoro-l -nitrobenzene (2 g, 0.012mol) in DMSO (60 ml) was added K2C03 (5.2 g, 0.037mol). Then pyridin-3-ylmethanarmne (1.05 g, 0.013mol) was added drop wise and the resulting solution was continued to stir at room temperature for 6 h. After complete conversion of 2,4-difiuoro-l -nitrobenzene monitored by MS sodium thio- methoxide (1.2 g, 0.013 mol) was added and heated at 60°C for the next 12 h. The reaction was diluted with ice cold water and extracted with ethyl acetate (3 x 100 ml). The combined organic layers were washed with brine dried over Na2S04 and concentrated under vacuum to afford the crude compound which was purified by chromatography to obtain title compound 5 -(methyl - thio)-2-nitro-N-(pyridin-3-ylmethyl)aniline as a yellow solid. 1H NMR (400 MHz, CDC13), δ: 8.65 (s, 1H), 8.58 (s, 2H), 8.1 1-8.09 (d, J= 9.2 Hz, 1H), 7.69-7.67 (d, J= 7.6 Hz, 1H), 7.33-7.29 (m, 1H), 6.54-6.51 (dd, J= 7.2 Hz, J= 1.6 Hz, 1H), 6.43 (s, 1H), 4.58-4.57 (d, J= 5.6 Hz, 2H), 2.48 (s, 3H). MS (M+l): 276.
Step B. 5 -( methyl-thioV2- pyridin-3 -vD- 1 H-benzo d imidazol- 1 -ol :
To a stirred solution of 5-(methyl-thio)-2-nitro-N-(pyridin-3-ylmethyl) aniline (0.8 g, 0.002 mol) in THF (20 ml) was added NaH (60% suspension in mineral oil), (0.14 g, 0.006 mol) and the resulting solution was continued to stir at 60°C for 8 h. The reaction was quenched with ice chips and extracted with dichloromethane (3 x 100 ml). The combined organic layers were washed with brine dried over Na2S04 and concentrated under vacuum to afford to afford the crude compound which was purified by chromatography to obtain title compound 5-(methyl- thio)-2-(pyridin-3-yl)-lH-benzo[d]imidazol-l-ol as an off white solid. !H NMR (400 MHz, DMSO-i tf), δ: 12.28 (bs, 1H), 9.36 (s, 1H), 8.71-8.70 (m, 1H), 8.55-8.53 (d, J = 8 1H), 7.62- 7.59(m, 2H), 7.52-7.50 (d> J = 8Hz, 1H), 7.28-7.26 (dd, 7= 1.2 Hz, J = 8 Hz, 1H), 2.53 (s, 3H). MS (M+1): 258.
Step C. 1 -methoxy-5 -(methyl-thioV2-(pyridin-3-yl)- 1 H-benzo [d] imidazole :
To a stirred solution of 5-(methyl-thio)-2-(pyridin-3-yl)-l H-benzo [d] imidazol- l-ol (0.36 g, 0.001 mol) in THF (20 ml) NaH (60% suspension in mineral oil), (0.14 g, 0.003 mol) was added. After stirring for the next 20 rain at room temperature methyl iodide (0.39 g, 0.002 mol) was added drop wise. The resulting solution was continued to stir at room temperature for the next 3 h. The reaction was quenched with ice cold water and extracted with ethyl acetate (3 x 100 ml). The combined organic layers were washed with brine dried over Na2S04 and concentrated under vacuum to afford to afford the crude compound which was purified by chromatography to obtain title compound l~methoxy-5-(methyl-thio)-2-(pyridin-3-yl)-lH-benzo[d]imidazole as a stick brown solid. !H NMR (400 MHz, DMSO-<¾), 5 9.47 (s, 1H), 8.74-8.73 (m, 1H), 8.53-8.50 (m, 1H), 7.71 (s, 1H), 7.49-7.33 (m, 3H), 4.05 (s, 3H,) 2.58 (s, 3H). MS (M+l): 272.
Step D. l-methoxy-5 -(methylsulfinyl -2-(pyridin-3-yl)-lH-benzimidazole (342) and 1-methoxy- 5-(methylsulfonyl)-2-(pyridin-3-vl)- lH-benzimidazole (343)
To a stirred solution of l-methoxy-5-(methyl-thio)-2-(pyridin-3-yl)-lH- benzo[d] imidazole (0.22 g, 0.0008 mol) in DCM (15 ml) m-chloroperbenzoic acid (0.21 g, 0.001 mol) solution in DCM (5ml) was added at 0°C.Then the reaction mixture was allowed to stir for the next 1 h at room temperature . Two spots were observed by TLC. The reaction was diluted with cold water and extracted with dichloromethane (3 x 100 ml). The combined organic layers were washed with brine dried over Na2S04 and concentrated under vacuum to afford the crude compound which was purified by chromatography and isolated the both l-methoxy-5- (methylsulfinyl)-2-(pyridin-3-yl)-lH-benzimidazole (342) as an off white solid and l-methoxy-5- (methylsulfonyl)-2-(pyridin-3-yl)-lH-berrzimidazole (343) as a off white solid. Compound 342: !H NMR (400 MHz, CDC13), δ: 9.49 (s, 1H), 8.78-8.77 (d, J= 4.4 Hz, 1H), 8.56-8.54 (d, J= 8Hz, 1H), 8.07 (s, 1H), 7.74-7.68 (m, 2H), 7.52-7.49 (m, 1H), 4.07(s, 3H), 2.78 (s, 3H). MS (M+l): 288, Purity 98.37%; Compound 343: 1H NMR (400 MHz, CDC13), δ: 9.50 (s, 1H), 8.11- 8.00 (d, J= 4.4 Hz, 1H), 8.57-8.55 (d, J= 8 Hz, 1H), 8.43(s, 1H), 7.97-7.95 (d, J= 8.4 Hz, 1H), 7.70-7.68 (d, J-8.4 Hz, 1H), 7.54-7.51(m, 1H), 4.085 (s, 3H), 3.12 (s, 3H). MS (M+l): 304; Purity 98.58%.
The compound in Table 9 were prepared following the synthetic procedure as described in Examples 342 and 343
Table 9
Figure imgf000086_0001
Figure imgf000087_0001
"1 benzimidazole
Figure imgf000088_0001
Figure imgf000088_0002
NJ-dimethyl-2-(pyridin-3-yl)-lH-benzimidazoIe-7»carboxamide
Figure imgf000088_0003
Step A. N-methyl-2-fmethyl-amino)-3-nitrobenzamide:
To a stirred solution of methyl-2-iodo-3-nitrobenzoate (0.5 g, 0.00162 mol) in DCM (20 ml) was added K2C03 (0.45 g, 0.00325 mol) and methyl amine (5.0 ml) was added portion wise under cooling condition with constant stirring. The reaction mixture was allowed to stir at room temperature for 12h. The reaction was diluted with cold water (15 ml) and extracted with dichloromethane ( x 15 ml). The combined organic layers were washed with brine dried over Na2S04 and concentrated in vacuo and purified by column chromatography on silica gel to afford the desired product N-methyl-2-(methyl-amino)-3-nitrobenzamide as a yellow solid. 1H NM (400 MHz, DMSO-d6), δ: 8.49 (bs, 1H), 8.29 (bs, 1H), 8.02-8.0 (d, J= 8.0 Hz, 1H), 7.53-7.51 (d, J= 7.6 Hz, 1H), 6.71-6.67 (t, J= 8.0 Hz, 1H)} 2.81-2.8 (d, J = 5.6 Hz, 3H), 2.75-2.74 (d, J= 4.4 Hz, 3H)XCMS (ES) m/e MS (M+l =210) Purity: 87.19 %.
Step B. 3-amino-N-methyl-2-(methyl-amino) benzamide:
To a stirred solution of N-methyl-2-(methyl-amino)-3-nitrobenzamide (17; 0.22 g, 0.00104 mol) in THF (10 ml) was added 10 % palladium on carbon (catalytic amount) portion wise at room temperature. The reaction mixture was allowed to stir under the atmosphere of hydrogen gas supplied by balloon at room temperature for 3h. The reaction mixture was filtered through CELITE® and filtrate was concentrated to afford the desired product 3-amino-N-methyl- 2-(methyl-amino) benzamide after drying and carry forward to next step by checking
LCMSXCMS (ES) m/e MS (M+l =180) Purity: 85.6 %.
Step C. N,l-dimethyl-2-(pyridin-3-yl -lH-benzimidazole-7-carboxamide (360):
To a stirred solution of 3-amino~N-methyl-2-(methyl-amino) benzamide (18; 0.2 g,
0.0011 mol) in the mixture of DMF (5 ml) and water (1 ml) was added OXONE® (0.81 g, 0.0013 mol) and followed by nicotinaldehyde (0.13 g, 0.00122 mol) was added portion wise under cooling condition with constant stirring. The reaction mixture was allowed to stir at room temperature for 3h. The reaction mixture was concentrated on a high vacuo pump and purified by column chromatography on silica gel to afford the desired product N,l-dimethyl-2-(pyridin-3-yl)- lH-benzimidazole-7-carboxamide as brown solid. 1H NMR (400MHz, DMSO-d6), S: 9.0 (s, 1H), 8.76-8.75 (d, J= 4.0 Hz, 1H), 8.59 (bs, 1H), 8.25-8.23 (d, J= 7.6 Hz, 1H), 7.81-7.8 (d, J= 7.6 Hz, 1H), 7.64-7.61 (m, 1H), 7.35-7.27 (m, 2H), 3.79 (s, 3H), 2.85-2.84 (d, J= 4.4 Hz, 3H). LCMS (ES) m/e MS (M+l=267) Purity: 98.5 %.
The compounds in Table 10 were prepared following the synthetic procedure as described in Example 360.
Table 10
Figure imgf000089_0001
2-(5-fluoropyridin-3 -yl)-
362 jV, 1 -dimethyl- 1 H-benz- 285.23 imidazole-7 -carboxamide
EXAMPLE 363
Figure imgf000090_0001
N lHmethyl-2- ridin-3-YlHiy-benz^
Figure imgf000090_0002
Step A. N-(4-fluoro-3-mtrophenyl methane sulfonamide:
To a stirred solution of 4-fluoro-3-nitroaniline (0.5 g, 0.023 mol) in DCM (10 ml) and pyridine (0.98 g, 0.012 mol) was added methanesulfonyl chloride (0.54 g, 0.0048 mol) portion wise at 0°C with constant stirring. The reaction mixture was allowed to stir at 0°C for 4 h. The reaction mixture was concentrated and diluted with water (20 ml) and extracted with DCM (3 x 15 ml). The combined organic layers were washed with 1 N HQ and NaBC03 solution dried over Na2S0 and concentrated in vacuo to afford the desired product N-(4-fiuoro-3- nitrophenyI)methane sulfonamide as off a white solid. 1H NMR (400 MHz, DMSO-d6), δ: 10.23 (s, IH), 7.93-7.91 (d, J- 8.4 Hz, 1H), 7.62-7.54 (m, 2H), 3.59 (s, 3H). LCMS (ES) m/e MS CM- 1= 233). Purity: 80 %.
Step B. N-(4-(methyl amino>3-nitrophenyDmethane sulfonamide:
To a stirred solution of N-(4~fluoro-3-nitrophenyl) methane sulfonamide (0.5 g, 0.0021 mol) in DMSO (10 ml) was added NaOAc (1.75 ml, 0.0021 mol) and methyl amine (0.65 g, 0.0021 mol) portion wise with constant stirring. The reaction mixture was allowed to stir at 120°C for 10 h. The reaction mixture was concentrated and diluted with water (10 ml) and extracted with DCM (3 15 ml). The combined organic layers were washed with brine dried over Na2S04 and concentrated in vacuo to afford the desired product N-(4-(methyl amino)-3- nitrophenyl)methane sulfonamide (21) as a red color solid. 1H NMR (400 MHz, DMSO-d6), S: 9.4 (s, 1H), 8.16 (bs, 1H), 7.93 (s, 1H), 7.46-7.43 (dd, J= 9.2Hz, 2.4 Hz, 1H), 7.04-7.01 (d, J = 9.2 Hz, 1H), 2.95-2.94 (d, J - 4.8 Hz, 3H), 2.92 (s, 3H). LCMS (ES) m/e MS (M-l=244). Purity: 94 %.
Step C. N-(3-amino-4-(methyl amino) phenyl) methane sulfonamide:
To a stirred solution of N-(4-(methyl amino)-3-nitrophenyl) methane sulfonamide ( 1; 0.4 g, 0.0016 mol) in THF (40ml) was added raney nickel (catalytic amount) portion wise at room temperature. The reaction mixture was allowed to stir under the atmosphere of hydrogen gas supplied by balloon at room temperature for 3h. The reaction mixture was filtered through
CELITE and filtrate was concentrated to afford the desired product N-(3-amino-4-(methyl amino) phenyl) methane sulfonamide (0.45 g, crude) after drying and carry forward to next step. LCMS (ES) m/e MS (M- 1 =244). Purity: 90 %.
Step P. N- l-methyi-2-(pyridin-3-yl)-lH^enzimidazol-5-yl methanesiilfonamide (363):
To a stirred solution of N-(3-amino-4-(methyl amino) phenyl) methane sulfonamide (0.3 g, 0.0013 mol) in the mixture of DMF (10 ml) and water (2 ml) was added OXONE® (1.02 g, 0.0016 mol) and followed by nicotinaldehyde (0.16 g, 0.0015 mol) was added portion wise with constant stirring. The reaction mixture was allowed to stir at room temperature for 3 h. The reaction mixture was concentrated on a high vacuo pump and diluted with cold water (10 ml) and extracted with ethyl acetate (3 x 15 ml). The combined organic layers were washed with brine dried over Na2S04 and concentrated in vacuo and purified by column chromatography on silica gel to afford the desired product N-[l -methyl-2-(pyridin-3-yl)-lH-benzimidazol-5- yl]methanesulfonamide (363) as a brown solid. 1H NMR (400 MHz, DMSO-d6), S: 9.53 (bs, 1H), 9.04 (s, 1H), 8.75-8.77 (d, J= 4.0 Hz, 1H), 8.28-8.26 (d, J= 8.0 Hz, 1H), 7.68-7.57 (m, 3H)5 7.24-7.21 (d, J= 8.4 Hz, 1H), 3.89 (s, 3H), 2.91 (s, 3H). LCMS (ES) m/e MS (M+l=244), Purity 95.64%.
The compounds in Table 11 were prepared following the synthetic procedure as described in Example 363.
Table 11
Figure imgf000092_0001
^ F methanesulfonamide
Figure imgf000092_0002
5,6-Difluoro-2-(5-fluoropyridip-3-yl)-lH-benzimidazol-l-ol
Figure imgf000093_0001
Step A. Oxime:
To a solution of 5-fluoronicotinaldehyde (1.6 g, 0.012 mol) in EtOH (13 ml) was added hydroxylamine hydrochloride (1 g, 0.014 mol) and sodium acetate (1.162 g, 0.014 mol) and stirred at room temperature overnight. After the consumption of 5-fluoronicotinaldehyde (by TLC) water was added and the desired compound was extracted with EtOAc (3x30mL). The organic phase was dried with Na S04 and concentrated under vacuum to give oxime as a white solid. 1H NM (400 MHz, DMSO-<¾), δ: 1 1.75 (s, 1H), 8.63 (d, J- 10 Hz, 1H), 8.24 (s, 1H), 7.86 (d, J= 10 Hz, 1H). MS (M+l): 141
Step B. C5-fluorop idin-3yl methanamine TFA salt:
To a solution of the oxime formed in Step A (0.58 g, 0.0041 mol) in MeOH (20 mL) was added Pd C (0.12 g) under nitrogen atmosphere followed by TFA (2 ml ) at room temperature and was stirred under a balloon of ¾ until the oxime is completely consumed (by TLC). The reaction mixture was then filtered through CELITE® and the filtrate was concentrated under vacuum. The crude (collected by repeating the reaction 3X) was combined and the desired product was obtained by chromatography (Alumina: 1-10% MeOH / DCM) as a viscous gel (5- fluoropyridm-3yl)methanamine TFA salt (; 1.02 g, - 50% LC-MS) and was used directly in the next step. 1H NMR (400 MHz, DMSO-<¼), δ: 8.49 (s, 1H), 8.43 (s, 1H), 7.72 (d, J=10 Hz, 1H), 3.82 (s, 2H), 3.42(br, 2H). MS (M+l): 127
Step C. 4,5-difluoro-N-(5-fluoropyridin-3-yl) methyl -2-nitroanilme:
2,4,5-tri-fluoronitrobenzene (2.864 g, 0.016 mol), K2C03 (2.236 g, 0.0161 mol) and (5- fluoropyridin-3yl)methanamine TFA salt (1.02 g, 50% LC-MS) were dissolved in THF (25 mL) and stirred at room temperature for 16 hours. The reaction mixture was then diluted with EtOAc (lOOmL) and washed with ¾0. The organic phase was dried and concentrated under vacuum to give the ortho- substitution product, 4J5-difluoro-N-(5-fiuoropyridin-3-yl) methyl)-2-nitroaniline as a yellow solid. 1H NMR (400 MHz, DMSO-<¾), δ: 8.72 (br, 1H)5 8.43 (s, 1H), 8.39 (s, 1H), 8.15 (dd, J - JO Hz, 8.8 Hz, 1H), 7.65(d, J= 2 Hz, 1H), 6.83(dd, J=12.8 Hz, 7.8Hz, 1H), 4.71(s, 2H). MS (M+l): 284 Step P. S^-difluoro^-^S-fluoropyridin-S-ylVlH-benzimidazol-l-ol (371):
To a solution of 4,5-difluoro-N-(5-fluoropyridin-3-yl) methyl 2-nitroaniline (0.55 g, 0.0019 mol) in THF (13 ml) was added NaH (0.24 g, 0.0058 mol) portion-wise at room temperature. After the consumption of the starting material (by TLC) the reaction mixture was quenched by the addition of NH4OH (saturated solution) and extracted with EtOAc (2x3 OmL). The organic layer was dried and concentrated under vacuum. The crude was further purified by first washing with Et20 followed by triturating with Hexanes/Et20 and finally washing with Hexanes to obtain the desired compound 5i6-difluoro-2-(5-fluoropyridin-3-yl)-lH-benzimidazol-l-ol (371). LC-MS - 70% purity. The compound was taken to the next step without further purification. 1H NMR (400 MHz, D SO-ifc), δ: 12.67 (m, 1H), 9.22 (s, 1H), 8.75 (s, 1H), 8.37 (d, J= 9.6 Hz, 1H), 7.81 (dd, J- 10 Hz, 7.2 Hz, 1H), 7.72 (dd, J= 9.2 Hz, 7.4 Hz, 1H). MS (M+l): 266; Purity 99.51%.
Figure imgf000094_0001
S^-difluoro^-iS-fluoropyridin-S-vIVl-methoxy-lH-benzimidazole
Figure imgf000094_0002
Step A. 5,6-difluoro-2-(5-fluoropyridin-3-yl)-l-methoxy-lH-benzimidazole (372):
To a solution of 5,6-difluoro-2-(5-fiuoropyridin-3-yl)-lH-benzo[d]imidazol-l-ol 0.15 g, 0.0003 mol) in THF (3.5 ml) was added NaH (0.045 g5 0.0011 mol) at room temperature. After stirring for 5 min at room temperature Mel (0.04 mL, 0.00059 mol) was added in one shot and further stirred for another 1 hr. After the consumption of the starting material (by TLC) the reaction mixture was washed with H20 and extracted with EtOAc (2x3 OmL). The organic phase was dried and concentrated under vacuum. The crude was washed with Hexanes and further purified by chromatography (5-40% EtOAc/Hexanes) to give the desired compound 372 as a white solid. 1H NMR (400 MHz, DMSO-< ), 5: 9.28 (s, 1H), 8.62 (s, 1H), 8.24 (s, 1H), 7.58 (s, 1H), 7.32 (s, 1H), 4.06 (s, 3H). MS (M+l): 280, Purity 99.67%.
The compounds in Table 12 were prepared following the synthetic procedure as described in Example 372.
Table 12
Figure imgf000095_0001
Figure imgf000095_0002
l-Cvclopropyl-5-methoxy-2-fpyridin-3-yI -lH-benzimidazole
Figure imgf000095_0003
Step A. cvclopropyl-(4-methoxy-2-nitro-phenyI)-amine:
To a stirred solution of Hodo-4-methoxy-2-nitrobenzene ( 0.2 g, 0.0007 mol) in toluene (6.0 mL) was added cyclopropylamine (0.068 ml, 0.0008 mol) potassium tert-butoxide (0.094 g, 0.0098 mol) and Ruphos (0.049 g, 0.00010 mol) at room temperature and purged with argon for 15 min. Then Pd2(dba)3 (0.064 g, 0.00007 mol) was added and resulting mixture was heated to 100 °C in CEM microwave for 30 min. After the reaction was complete the reaction mixture was filtered through CELITE® bed and the bed was thoroughly washed with ethyl acetate. The filtrate was washed with water brine dried over Na2S04 and concentrated under reduced pressure to afford the crude compound, which was purified by column chromatography to obtain title compound cyclopropyl-(4-methoxy-2-nitro-phenyl)-amine (yellow solid). Ci0Hi2N2O3; 1H NMR (400 MHz, CDCI3), 6: 7.98 (s, 1H), 7.60 (d, J= 2.8 Hz, 1H), 7.30 (s, 1H), 7.19 - 7.16 (m, 1H), 4.12 (q, J= 6.8, 1H), 3.80 (s, 1H), 0.89 (dd> Jx = 12.0 Hz, J2 - 6.0 Hz, 2H), 0.64 (t, J- 6.8 Hz, 2H). MS (M+1): 209.1.
Step B. Nl-cvclopropyI-4-methoxy-benzene-l,2-diamine:
A stirred solution of cyclopropyl-(4-methoxy-2-nitro~phenyl)-amine (0.8 g, 0.0038 mol) in ethylacetate (25 ml) was hydrogenated using 10% Pd/C for 6h at room temperature. The reaction was filtered through CELITE® and the filter bed was thoroughly washed with EtOAc. The resulting solution was concentrated to provide Nl-cyclopropyl-4-methoxy-benzene-l,2-diamine as a brown liquid. CjoH14N20; Crude Ή NMR (400 MHz, DMSO- ), δ: 6.66 (d, J= 8.8 Hz, 1H), 6.18 - 6.15 (m, 1H), 6.08 (d, J- 6.0 Hz, 1H), 4.03 (d, J- 6.8 Hz, 1H), 3.75 - 3.68 (m, 2H), 3.58 (s, 3H), 0.63 (d, J= 6.0 Hz, 2H), 0.40 (s, 2H). MS (M+l): 179.2.
Step C. l-cvclopropyl-5-methoxy-2-fpyridin-3-yl)-lH-benzimidazole (376):
To a solution of Nl-cyclopropyl-4-methoxy-benzene-l,2-diamine (0.2 g, 0.001 1 mol) and pyridine-3-carbaldehyde (0.12 g, 0.001 1 mol) in DMF (5 ml) and ¾0 (2 ml) was added
OXONE® monopersulphate (0.81 g, 0.00132 mol). Reaction mass was stirred at room
temperature for 3h. The reaction mixture was basif ed with 10% K2C03 solution to pH~8-10 and extracted with EtOAc (3 x 20 ml). The combined organic layers were washed with brine dried over Na2S04 and concentrated under vacuum to afford the crude compound which was purified by column chromatography to obtain title compound l-cyclopropyl~5-methoxy-2-(pyridin-3-yl)- lH-benzimidazole (376). 1H NMR (400 MHz, DMSO-<¼), δ: 9.16 (s, 1H), 8.70 (s, 1H), 8.37 (d, J= 8.8 Hz, 1H), 7.55 (d, J= 8.4 Hz, 2H), 7.23 (s, 1H), 6.96 (d, J= 8.8 Hz, 1H), 3.80 (s, 3H), 1.10 (d, J = 6.4 Hz, 2H ), 0.64 (s, 2H). MS (M+l): 266.1, Purity 98.98%.
The compound in Table 13 was prepared by following the synthetic procedure as described in Example 376.
Table 13
Figure imgf000096_0001
EXAMPLE 378
Figure imgf000097_0001
5- ethoxy-l-methYl-2-f5-(lH-pyrazol-4-v^
Figure imgf000097_0002
Step A. (4-methoxy-2-nitro-phenvD-methyl-amme:
To a solution of 4-memoxy-2-nitro-phenylamine ( 5,0 g, 0.029 rnol) in DMF (25 ml) was added NaH (0.9 g5 0.035 mol) at 0°C and stirred at that temperature for 30 min. Methyl iodide (2.17 ml, 0.035 mol) was added and the resulting solution was stirred at room temperature for 30 min. The reaction was quenched with ice-water and extracted with ethyl acetate (3 x 100 ml). The combined organic layers were washed with brine dried over Na2S0 and concentrated under vacuum to afford the title compound (4-methoxy-2-nitro-phenyl)-methyl-amine as a red solid. C8HioN203; ¾ NMR (400 MHz, CDC13), 6: 8.00 (brs, 1H), 7.62 (d, J= 2.4 Hz, 1H), 7.18 (dd, Ji = 9.2 Hz, J2 = 2.0 Hz, 1H), 6.82 (d; J = 9.6 Hz, 1H), 3.81 (d, J- 14.8 Hz, 3H), 3.02 (s, 3H). MS (M+l): Ϊ83.1.
Step B. 4-methoxy-N 1 -methyl-benzene- 1 ,2-diamine:
A stirred solution of 4-methoxy-2-nitro-phenyl)-methyl-amine (2.5 g5 0.013mol) in ethyl acetate (25 ml) was hydrogenated using 10% Pd/C for 6h at room temperature. The reaction was filtered through CELITE® and the bed was thoroughly washed with EtOAc. The resulting solution was concentrated to provide 4~methoxy-Nl -methyl-benzene- 1,2-diamine as a brown solid. C8H12N20; Crude 1H NMR (400 MHz, DMSO-rfi), δ: 6.27 (d, J= 8.8 Hz, 1H), 6.19 (d, J- 2.8 Hz, 1H), 6.07 (dd, Ji = 8.4 Hz, J2 = 2.4 Hz, 1H), 4.49 (s, 2H), 4.08 (s, 1H), 3.56 (s, 3H)} 2.63 (s, 3H). MS (M+l): 153.2.
Step C. 2-f 5-bromo~pyridin-3-yl)-5~methoxy- 1 -methyl- 1 H-benzoimidazole:
To a solution of 4-methoxy-Nl -methyl-benzene- 1,2-diamine (34; 0.5 g, 0.00328 mol) and 5-bromo-pyridine-3-carbaldehyde (0.61 g, 0.00328 mol) in DMF (10 ml) and H20 (4 ml) was added OXONE® monopersulphate (2.42 g, 0.00394 mol). Reaction mass was stirred at room temperature for 3h. The reaction mixture was basified with 10% K2CO3 solution to pH~8-10 and extracted with EtOAc (3 x 20 ml). The combined organic layers were washed with brine dried over a2S0 and concentrated under vacuum to afford the crude compound which was purified by column chromatography to obtain title compound 2-(5-bromo-pyridin-3-yl)~5~methoxy-l- methyl- IH-benzoimidazole (35).
Step D. 5-methoxy-l-methyl-2-[5-("lH-pyrazol-4-yl)pyridin-3-yl]-lH-benzimidazole (378):
To a solution of 2-(5-bromo-pyridin-3-yl)- 5 -methoxy-1 -methyl- IH-benzoimidazole (0.15 g, 0.00047 mol) in ethanol toluene water (6 ml, 3ml, 1.5 ml, respectively) mixture in a sealed tube was added 4-(4J4,5,5-Tetramethyl-[l,3f2]dioxaborolan-2-yl)-lH-pyrazole (0.18 g, 0.000942 mol) and Na2C03 (0.14 g, 0.0014 mol) and argon was purged for 15 min. Then Pd (PPh3)4 (0.027 g, 0.000023 mol) was added and heated at 100°C for 24h. The solvent was evaporated and the resulting residue was added water. The aqueous layer was extracted with ethyl acetate (3 x 20 ml). The combined organic layers were washed with brine dried over Na2S04 and concentrated under vacuum to afford the crude compound which was purified by column chromatography to obtain title compound 5-methoxy-l-methyl-2-[5-(lH-pyrazol-4-yl)pyridin-3-yl]-lH- benzimidazole as an off white solid. 1H NMR (400 MHz, DMSO-_¾)s 5: 13.11 (s, 1H), 9.01 (s, 1H), 8.79 (s, 1H), 8.44 (s, IB), 8.38 (s, 1H), 8.13 (s, 1H)> 7.54 (d, J= 8.8 Hz, 1H), 7,22 (s, 1H ), 6.95 (d, J= 8.8 Hz, 1H), 3.89 (s, 3H), 3.79 (s, 3H ). MS (M+l): 306.1, Purity 99.0%.
The compound in Table 14 was prepared by following the synthetic procedure as described in Example 378.
Table 14
Figure imgf000098_0001
271.1
383 "XX > 5~methoxy-2-(5-methoxypyridin~3- yl)- 1 -methyl- 1 H-benzimidazole
290.5
384 "XXH 4-(5 -methoxy- 1 -methyl- 1 H- benzimidazol-2-yl)-4a,8a- dihydroisoquinohne
5 -methoxy- 1 -methyl-2-(4- 254.6
385 methylpyridin-3 -yl)- 1 H- benzimidazole
2-(5 -bromo-4-methy lpyridin-3 -yl)-
386 5-methoxy- 1 -methyl- 1 H~ 333.3 benzimidazole
2-[5-(3 ,5-dimethylisoxazol-4-
387 yl)pyridin-3-yl]-5-methoxy- 1 - 335.1
methyl- 1 H-benzimidazole
388 4- [ 1 -methyl -5-(propan-2-yloxy)- 318.23
lH-benzimidazol-2-yljisoquinoline
Figure imgf000099_0001
2-j5,6-difluoro-2-f5-fluoropYridm-3-yl -lJy-benzimidazol-l-yllethanol
Figure imgf000099_0002
Step A. N-ethyl-4,5-difluoro-2-nitroaniline:
To a stirred solution of l,2,4-trifiuoro-5-nitrobenzene (0.5 g, 0.0028 mol) in acetonitrile (5 ml) was added DIPEA (0.98 ml, 0.0056 mol) and 2-(tert-butyldimethylsilyloxy)ethanamine (0.49 g, 0.0028 mol) was added portion wise under cooling condition with constant stirring. The reaction mixture was allowed to stir at room temperature for 4 h. The reaction was concentrated and diluted with water (20 ml) and extracted with ethyl acetate (3 x 25 ml) .The combined organic layers were washed with brine dried over Na2S04 and concentrated in vacuo and purified by column chromatography on silica gel to afford the desired product N-ethyl-4,5-difluoro-2- nitroaniline. (37as yellow solid. 1H NMR (400MHz, DMSO-d6) : 8.37 (bs, 1H), 8.13-8.17 (dd, J - 8.4, 8.4 Hz, 1H), 7.21-7.27 (dd, J = 7.2, 7.2 Hz, 1H), 3.8-3.82 (t, J= 5.2 Hz, 2H) 3.45-3.49 (m, 2H), 0.84 (s, 9H), 0.021 (s, 6H). MS (M+l=333).
Step B. Nl -f2-ftert-butyldimethylsilyloxy ethyl)-4,5-difluoroberizene-l ,2-diamine:
To a stirred solution of N-(2-(tert-butyldimethylsilyloxy)ethyl)-4,5-difluoro-2-nitroaniline (37) in methanol (5 ml) was added 10 % palladium on carbon (catalytic amount) portion wise at room temperature. The reaction mixture was allowed to stir under the atmosphere of hydrogen gas supplied by balloon at room temperature for 2 h. The reaction mixture was filtered through celite and filtrate was concentrated to afford the desired product 1 -(2-(tert- butyldimethylsilyloxy)ethyl)-4,5-difluorobenzene-l,2-diamine (0.09 g; crude). LCMS
(M+l=303).
Step C. 2-[5.6-difluoro-2-(5-fiuoropyridin-3-yl)-lHr-benzimidazol-l-yl]ethanol:
To a stirred solution of l-(2-(tert-butyldimethylsilyloxy)ethyl)-4,5-difluorobenzene-l;2- diamine (38; 0.09 g, 0.0003 mol) in the mixture of DMF (3 ml) and water (0.3 ml) was added ΟΧΟΝΕΦ (0.218 g, 0.0004 mol) and followed by 5-fluoronicotinaldehyde (0.041 g, 0.0003 mol) was added portion wise under cooling condition with constant stirring. The reaction mixture was allowed to stir at room temperature for 3 h. The reaction mixture was concentrated and diluted with cold water (10 ml) and extracted with ethyl acetate (3 15 ml). The combined organic layers were washed with brine dried over Na2S04 and concentrated in vacuo and purified by column chromatography on silica gel to afford the desired product 2-[5,6-difluoro-2-(5- fluoropyridin-3-yl)-lH-benzimidazol-l-yl]ethanol as an off white solid. 1H NMR (400 MHz, DMSO-d6), δ: 8.93 (s, 1H), 8.77 (m, 1H)> 8.33 (m, 1H), 7.96 (m, 1H), 7.81 (m, 1H), 5.09-5.11 (t, J = 5.2 Hz, 1H)5 4.35-4.38 (t, J - 5.0 Hz, 2H), 3.75-3.76 (m, 2H). LCMS (ES) m/e MS
(M+l=294) Purity 99.33%.
The compound in Table 15 was prepared by following the synthetic procedure as described in Example 389.
Table 15
Figure imgf000101_0001
Example 397
Figure imgf000101_0002
5-Bromo-l-methyl-2-fDyridin-3-yl)-ljfir-benzimida¾ole-6-carbonitrile Br- Br-
NBS, AIBN,
NC" NH DMF, 80°C NH NC
OXO
Figure imgf000102_0001
NE, DMF/H3O
Step A. 2-bromo-5-(methylaminoV4-nitrobenzonitrile:
To a stirred solution of 3-(methylamino)-4-nitrobenzonitrile (0.9 g, 0.005 mol) and NBS (0.9 g, 0.005 mol) in DMF (15 ml), AIBN (catalytic) was carefully added and the resulting solution was stirred at 80°C for 3h. The reaction was diluted with ¾0 and extracted with dichloromethane (3 x 30 ml). The combined organic layers were washed with brine, dried over Na2S04 and concentrated under vacuum to afford the title compound 2-bromo-5-(methylamino)- 4-nitrobenzonitrile as a yellow solid. Ή NMR (400 MHz, CDC13), δ: 8.44 (s, IH), 8.04 (bs, IH), 7.18 (s, IH), 3.05 (s, 3H).MS (M+l): 256.12.
Step B. 4-amino-2-bromo-5-(methylamino benzonitrile:
A stirred solution of 2-bromo-5-(methylamino)-4-nitrobenzonitrile (0.3 g, 0.001 mol) in EtOH (10 ml) was hydrogenated using Pd/C for 2h at room temperature. The reaction was filtered through CELITE® and the filter bed was thoroughly washed with EtOH. The resulting solution was concentrated to provide 4-amino-2-bromo-5-(methylamino)benzonitrile; as a brownish a solid. Crude LCMS (M+l): 226.12. Purity: 63 %.
Step C. 5-Bromo- 1 -methyl-2-(pyridin-3 -yl - 1 H-benzimidazole-6-carbonitri!e :
To solution of 4-amino-2-bromo-5-(methylamino)benzonitrile (0.2 g, 0.0008 mol) and nicotinaldehyde (0.094 g, 0.0008 mol) in DMF (5 ml) and H20 (2 ml) was added OXONE® monopersulphate (0.43 g, 0.0007 mol). Reaction mass was stirred at room temperature for 3h. The reaction mixture was quenched with 10% K2CO3 solution to PH-8-10 and extracted with
EtOAc (3 x 20 ml). The combined organic layers were washed with brine, dried over Na2S0 and concentrated under vacuum to afford the crude compound, which was purified by column chromatography to obtain title compound 5-bromo-l-methyl-2-(pyridin-3-yl)-lH-benzimidazole- 6-carbonitrile. (3971H NMR (400 MHz, DMSO-t¾), 6: 9.08 (s, IH), 8.80-8.79 (d, J=4 Hz, IH), 8.53(s, IH), 8.34-8.32 (d, J- 7.2 Hz, IH), 8.23(s, IH), 7.67-7.63 (m, IH), 3.96(s, 3H). MS (M+l): 313.12, Purity 93.84%.
The compound in Table 16 was prepared by following the synthetic procedure as described in Example 397.
Table 16
Figure imgf000103_0001
EXAMPLE 399
Figure imgf000103_0002
5-Fluoro-2-f5-fluoropyridin-3-yl}-l-methyl-lH-benzimidazole-6-carbonitri e
Figure imgf000103_0003
OXONE, DMF/ HjO
Step A. 5-bromo-4-fluoro-2-nitro-phenyl)-methyl-amine:
To a solution of l-Bromo-2,5-difluoro-4-nitro-benzene (1.5 g, 0.0063 mol) in DMF (15 raL), was added DIPEA (2.75 mL, 0.0157 mol) and methyl amine (2 M solution in THF) (4.66 ml, 0.00945 mol ) carefully and the resulting solution was stirred at room temperature for 14h. The reaction was quenched with ice-water and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine, dried over Na2S0 and concentrated under vacuum to afford the crude compound, which was purified by column chromatography to obtain title compound 5-bromo-4-fluoro-2-nitro-phenyl)-methyl-amine as a brick red solid.
C7H6BrFN202; Ή NMR (400 MHz, CDC13) δ 7.95 (d, J - 8.8 Hz, 1H), 7.88 (brs, 1H), 7.07 (d, J = 5.6 Hz, 1H), 3.02 (d, J= 5.6 Hz, 3H).
Step B. 2-Fluoro-5-methylamino-4-nitro-benzonitrile:
A stirred solution of (5-Bromo-4-fluoro-2-nitro-phenyl)-methyl-amine (0.5 g, 0.0020 mol) in DMF (10 ml) was purged with Argon for 15 min. To the above mixture, Pd2(dba)3 (0.09 g, 0.001 mol), dppf (0.13 g, 0.0024 mol), and zinc cyanide (0.14 g, 0.0012 mol) was added carefully under argon atmosphere. The reaction mixture was heated at 120°C for 22h. Cooled to RT, diluted with saturated solution of ammonium chloride, filtered through CELITE® and the filter bed was thoroughly washed with ethyl acetate. The resulting mixture was separated, organic layer was washed with water, brine, dried over Na2S04, filtered and concentrated under vacuum to afford the crude compound, which was purified by column chromatography to obtain title compound 2-fluoro-5-methylamino-4-nitro-benzonitrile as a brick red solid. C8H6FN3O2; !H NMR (400 MHz, CdCl3) δ 8.04 (d, J= 9.2 Hz, 1H), 7.85 (brs, 1H), 7.11 (d, J- 4.8 Hz, 1H), 3.05 (d, J= 4.8 Hz, 3H). MS (M+l): 195.1.
Step C. 4-Amino-2-fluoro-5-methylamino-benzonitrile:
A stirred solution of 2-Fluoro-5-methylamino-4-nitro-benzonitrile (1.0 g, 0.0051 mol) in EtOH (20 mL) was hydrogenated using Pd/C for 3h at room temperature. The reaction was filtered through CELITE® and the filter bed was thoroughly washed with EtOH. The resulting solution was concentrated to afford the crude 4-amino-2-fluoro-5-methylamino-benzonitrile as a brownish black solid. Cg¾FN3; Crude LCMS (M+l): 166.2; LCMS Purity: 85.05%.
Step D. 5-fluoro-2-('5-fluoropyridin-3-ylVl-methyl-lH-benzimidazole-6-carbonitrile (399):
To a solution of 4-amino-2-fluoro-5-methylamino-benzonitrile (0.15 g, 0.00090 mol) and 5-Fluoro-pyridine-3-carbaldehyde (0.1 1 g, 0.0090 mol) in DMF (5 mL) and H20 (2 mL) was added OXONE® monopersulphate (0.19 g, 0.0012 mol). The reaction mixture was stirred at room temperature for 5h, and was diluted with 10% 2C03 solution to PH~8-10 and extracted with EtOAc (3 30 mL). The combined organic layers were washed with brine, dried over a2S04 and concentrated under vacuum to afford the crude compound, which was purified by column chromatography to obtain title compound 5-fiuoro-2-(5-fluoropyridin-3-yl)-l-methyl-lH- benzimidazole-6-carbonitrile (398) as a brown solid. Ci4HsF2N4; 1H NMR (400 MHz, DMSO-c¾) 5 8.96 (s, 1H), 8.83 (d, J - 2.4 Hz, 1H), 8.47 (d, J = 5.4 Hz, 1H), 8.29 (d, J= 9.6 Hz, 1H), 7.88 (d, J - 9.6 Hz, 1H), 3.98 (s, 3H); MS (M+l): 271.1. HPLC purity: 99.44%.
The compound in Table 17 was prepared by following the synthetic procedure as described in Example 399.
Table 17
Figure imgf000104_0001
Figure imgf000105_0001
Assay Description and Results
Methods for V79-Human -CYPl 1B2 and V79-Human-CYP11B1 Assays: V79 cell lines stably expressing the either the human CYPl 1B2 or the human CYPl 1B1 enzyme were generated using a standard transfection protocol. V79 cells were transfected with plasmids pTriEx3-Hygro-hCypl 1B2 or pTriEx3-Hygro-hCy l 1B1 using Lipofectamine2000 reagent. V79 cells that stably express the human CYPl 1B2 or human CYPl 1B1 enzyme were selected for and maintained in DMEM supplemented with 10% FBS and 400 μ /mL hygromycin for -2 weeks. Single cell clones were generated by infinite dilution in DMEM supplemented with 10% FBS and 400 pg mL hygromycin until single colonies were obtained. Clones V79-hCYPl 1B2- CLE9 and V79-hCYPl 1B1-8C7, were determined to produce the most aldosterone and Cortisol, respectively, and were selected for inhibitor screening. For testing of inhibitors, cells were harvested at 80% confluency with 0.5% Trypsan-EDTA, washed once in PBS, and reconstituted in DMEM + 0.1% BSA media at a cell concentration of 400,000 cells/mL. 25 μΐ of cells were added to a 384 well tissue culture treated plate and mixed with 0.25 μΐ of inhibitor or DMSO (1% final DMSO concentration) for 1 hour at 37 °C> 5% C02. After pre-incubation with inhibitor, the reaction was initiated by adding 5 μΐ of substrate (final concentration of 125 nM 11 -deoxycorticosterone for the CYPl 1B2 assay or 250 nM 11-deoxycortisol for the CYPl 1B1 assay). The reaction was carried out for 3 hours at 37 °C, 5% C02 and was stopped by harvesting the supernatants. The amount of product in the supernatant (aldosterone for CY l 1B2 assay and Cortisol for the CYPl 1B1 assay) was measured using HTRF-based assay kit (Aldosterone HTRF- CisBio#64ALDPBB, Cortisol HTRF-CisBio #63IDC002-CORT). IC50's for the inhibitor were determined by plotting the amount of product formed against the concentration of inhibitor using sigmoidal dose-response curve (variable slope) fit in GraphPad.
The compounds of Examples 1-52 were tested in the V79-Human~CY l 1B2 cell assay and found to have ICsos for inhibition of human CYPl 1B2 of less than 1000 nM. Preferred compounds had IC50S less than or equal to 100 nM and more preferred compounds had ICso's less than or equal to 20 nM.
The compounds of Examples 1-52 were also tested in the V79-Human-CYP1 1B1 cell assay and found to have at least 3 -fold greater inhibition of CYPl 1B2 as compared to CYPl IB 1. A sub-group of compounds were at least 30-fold more selective for inhibition of CYPl 1B2 as compared to C YP 11 B 1 , and a further sub-group of compounds were at least 100-fold more selective for inhibition of CYPl 1B2. Representative examples of data collected for compounds of the present invention are shown in Table 18 below.
Table 18
Figure imgf000106_0001
1 -cyclopropyl-2-(5- methoxypyridin-3 -yl)- 1 H- 0.4222 1754 benzimidazole-6-carbonitrile
1 ~methyl-2-(pyridin-3-yl)- 1 H~ 0.3162 98 benzimidazole-6-carbonitrile
6-chloro-l -cyclopropyl-5- 0.8102 161.4 fl oro-2~(5-fluoropyridin-3-yl)- lH-benzimidazole
4-(6-chloro- 1 -cyclopropyl- 5 - 0.1264
fluoro- 1 H-benzimidazol-2- yl)isoqmnoline
6-chloro- 1 -cyclopropyl-5- 0.5965 10000 fluoro-2-(pyridin-3-y 1)- 1 H- benzimidazole
6-chloro-l -cyclopropyl- 5- 0.2262 602.5 fluoro-2-(5-methylpyridin-3-yl)- 1 H-benzimidazole
6-bromo- 1 -cyclopropyl-2-(5- fluoropyridin-3 -yl)- 1 H- 3.551 945.8 benzimidazole
5,6-difluoro-l -methyl-2-(5- methylpyridin-3 -yl)- 1 H- 0.5852 149.4 benzimidazole
1 -cyclopropyl-5,6-difluoro-2- (4-methoxy-5-me†hylpyridin~3- 1.124 790.5 yl)- 1 H-benzimidazoIe
6-chloro-2-(5-methoxypyridin-
3-yl)-l-methyl-lH- 0.2002 162.2 benzimidazole
6-chloro-l -methyl-2-(pyridin-3- 1.15 269.5 yl)- 1 H-benzimidazole
6-chloro- 1 -cyclopropyl-2-
(pyridin-3-yl)-lH- 1.594 425.2 benzimidazole
4-(5 ,7-difluoro- 1 -methyl- 1 H- 0.3457 490.4 benzimidazol-2-yl)isoquinoline
5-(6,7-difluoro-l -methyl-lH- 0.151 205.5 benzimidazol-2-yl)pyridine~3- carbonitrile
2-(455-dimethylpyridin-3-yl)- 0.2336 1 16.8 6,7-difluoro-l -methyl- 1H- benzimidazole 4-(l -cyclopropyl~6,7-difluoro-
279 1H-benzimidazoI-2- 0.2819 206
yl)isoquinoline
1 -cyclopropyl-2-(4,5-
282 dimethylpyridin-3-yl)-6,7- 0.4171 294.8
difiuoro - 1H-benzimidazole
1 ~cyclopropyl-6,7~difluoro-2-
284 (4-methylpyr idin-3 -yl)- 1H- 1.353 300.2
benzimidazole
6-chloro-5-fluoro- 1 -methyl-2-
335 [4-(trifluoromethyl)pyridin-3 - 2.851 562.7
yl] - 1H-benzimidazole ;
1 -(benzyloxy)-5 ,6-difluoro-2~
373 (5 -fiuoropyridin-3 -y 1)- 1H- 0.5 71.5
benzimidazole
While the invention has been described with reference to certain particular embodiments thereof, numerous alternative embodiments will be apparent to those skilled in the art from the teachings described herein. Recitation or depiction of a specific compound in the claims (i.e., a species) without a specific stereoconfiguration designation, or with such a designation for less than all chiral centers, is intended to encompass the racemate, racemic mixtures, each individual enantiomer, a diastereoisomeric mixture and each individual diastereomer of the compound where such forms are possible due to the presence of one or more asymmetric centers. All patents, patent applications and publications cited herein are incorporated by reference in their entirety.

Claims

WHAT IS CLAIMED IS:
1. A compound of the formula Formula I
Figure imgf000109_0001
I or a pharmaceutically acceptable salt thereof
wherein:
Het is a heteroaromatic
Figure imgf000109_0002
Rla, Rib and Rlc are independently:
H; halogen; -CN; ~N02; -OR5; -NRsR9; ~N(R13)C(0)R10; -N(R13)S02-R10; -C(0)R,() ; - C(0)N(R6)(R7), -C(0)OR10 ; -S02N(R6)(R7) or -S(0)m-R10; alkyl optionally substituted one or more times by halogen, -CN, -OR5, -N(RI3)C(0)R10 or -C(0)N(R6)(R7);
cycloalkyl optionally substituted one or more times by halogen, alkyl, or haloalkyl; aryl optionally substituted one or more times by halogen, -OR5, alkyl, or haloalkyl or
lieteroaryl optionally substituted one or more times by halogen, -OR5, alkyl or haloalkyl;
R2 is:
-OR5, alkyl; alkyl-Rll; cycloalkyl optionally substituted one or more times by alkyl and halogen; and -C1-C2 alkyl-cyclo lkyl wherein the cycloalkyl group is optionally substituted one or more times by alkyl and halogen;
R3 is:
H; halogen; -CN; -N02; -OR5a; -NR8R9; -N(R13)C(0)R10; -C(0)R10 -C(0)N(R6)(R7), - C(0)OR10 or -S(0)m-RI&; alkyl optionally substituted one or more times by halogen or - OR5 ; cycloalkyl optionally substituted one or more times by halogen, -OR5a, alkyl, or haloalkyl; aryl optionally substituted one or more times by halogen, -OR5a, alkyl, or haloalkyl or heteroaryl optionally substituted one or more times by halogen, -OR a, alkyl or haloalkyl;
R4 is:
H; halogen; -CN; -N02; -OR5b; -NR8R?; -N(R )C(0)R10; -C(0)R10 -C(0)N(R6)(R7), - C(0)OR10 or -S(0)RO-RIE; alkyl optionally substituted one or more times by halogen or - OR5b ; cycloalkyl optionally substituted one or more times by halogen, -OR5b, alkyl, or haloalkyl; aryl optionally substituted one or more times by halogen, -OR5b s alkyl, or haloalkyl or heteroaryl optionally substituted one or more times by halogen, -OR5b, alkyl or haloalkyl;
or R3 and 4 are joined together to form a 5-7 membered carbocyclic or heterocyclic ring that is fused to the pyridyl ring to which R3 and R4 are attached, wherein the ring formed by R3 and R4 is optionally substituted with 1 to 3 of Rl2;
R5, R5 and R5h are each independently H; alkyl optionally substituted with halogen; or
aralkyl wherein the aryl ring is optionally substituted one or more times by halogen, - OR50, alkyl or haloalkyl;
R5c is H or alkyl optionally substituted with halogen;
R6 and R? are each independently:
H, alkyl optionally substituted with halogen; cycloalkyl optionally substituted with alkyl or halogen; aryl optionally substituted one or more times by halogen, -OR5, alkyl, or haloalkyl or heteroaryl optionally substituted one or more times by halogen, -OR , alkyl or haloalkyl;
or R6 and R? join together with the nitrogen to which they are attached to form a 3-7
membered saturated heterocyclic ring;
8 and R^ are each independently:
H; alkyl; or aralkyl wherein the aryl ring is optionally substituted one or more times by halogen, -OR5, alkyl or haloalkyl;
RlO is independently H; alkyl optionally substituted one or more times with halogen; cycloalkyl optionally substituted one or more times by halogen, alkyl or haloalkyl; or aryl wherein the aryl ring is optionally substituted one or more times by halogen, -OR5, alkyl or haloalkyl
Rll is haloalkyl or -OR5 ; Rl2 is independently halogen or alkyl optionally substituted one or more time by halogen; Rl3 1S H or alkyl; and
m is 0, 1 or 2.
2. The compound as defined in claim 1 or a pharmaceutically acceptable salt thereof wherein:
Rla , Rl or Rlc is selected from the group consisting of -H, -F, -CI, -Br, -N02, -CN, Q- C6 alkyl, Ci-C6 alkyl substituted with -OH, halogen or -N( 13)C(0)-CrC6 alkyl, -OCrC6 alkyl, -N(R13)C(0>CrC6 alkyl, -C(0)N(H)Cj-C6 alkyl, -NH2, -NH(CrC6 alkyl), -N(d-C6 alkyl)( Cr C6 alkyl), -C(0)OH, -C(0)0-C,-C6alkyl, -S-Cj-C6 alkyl, -S(0 C C6 alkyl, -S(0)2-C C6 alkyl, - N(R33)S(0)2-CrC6 alkyl, or optionally Ci-C6 alkyl substituted heteroaryl, wherein the heteroaryl is an isooxazolyl, pyrazolyl, oxazolyl, imidazolyl or pyridyl ring;
R2 is ~OH, Ci-C6 alkyl, Ci-C6 alkyl substituted with -OH or halogen, -0-CrC6 alkyl, cyclopropyl optionally substituted by halogen, -OH or -0-C\-C alkyl or -OCH2-phenyl, wherein the phenyl ring is optionally substituted by halogen, -OH or -O-Cj-Cg alkyl; and
R3 and R4 are independently H, halogen -CN, -Q-C6 alkyl substituted optionally substituted with -OH, -O-Q-Ce alkyl, or halogen, -0-CrC6 alkyl, - C(0)C1-C6alkyl, -C(0)OH, -C(0)0-Ci-C6 alkyl, -S-C C6 alkyl, -S(0)-CrC6 alkyl, -S(0)2-CrC6 alkyl, -NH2, - H(CrC6 alkyl), -NiQ-Ce alkyl)( Ci-C6 alkyl), optionally halo substituted phenyl, or optionally Ci-C6 alkyl substituted heteroaryl, wherein the heteroaryl is an isooxazolyl, pyrazolyl, oxazolyl, imidazolyl or pyridyl ring or
3 and R4 together with the pyridyl ring form:
Figure imgf000111_0001
3, The compound as defined in claim 1 having the structural formula
Figure imgf000111_0002
la
or a pharmaceutically acceptable salt thereof
wherein:
Rla Rib and R^c are independently selected from the group consisting of:
-H, -F; -CI, -Br, -CN, -OR5, -S02NR6R7,
-Ci-Cg alkyl optionally substituted with 1 to 3 of-F, or
-C3-C7 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of -CH3 or ~F;
2 is selected from the group consisting of:
(a) -C1-C5 alkyl-Rl 1, (b) -C1-C4 alkyl; (c) cyclopropyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of -CH3 or -F or (b) - C\~ C2 alkyl-cyclopropyl wherein cyclopropyl is optionally substituted with 1 or 2
substituents independently selected from the group consisting of-C]¾ or -F;
R3 is selected from the group consisting of:
-H, -F, -CI, -Br, -CN, -OR5a -C1-C6 perfluoroalkyl,
-Ci-Cg alkyl optionally substituted with 1 to 3 of-F oroptionally substituted with OH, or
-C3-C7 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of -CH3 and -F;
R4 is selected from the group consisting of:
(a) -H, -F, -CI, -Br, -CN, -OR5b -NR8 5 -CO2R10 or-CORlO,
(b) -C1-C6 perfluoroalkyl,
(c) -C1-C7 alkyl optionally substituted with 1 to 6 of -F and optionally substituted with 1 or 2 substituents independently selected from the group consisting of (i) -OR5b or (ii) aryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of -F, -CI or -Ci-C3alkyl optionally substituted with 1 to 3 of-F,
(d) -C3-C7 cycloalkyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of -Cl-Cg alkyl, -CF3 or -F,
(e) aryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of-F, -CI or -C1-C3 alkyl optionally substituted with 1 to 3 of-F or (ί) heteroaryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of-F, -CI or -C1 -C3 alkyl optionally substituted with 1 to 3 of-F; or R.3 and 4 are joined together to form a 5-7 membered carbocyclic or heterocyclic ring that is fused to the pyridyl ring to which R.3 and R.4 are attached, wherein the ring formed by R.3 and R4 is optionally substituted with 1 to 3 of Rl 2;
R5, R5a and R5b are each independently selected from the group consisting of -H or -Cj-Cg alkyl optionally substituted with 1 to 3 of -F;
R6 and R? are each independently selected from the group consisting of
(a) -Cj-Cg alkyl optionally substituted with 1 to 3 of -F, (b) -C3-C7 cycloalkyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of -CH3 and -F, (c) aryl or (d) heteroaryl,
or R<> and R7 join together with the nitrogen to which they are attached to form a 3-7
membered saturated heterocyclic ring;
R8 and R9 are each independently selected from the group consisting of
-H, -Ci-C<5 alkyl, or -CH2-phenyl wherein phenyl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of-F, -CI or -CF3 ,;
RlO is selected from the group consisting of
-Ci- alkyl optionally substituted with 1 to 3 of-F, or
-C3-C7 cycloalkyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of -CH3 and -F; or
-phenyl wherein the phenyl is optionally substituted with 1 to 3 substituents
independently selected from the group consisting of -F. -CI or -CF3;
Rll is selected from the group consisting of -CI¾F, -CHF2 or -CF3 ;
Rl2 is independently selected at each occurrence from the group consisting of-F, -CI or
-C1 -C3 alkyl optionally substituted with 1 to 3 of-F.
4. The compound as defined in claim 3 or a pharmaceutically acceptable salt thereof wherein Rl° is ~-H and R2 is cyclopropyl optionally substituted with one or two substituents independently selected from the group consisting of-CH3 or -F.
- I l l -
5. The compound as defined claim 3 or a pharmaceutically acceptable salt thereof wherein (a) R3 is ~H and R4 is selected from the group consisting of -Π, -F, -CI, -Br, -CN or - C1-C7 alkyl optionally substituted with 1 to 6 of-F or optionally substituted with 1 or 2 of
-OR5b; or (b) R3 and R are joined together to form a 5-7 member carbocyclic or heterocyclic ring that is fused to the pyridyl ring to which R? and R are attached wherein the ring formed by R3 and R4 is optionally substituted with 1 to 3 of Rl2.
6. The compound as defined in claim 5 or a pharmaceutically acceptable salt thereof wherein Rlc 1S and R2 is cyclopropyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of-CH3 or -F.
7. The compound as defined claim 3 or a pharmaceutically acceptable salt thereof wherein
Figure imgf000114_0001
wherein R5b is -H or -C1-C3 alkyl optionally substituted with 1 to 3 of-F, and R4a and R4b are each independently selected from the group consisting of (a) -C1-C3 alkyl, (b) -C1-C3 alkyl substituted with 1 to 3 of-F or (c) aryl optionally substituted with 1 or 2 substituents independently selected from the group consisting of-F, -CI or -C1-C3 alkyl optionally substituted with 1 to 3 of -F.
8. The compound as defined in claim 3 or a pharmaceutically acceptable salt thereof wherein:
Rla, Rib and R¾c are each independently selected from -H, -F, -CF3 or -OCH3;
R2 is selected from (a) -Ci-C3alkyl, (b) -Ci-C2alk lTU 1 , (c)™(CH2)(i-2)-cyclopropyl wherein cyclopropyl is optionally substituted with -CH3 or -F, or (d) cyclopropyl optionally substituted with -CH3 or -F;
R3 is -H or is joined together with R4 to form a 5-7 membered carbocyclic or heterocyclic ring that is fused to the pyridyl ring to which 3 and R4 are attached selected from the group consisting of
Figure imgf000115_0001
R when not joined with R3s is selected from -H, -F, -CN, -OCH3, -COCH3, -COOCH3, -CF3,
Figure imgf000115_0002
wherein R5b is™H or -CH3, and R4a and R4b are each independently selected from the group consisting of -CH3 or -CF3; and
R5 and R5a are each independently selected from the group consisting of -H, -CH3 and -CF3.
9. The compound as defined in claim 1 having the structural formula
Figure imgf000115_0003
lb
or a pharmaceutically acceptable salt thereof wherein
Rl¾, Rib and Rlc are independently selected from the group consisting of:
-H, -F, -CI, -Br, -CN, -OR5, -S02N 6R7, -C(0)OR10
-Ci-Cg alkyl optionally substituted with 1 to 3 of-F, or
- 3-C7 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of-CH3 and -F;
R2 is selected from the group consisting of:
(a) -C1-C5 alkyl-Rl ls (b) ~Ci-C alkyl; (c) cyclopropyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of -CH3 or -F or (d) - Ci- C2 alkyl-cyclopropyl wherein cyclopropyl is optionally substituted with 1 or 2
substituents independently selected from the group consisting of -CH3 or -F;
R.3 is selected from the group consisting of:
-H, -F, -CI, -Br, -CN, -OR5a -C1-C6 perfluoroalkyl,
-Q-Cg alkyl optionally substituted with 1 to 3 of-F and optionally substituted with OH, or
-C3-C7 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of™CH3 or -F;
R4 is selected from the group consisting of:
(a) -H, -F, -CI, -Br, -CN, -OR5b -NR8R9, -CO2RIO or -CORlO,
(b) -Ci-C^ perfluoroalkyl,
(c) -C1-C7 alkyl optionally substituted with 1 to 6 of ~~F and optionally substituted with 1 or 2 substituents independently selected from the group consisting of (i) -OR5b or (ii) aryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of ~F, -CI or -Ci~C3alkyl optionally substituted with 1 to 3 of ~F,
(d) -C3-C7 cycloalkyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of -C1-C6 alkyl, -CF3 or ~F,
(e) aryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of -F, -CI or -Ci-C3alkyl optionally substituted with 1 to 3 of -F and
(f) heteroaryl optionally substituted with 1 to 3 substituents independently selected from the group consisting of-F, -CI or -C1-C3 alkyl optionally substituted with 1 to 3 of -F; or R3 and R4 are joined together to form a 5-7 membered carbocyclic or heterocyclic ring that is fused to the pyridyl ring to which R and R4 are attached, wherein the ring formed by R3 and R4 is optionally substituted with 1 to 3 of Rl2;
RS, R5a and R^ are each independently selected from the group consisting of -H or -Cj-Cg alkyl optionally substituted with 1 to 3 of -F;
R6 and R? are each independently selected from the group consisting of
(a) -C1-C6 alkyl optionally substituted with 1 to 3 of-F, (b) -C3-C7 cycloalkyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of -CH3 or™F, (c) aryl or (d) heteroaryl, or R6 and R^ join together with the nitrogen to which they are attached to form a 3-7 membered saturated heterocyclic ring;
R8 and R9 are each independently selected from the group consisting of
-H, -Ci-Cg alkyl or -CH2-phenyl wherein phenyl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of -F„ -CI or -CF3;
RlO is selected from the group consisting of
-C1-C6 alkyl optionally substituted with 1 to 3 of -F,
-C3-C7 cycloalkyl optionally substituted with 1 or 2 substituents independently selected from the group consisting of -CH3 or -F; or
- phenyl which is optionally substituted with 1 to 3 substituents independently selected from the group consisting of -F, -CI or -CF3;
Rll is selected from the group consisting of -CH2F, -CHF2 or -CF3;
Rl2 is independently selected at each occurrence from the group consisting of -F, -CI or
-C1-C3 alkyl optionally substituted with 1 to 3 of -F.
10. The compound as defined in claim 9 or a pharmaceutically acceptable salt thereof wherein:
Rla^ Rib and Rlc are independently selected from the group consisting of:
-H, -F, -CI, -Br, -C , -OR5, -C(0)OR10, or -C\-Ce alkyl optionally substituted with 1 to 3 of-F;
R2 is selected from the group consisting of:
C1-C4 alkyl or cyclopropyl;
R3 is selected from the group consisting of:
-H, -F, -CI, -Br, -CN, -OR5a -C 1 -C6 perfluoroalkyl, or -C 1 -C6 alkyl;
R4 is selected from the group consisting of:
-H, -F, -CI, -Br, -CN, -OR5b and -C 1 -C6 perfluoroalkyl,
R5 and R5b are each independently selected from the group consisting of -H and -Ci- j alkyl optionally substituted with 1 to 3 of -F; and
RlO is selected from the group consisting of
-C]-C6 alkyl optionally substituted with 1 to 3 of-F
11. The compound of claim 1 selected from the group consisting of : 4-( 1 -cyclopropyl-6-fluoro- 1 H-benzimidazol-2-yl)isoquinoline ;
4-( 1 -cyclopropyl-5 ,6-difluoro- 1 H-benzimidazol-2-yl)isoquinoline;
l-cyclopropyl-6-fluoro-2-[5-(2-methoxypropan-2-yl)pyridm-3-yl]-lH-benzimidazole;
4-(l-ethyl-556-difluoro-lH-benzimidazol-2-yl)isoquinoline;
4-( 1 -cyclopropyl-5-fluoro- 1 H-benzimidazol-2-yl)isoquinoline;
2- [5 -( 1 -ethyl-5 ,6-difluoro- 1 H-benzimidazol-2-yl)pyridin-3 -yl]propan-2-ol;
methyl 5-(l-cyclopropyl-6-fluoro-lH-benzimidazol-2-yl)pyridine-3-carboxylate;
4-( 1 -ethyl-5 -fluoro- 1 H-benzimidazol-2-yl)isoquinoline ;
1- cyclopropyl-6-fluoro-2-(5-fluoropyridin-3-yl)-lH-benzimidazole;
1 -cyclopropyl-6,7-difluoro-2-(pyridin-3-yl)- 1 H-benzimidazole;
6-fluoro- 1 -( 1 -methylcyclopropyl)-2-(pyridin-3 -yl)- 1 H-benzimidazole;
2- [5-(l -cyclopropyl-5 J7-difluoro-lH-benzimidazol-2-yl)pyridin-3-yl]propan-2-ol;
5-fmoro-l -methyl~2-(pyridin-3-yl)-i H-benzimidazole;
8-( 1 -cyclopropyl-6-fiuoro- 1 H-benzimidazol-2-yl)- 1 ,6-naphthyridine;
8-(l -ethyl- 5 ,6-difluoro- lH-benzimidazol^-y^-l^-naphthyridine;
l-cyclopropyl-6-fluoro-2-(pyridin-3-yl)-lH-benzimidazole;
l-cyclopropyl-5-fluoro-2-(pyridin-3-yi)-lH-benzimidazole;
2- [5 -( 1 -cyclopropyl-6-fluoro- 1 H-benzimidazol-2-yl)pyridin-3 -yl]propan-2-ol ;
1 -cyclopropyl-5 , -difluoro-2-(pyridin-3 -yl)- 1 H-benzimidazole ;
1- cyclopropyl-4,6-difluoro-2-(pyridin-3-yl)-lH-benzimidazole;
1 -cyclopropyl-5 , 7-difTuoro-2-(pyridin-3 -yl)- 1 H-benzimidazole ;
2- [5-( 1 -cyclopropyl-5-fluoro- 1 H-benzimidazol-2-yl)pyridin-3 -yl]propan-2-ol;
8-(l -cyclopropyl-5 ,6-difluoro- lH-benzimidazol-2-yl)- 1 ,6-naphthyridine;
2-[5-(l-cyclopropyl-5,6-difluoro-lH-benzimidazol-2-yl)pyridin-3-yl]propan-2-ol;
2-[5-(l-cyclopropyl-5,6-difluoro-lH-benzimidazol-2-yl)pyridin-3-yl]-l,l ,l-trifluoropropan-2- l-cyclopropyl-5,6-difluoro-2-(5-fluoropyridin-3-yl)-lH-benzimidazole;
l-cyclopropyl-5,6-difluoro-2-(5-fluoro-4-methylpyridin-3-yl)-lH-benzimidazole;
1 -cyclopropyl-5 ,6 -difluoro-2 -(4-methylpyridin-3 -yl)- 1 H-benzimidazole ;
6-fluoro-2-(4-methylpyr idin-3 -yl)- 1 -methyl- 1 H-benzimidazole;
1 -ethyl-6-fluoro-2-(4-methylpyridin-3-yl)- 1 H-benzimidazole;
5}6-di-difluoro-2-(4-methylpyridin-3-yl)-l-methyl-lH-benzimidazole;
5.6- di-difluoro-2-(2-hydroxy-2-propylpyridin-3-yl)-l-methyl-lH-benzimidazole 1 -cyclopropyl-6-fluoro-2-(5-fluoro4-methylpyridin-3-yl)- 1 H-benzimidazole;
6.7- diiluoro-2-(4-methylpyndin-3-yl)-l-methyl-lH-benzin idazole;
5,7-difluoro-2-(5-fluoro-4-methylpyridin-3-yl)-l-methyl-lH-benzimidazole;
l-cyclopropyl-5,7-difluoro-2-(5-fluoro-4-memylp^
5 ,7-difluoro-2-(4-methylpyridin-3 -yl)- 1 -methyl- 1 H-benzimidazole;
or a the pharmaceutically acceptable salts thereof,
12. The compound as defined in claim 1 selected from the group consisting of:
l-cyclopropyl-6-fluoro-2-(pyridin-3-yl)-lH-benzimidazole;
1- cyclopropyl-5-fluoro-2-(pyridin-3-yl)-lH-benzimidazole;
2- [5-( 1 -cyclopropyl-6-fluoro- 1 H-berrzimidazol-2-yl)pyridin-3 -yl]propan-2-ol;
1- cycIopropyl-5,6-difluoro-2-(pyridin~3-y])-lH-benzimidazole;
1 -cyclopropyl-4,6-difluoro-2-(pyridin-3 -yl)- 1 H-benzimidazole;
1 -cyclopropyl-5,7-difluoro-2-(pyridin-3-yl)-lH-benzimidazole;
2- [5 -( 1 -cyclopropyl-5 -fluoro- 1 H-benzimidazol-2-yl)pyridin- 3 -yl] propan-2-ol ;
8-( 1 -cyclopropyl-5 ,6-difluoro- 1 H-benzimidazol-2-yl)- 1 ,6-naphthyridme;
2-[5-( 1 -cyclopropyl-5,6-difluoro- 1 H-bervzimidazol-2~yI)pyridin-3 -yl]propan-2-ol;
2- [5-( 1 ~cyclopropyI-5,6-difluoro- 1 H-benzimidazol-2-yl)pyridin-3 -yl]- 1 ,1,1 -trifluoropropan-2-oI ; l-cyclopropyl-5,6-difluoro-2-(5-fluoropyridin-3-yl)-lH-benzimidazole;
1 -cyclopropyl- 5 }6-difluoro-2- (5-fluoro-4-methylpyridin-3 -yl)- 1 H-benzimidazole ;
1 -cyclopropyl-5 ,6-difluoro-2-(4-methylpyridin-3 -yl)- 1 H-benzimidazole;
6-fluoro-2-(4-methylpyridin-3 -yl)- 1 -methyl- 1 H-benzimidazole;
1 -ethyl-6-fluoro-2-(4-methylpyridin-3-yl)- 1 H-benzimidazole;
5 ,6-di-difluoro-2-(4-methy lpyridin-3 -yl)- 1 -methyl- 1 H-benzimidazole;
5.6- di-difluoro-2-(2-hydroxy-2-propylpyridin-3 -yl)- 1 -methyl- lH-benzimidazole;
1 -cyclopropyl-6-fluoro-2-(5-fluoro4-methylpyridin-3 -yl)- 1 H-benzimidazole;
6.7- difluoro-2-(4-methylpyridin-3-yl)-l -methyl- 1 H-benzimidazole;
5 ,7-difluoro-2~(5 -fluoro-4-methylpyridin- 3 -yl)- 1 -methyl- 1 H-benzimidazole ;
l-cyclopropyl-5,7-difluoro-2-(5-fluoro-4-methylpyridin-3-yl)-lH-benzimidazole;
5 !7-difluoro-2-(4-methylpyridin-3 -yl)- 1 -methyl- 1 H-benzimidazole;
or the pharmaceutically acceptable salts thereof.
13. The compound of claim 1 selected from the group consisting of:
1 -cyclopropyl-2-(pyridin-3-yl)~ 1 H-benzo[d]imidazole-6-carbonitrile;
l-cyclopropyl-2-(5-methoxypyridin-3-yl)-lH-benzimidazole-6-carbonitrile;
1- methyl-2-(pyridin-3-yl)-lH-benzimidazole-6-carbonitrile;
6-chloro- 1 -cyclopropyl-5-fluoro-2~(5-fluoropyridin-3 -yl)- 1 H-benzimidazole;
4- (6-chloro-l-cyclopropyl-5-fluoro-lH-benzimidazol-2-yl)isoquinoline;
6-chloro-l-cyclopropyl-5-fluoro-2-(pyridin-3-yl)-lH-benzimidazole;
6-chloro- 1 -cyclopropyl- 5 -fiuoro-2-(5 -methylpyr i din-3 -yl)- 1 H-benzimidazole ;
6-bromo- 1 -cyclopropyl-2-(5 -fluoropyridin-3 -y 1)- 1 H-benzimidazole ;
5,6-difluoro-l-methyl-2-(S-methylpyridin-3-yl)"lH-benzimidazole;
1 -cyclopropyl-5 , 6-difluoro-2-(4-methoxy-5-methy lpyridin-3 -yl)- 1 H-benzimidazole;
6-chloro-2-(5-methoxypyridin-3-yl)-l -methyl-1 H-benzimidazole;
6-chloro-2-(5-methoxypyridin-3-yl)-l -methyl-1 H-benzimidazole;
6-chloro- 1 -cyclopropyl-2-(pyridin-3 -yl)- 1 H-benzimidazole;
4-(557-difluoro-l-methyl-lH-benzimidazol-2-yl)isoquinoline;
5- (657-difluoro-l-methyl-lH~benzimidazol-2-yl)pyridine-3-carbonitrile;
2- (4!5~dimethylpyridin-3-yl)-6,7-difluoro-l-methyl-lH-benzimidazole;
4-(l-cyclopropyl-6,7-difluoro-lH-benzimidazol-2-yl)isoquinoline;
l-cyclopropyl-2-(4,5-dimethylpyridin-3-yl)-6,7-difluoro-lH-benzimidazole;
1 -cyclopropyl-6 , 7-difluoro-2-(4-methylpyridin-3 -y 1)- 1 H-benzimidazole;
6- chloro- 5-fluoro- 1 -methyl-2-[4-(trifluoromethyl)pyridin-3 -yl] - 1 H-benzimidazole ;
1 -(benzyloxy)- 5 ,6-difluoro-2-(5 -fluoropyridin-3 -yl)- 1 H-benzimidazole;
or a pharmacuetically acceptable salt thereof.
14. A method of inhibiting CYP 1 1 B2 comprising administering a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof in a CYPl 1B2 inhibitory effective amount to a patient in need thereof.
15. A method of reducing aldosterone levels in a patient comprising administering therapeutically effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof to a patient in need of thereof.
16. A method for treating or reducing the risk for a medical condition selected from the group consisting of hypertension, heart failure, diastolic dysfunction, left ventricular diastolic dysfunction, diastolic heart failure, systolic dysfunction, hypokalemia, renal failure, in particular chronic renal failure, restenosis, metabolic syndrome, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collagen, fibrosis and remodeling following hypertension and endothelial dysfunction, cardiovascular diseases, renal dysfunction, liver diseases, vascular diseases, cerebrovascular diseases, retinopathy, neuropathy, insulinopathy, endothelial dysfunction, ischemia, myocardial and vascular fibrosis, myocardial necrotic lesions, vascular damage, myocardial infarction, left ventricular hypertrophy, cardiac lesions, vascular wall hypertrophy, endothelial thickening, or fibrinoid necrosis of coronary arteries comprising administering a therapeutically or prophylactically effective amount of a compound as defined in claim 1 or a pharmaceuticaly acceptable salt thereof to a patient in need thereof.
17. The method as defined in claim 15 for treating hypertension or heat failure.
18. A pharmaceutical composition comprised of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
19. The pharmaceutical composition as defined claim 18 or a pharmaceutically acceptable salt thereof comprised of one or more additional pharmacologically active agents selected form the group consisting of an anti-hypertensive agent, anti-atherosclerotic agent, antidiabetic agent or an anti-obesity agent.
PCT/US2011/044598 2010-07-21 2011-07-20 Aldosterone synthase inhibitors WO2012012478A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/811,059 US9382226B2 (en) 2010-07-21 2011-07-20 Aldosterone synthase inhibitors
EP11810314.2A EP2595482A4 (en) 2010-07-21 2011-07-20 Aldosterone synthase inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36624310P 2010-07-21 2010-07-21
US61/366,243 2010-07-21
US201161473471P 2011-04-08 2011-04-08
US61/473,471 2011-04-08

Publications (1)

Publication Number Publication Date
WO2012012478A1 true WO2012012478A1 (en) 2012-01-26

Family

ID=45497159

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/044598 WO2012012478A1 (en) 2010-07-21 2011-07-20 Aldosterone synthase inhibitors

Country Status (3)

Country Link
US (1) US9382226B2 (en)
EP (1) EP2595482A4 (en)
WO (1) WO2012012478A1 (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012123522A1 (en) * 2011-03-16 2012-09-20 F. Hoffmann-La Roche Ag 6,5-heterocyclic propargylic alcohol compounds and uses therefor
WO2012148808A1 (en) 2011-04-26 2012-11-01 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
WO2013043520A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
WO2013151876A1 (en) * 2012-04-04 2013-10-10 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
WO2014055595A1 (en) 2012-10-05 2014-04-10 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitiors related applications
WO2014099833A1 (en) * 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Indazole compounds as aldosterone synthase inhibitors
WO2015163427A1 (en) 2014-04-24 2015-10-29 田辺三菱製薬株式会社 Novel disubstituted 1, 2, 4-triazine compound
JP2015193545A (en) * 2014-03-31 2015-11-05 国立大学法人京都大学 2-(3-pyridinyl)-1h-benzimidazole derivative compound, and radioactive pharmaceuticals containing the same
WO2015199205A1 (en) * 2014-06-26 2015-12-30 日本メジフィジックス株式会社 2-(3-pyridinyl)-1h-benzimidazole derivative compound and medicine containing same
US9351973B2 (en) 2011-09-22 2016-05-31 Merck Sharp & Dohme Corp. Pyrazolopyridyl compounds as aldosterone synthase inhibitors
US9518055B2 (en) 2011-09-22 2016-12-13 Merck Sharp & Dohme Imidazopyridyl compounds as aldosterone synthase inhibitors
WO2017069226A1 (en) * 2015-10-23 2017-04-27 田辺三菱製薬株式会社 Novel nitrogen-containing aromatic heterocyclic compound
JP2017081911A (en) * 2015-10-22 2017-05-18 田辺三菱製薬株式会社 Pharmaceutical composition
WO2018125800A2 (en) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
WO2019131458A1 (en) 2017-12-28 2019-07-04 日本メジフィジックス株式会社 2-[5-(imidazole-1-ylmethyl)pyridine-3-yl]benzimidazole derivative compound, and medicine including same
US10538511B2 (en) 2016-12-29 2020-01-21 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
WO2023203162A1 (en) * 2022-04-22 2023-10-26 Universite Paris Cite Compounds inducing production of proteins by immune cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387592A (en) * 1991-06-25 1995-02-07 Imperial Chemical Industries Plc Substituted benzoxazole, benzthiazole, and benzimidazole derivatives as angiotensin II antagonists
US20060014756A1 (en) * 2001-10-26 2006-01-19 Aventis Pharmaceuticals Inc. Benzimidazoles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145071A0 (en) * 1999-12-27 2002-06-30 Japan Tobacco Inc Fused ring compounds and pharmaceutical compositions containing the same
EA006302B1 (en) 2000-01-14 2005-10-27 Шеринг Акциенгезельшафт 1,2-diaryl benzimidazoles for treating diseases associated with a microglia activation
CA2504448C (en) * 2002-11-01 2012-06-19 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
WO2005118555A1 (en) * 2004-06-04 2005-12-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1993536A4 (en) 2006-03-02 2010-05-19 Glaxosmithkline Llc Thiazolones for use as pi3 kinase inhibitors
ES2459468T3 (en) * 2009-05-15 2014-05-09 Novartis Ag Arylpyridines as aldosterone synthase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387592A (en) * 1991-06-25 1995-02-07 Imperial Chemical Industries Plc Substituted benzoxazole, benzthiazole, and benzimidazole derivatives as angiotensin II antagonists
US20060014756A1 (en) * 2001-10-26 2006-01-19 Aventis Pharmaceuticals Inc. Benzimidazoles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2595482A4 *

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103476768B (en) * 2011-03-16 2015-07-08 弗·哈夫曼-拉罗切有限公司 6,5-heterocyclic propargylic alcohol compounds and uses therefor
WO2012123522A1 (en) * 2011-03-16 2012-09-20 F. Hoffmann-La Roche Ag 6,5-heterocyclic propargylic alcohol compounds and uses therefor
US8901313B2 (en) 2011-03-16 2014-12-02 Genentech, Inc. 6,5-heterocyclic propargylic alcohol compounds and uses therefor
CN103476768A (en) * 2011-03-16 2013-12-25 弗·哈夫曼-拉罗切有限公司 6,5-heterocyclic propargylic alcohol compounds and uses therefor
WO2012148808A1 (en) 2011-04-26 2012-11-01 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
US9073929B2 (en) 2011-04-26 2015-07-07 Elexopharm Gmbh Aldosterone synthase inhibitors
US9844553B2 (en) 2011-09-22 2017-12-19 Merck Sharp & Dohme Corp. Pyrazolopyridyl compounds as aldosterone synthase inhibitors
WO2013043520A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
US9567333B2 (en) 2011-09-22 2017-02-14 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
US9518055B2 (en) 2011-09-22 2016-12-13 Merck Sharp & Dohme Imidazopyridyl compounds as aldosterone synthase inhibitors
US9193724B2 (en) 2011-09-22 2015-11-24 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
US9351973B2 (en) 2011-09-22 2016-05-31 Merck Sharp & Dohme Corp. Pyrazolopyridyl compounds as aldosterone synthase inhibitors
WO2013151876A1 (en) * 2012-04-04 2013-10-10 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
US9278093B2 (en) 2012-04-04 2016-03-08 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
US9745282B2 (en) 2012-10-05 2017-08-29 Merck Sharp & Dohme Corp Indoline compounds as aldosterone synthase inhibitors
US9550750B2 (en) 2012-10-05 2017-01-24 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitors
WO2014055595A1 (en) 2012-10-05 2014-04-10 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitiors related applications
WO2014099833A1 (en) * 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Indazole compounds as aldosterone synthase inhibitors
US9522141B2 (en) 2012-12-20 2016-12-20 Merck Sharp & Dohme Corp. Indazole compounds as aldosterone synthase inhibitors
JP2015193545A (en) * 2014-03-31 2015-11-05 国立大学法人京都大学 2-(3-pyridinyl)-1h-benzimidazole derivative compound, and radioactive pharmaceuticals containing the same
WO2015163427A1 (en) 2014-04-24 2015-10-29 田辺三菱製薬株式会社 Novel disubstituted 1, 2, 4-triazine compound
US10029993B2 (en) 2014-04-24 2018-07-24 Mitsubishi Tanabe Pharma Corporation Disubstituted 1, 2, 4-triazine compound
JPWO2015163427A1 (en) * 2014-04-24 2017-04-20 田辺三菱製薬株式会社 Novel disubstituted 1,2,4-triazine compounds
KR101921404B1 (en) 2014-04-24 2018-11-22 미쓰비시 타나베 파마 코퍼레이션 Novel disubstituted 1,2,4-triazine compound
US10329263B2 (en) 2014-04-24 2019-06-25 Mitsubishi Tanabe Pharma Corporation Disubstituted 1, 2, 4-triazine compound
AU2015281060B2 (en) * 2014-06-26 2019-03-14 Kyoto University 2-(3-pyridinyl)-1H-benzimidazole derivative compound and medicine containing same
KR20170017871A (en) 2014-06-26 2017-02-15 니혼 메디피직스 가부시키가이샤 2-(3-pyridinyl)-1h-benzimidazole derivative compound and medicine containing same
CN106458995A (en) * 2014-06-26 2017-02-22 日本医事物理股份有限公司 2-(3-pyridinyl)-1H-benzimidazole derivative compound and medicine containing same
CN106458995B (en) * 2014-06-26 2019-12-20 日本医事物理股份有限公司 2- (3-pyridyl) -1H-benzimidazole derivative compound and medicine containing the same
US10358434B2 (en) 2014-06-26 2019-07-23 Nihon Medi-Physics Co., Ltd. 2-(3-pyridinyl)-1H-benzimidazole derivative compound and medicament containing same
WO2015199205A1 (en) * 2014-06-26 2015-12-30 日本メジフィジックス株式会社 2-(3-pyridinyl)-1h-benzimidazole derivative compound and medicine containing same
JPWO2015199205A1 (en) * 2014-06-26 2017-04-20 日本メジフィジックス株式会社 2- (3-pyridinyl) -1H-benzimidazole derivative compound and pharmaceutical comprising the same
US10189815B2 (en) 2014-06-26 2019-01-29 Nihon Medi-Physics Co., Ltd. 2-(3-pyridinyl)-1H-benzimidazole derivative compound and medicine containing same
JP2017081911A (en) * 2015-10-22 2017-05-18 田辺三菱製薬株式会社 Pharmaceutical composition
WO2017069226A1 (en) * 2015-10-23 2017-04-27 田辺三菱製薬株式会社 Novel nitrogen-containing aromatic heterocyclic compound
JPWO2017069226A1 (en) * 2015-10-23 2018-08-09 田辺三菱製薬株式会社 New nitrogen-containing aromatic heterocyclic compounds
US10717731B2 (en) 2015-10-23 2020-07-21 Mitsubishi Tanabe Pharma Corporation Nitrogen-containing aromatic heterocyclic compound
JP2020510693A (en) * 2016-12-29 2020-04-09 セレニティ・セラピューティクス・（バミューダ）・リミテッド Metal enzyme inhibitor compound
WO2018125800A2 (en) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
CN110691598A (en) * 2016-12-29 2020-01-14 赛列尼蒂治疗(百慕大)有限公司 Metalloenzyme inhibitor compounds
US10538511B2 (en) 2016-12-29 2020-01-21 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
JP7227157B2 (en) 2016-12-29 2023-02-21 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド metalloenzyme inhibitor compounds
EP4311577A3 (en) * 2016-12-29 2024-04-17 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
US10085984B2 (en) 2016-12-29 2018-10-02 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
EP3562487A4 (en) * 2016-12-29 2020-08-26 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
US11040034B2 (en) 2016-12-29 2021-06-22 Phasebio Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US11136309B2 (en) 2016-12-29 2021-10-05 Phasebio Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US11919883B2 (en) 2016-12-29 2024-03-05 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
CN111527079A (en) * 2017-12-28 2020-08-11 日本医事物理股份有限公司 2- [5- (imidazol-1-ylmethyl) pyridin-3-yl ] benzimidazole derivative compound and medicine comprising the same
CN111527079B (en) * 2017-12-28 2023-08-11 日本医事物理股份有限公司 2- [5- (imidazol-1-ylmethyl) pyridin-3-yl ] benzimidazole derivative compound and medicament containing the same
US11266753B2 (en) 2017-12-28 2022-03-08 Nihon Medi-Physics Co., Ltd. 2-[5-(imidazol-1-ylmethyl)pyridin-3-yl]benzimtdazole derivative compound, and medicament including same
WO2019131458A1 (en) 2017-12-28 2019-07-04 日本メジフィジックス株式会社 2-[5-(imidazole-1-ylmethyl)pyridine-3-yl]benzimidazole derivative compound, and medicine including same
WO2023203162A1 (en) * 2022-04-22 2023-10-26 Universite Paris Cite Compounds inducing production of proteins by immune cells

Also Published As

Publication number Publication date
US20130317057A1 (en) 2013-11-28
EP2595482A4 (en) 2013-12-25
EP2595482A1 (en) 2013-05-29
US9382226B2 (en) 2016-07-05

Similar Documents

Publication Publication Date Title
US9382226B2 (en) Aldosterone synthase inhibitors
US9844553B2 (en) Pyrazolopyridyl compounds as aldosterone synthase inhibitors
EP2701512B1 (en) Aldosterone synthase inhibitors
US9518055B2 (en) Imidazopyridyl compounds as aldosterone synthase inhibitors
EP2978425A2 (en) FACTOR XIa INHIBITORS
US9745282B2 (en) Indoline compounds as aldosterone synthase inhibitors
US9567333B2 (en) Triazolopyridyl compounds as aldosterone synthase inhibitors
EP2934144B1 (en) Indazole compounds as aldosterone synthase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11810314

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011810314

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011810314

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13811059

Country of ref document: US